{
  "questions": [
    {
      "id": "65d1350f1930410b13000038",
      "type": "yesno",
      "body": "Can Rozanolixizumab be used for treatment of multiple sclerosis?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37656420",
        "https://pubmed.ncbi.nlm.nih.gov/32886753",
        "https://pubmed.ncbi.nlm.nih.gov/29093180",
        "https://pubmed.ncbi.nlm.nih.gov/30130439",
        "https://pubmed.ncbi.nlm.nih.gov/37059507",
        "https://pubmed.ncbi.nlm.nih.gov/33219142",
        "https://pubmed.ncbi.nlm.nih.gov/34735735",
        "https://pubmed.ncbi.nlm.nih.gov/20224616",
        "https://pubmed.ncbi.nlm.nih.gov/8865021",
        "https://pubmed.ncbi.nlm.nih.gov/2993548"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37656420",
          "text": "Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO®) is a high affinity humanized immunoglobulin G4 monoclonal antibody directed against human neonatal Fc receptor (FcRn). Administered subcutaneously, it is being developed by UCB Pharma for the treatment of autoimmune diseases and received its first approval on 27 June 2023 in the USA for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive. Rozanolixizumab is the first agent to be approved in the USA for both anti-AChR and anti-MuSK antibody-positive gMG.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 617
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37059507",
          "text": "New treatments for this disease are needed because conventional therapies have limitations, such as side-effects (eg, increased infection risk) or inadequate control of symptoms. Rozanolixizumab is a neonatal Fc receptor blocker that might provide a novel therapeutic option for myasthenia gravis. We aimed to assess the safety and efficacy of rozanolixizumab for generalised myasthenia gravis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 107,
          "end_section": "abstract",
          "offset_in_end_section": 501
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37059507",
          "text": "Rozanolixizumab represents a potential additional treatment option for patients with generalised myasthenia gravis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 3513,
          "end_section": "abstract",
          "offset_in_end_section": 3628
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37059507",
          "text": "Rozanolixizumab represents a potential additional treatment option for patients with generalised myasthenia gravis. FUNDING\nUCB Pharma.",
          "begin_section": "abstract",
          "offset_in_begin_section": 3513,
          "end_section": "abstract",
          "offset_in_end_section": 3650
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37059507",
          "text": "New treatments for this disease are needed because conventional therapies have limitations, such as side-effects (eg, increased infection risk) or inadequate control of symptoms. Rozanolixizumab is a neonatal Fc receptor blocker that might provide a novel therapeutic option for myasthenia gravis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 107,
          "end_section": "abstract",
          "offset_in_end_section": 404
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37656420",
          "text": "Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO®) is a high affinity humanized immunoglobulin G4 monoclonal antibody directed against human neonatal Fc receptor (FcRn). Administered subcutaneously, it is being developed by UCB Pharma for the treatment of autoimmune diseases and received its first approval on 27 June 2023 in the USA for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 500
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32886753",
          "text": "Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 116
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37656420",
          "text": "Rozanolixizumab is the first agent to be approved in the USA for both anti-AChR and anti-MuSK antibody-positive gMG. A regulatory assessment of rozanolixizumab for the treatment of gMG is currently underway in the EU and Japan. Clinical development is ongoing for the treatment of leucine-rich glioma-inactivated 1 autoimmune encephalitis, myelin oligodendrocyte glycoprotein (MOG) antibody disease and severe fibromyalgia syndrome.",
          "begin_section": "abstract",
          "offset_in_begin_section": 501,
          "end_section": "abstract",
          "offset_in_end_section": 933
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37059507",
          "text": "Both doses were generally well tolerated. These findings support the mechanism of action of neonatal Fc receptor inhibition in generalised myasthenia gravis. Rozanolixizumab represents a potential additional treatment option for patients with generalised myasthenia gravis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 3355,
          "end_section": "abstract",
          "offset_in_end_section": 3628
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37656420",
          "text": "Rozanolixizumab is the first agent to be approved in the USA for both anti-AChR and anti-MuSK antibody-positive gMG. A regulatory assessment of rozanolixizumab for the treatment of gMG is currently underway in the EU and Japan.",
          "begin_section": "abstract",
          "offset_in_begin_section": 501,
          "end_section": "abstract",
          "offset_in_end_section": 728
        }
      ],
      "ideal_answer": "No, rozanolixizumab is not currently approved for the treatment of multiple sclerosis. It is being developed and has received approval for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive. Clinical development is ongoing for other autoimmune diseases, but multiple sclerosis is not among them.",
      "exact_answer": "no"
    },
    {
      "id": "65f77701c4010b4d78000030",
      "type": "yesno",
      "body": "Are FOLFIRINOX plus Bevacizumab the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/33336844",
        "https://pubmed.ncbi.nlm.nih.gov/32704062",
        "https://pubmed.ncbi.nlm.nih.gov/33539032",
        "https://pubmed.ncbi.nlm.nih.gov/37071094",
        "https://pubmed.ncbi.nlm.nih.gov/30595807",
        "https://pubmed.ncbi.nlm.nih.gov/35641204",
        "https://pubmed.ncbi.nlm.nih.gov/34012917",
        "https://pubmed.ncbi.nlm.nih.gov/34380594",
        "https://pubmed.ncbi.nlm.nih.gov/36249804",
        "https://pubmed.ncbi.nlm.nih.gov/32107929"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30595807",
          "text": "A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC), regardless of RAS or BRAF status. Our subanalysis of a phase II trial of the FOLFOXIRI triplet regimen plus bevacizumab in patients with mCRC who had RAS mutant tumors showed that tumor shrinkage was better and the duration of treatment was longer in patients with left-sided tumors than in those with right-sided tumors, leading to a higher rate of conversion to surgery in mCRC patients with left-sided tumors. The early and deep responses to the triplet-regimen in patients with left-sided tumors might facilitate conversion treatment resulting in favorable survival.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 770
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30595807",
          "text": "A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC), regardless of RAS or BRAF status. Our subanalysis of a phase II trial of the FOLFOXIRI triplet regimen plus bevacizumab in patients with mCRC who had RAS mutant tumors showed that tumor shrinkage was better and the duration of treatment was longer in patients with left-sided tumors than in those with right-sided tumors, leading to a higher rate of conversion to surgery in mCRC patients with left-sided tumors.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 612
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30595807",
          "text": "A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC), regardless of RAS or BRAF status.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 233
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32107929",
          "text": "Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 160
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32704062",
          "text": "The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which 50 cases received bevacizumab plus chemotherapy in both first-line and second-line therapies (Group A) and 51 cases received first-line cetuximab plus chemotherapy followed by second-line bevacizumab-containing regimens (Group B).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 531
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32704062",
          "text": "The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which 50 cases received bevacizumab plus chemotherapy in both first-line and second-line therapies (Group A) and 51 cases received first-line cetuximab plus chemotherapy followed by second-line bevacizumab-containing regimens (Group B). The progression free survival (PFS) and overall survival (OS) from start of first-line (PFS 1nd and OS 1nd) and second-line (PFS 2nd and OS 2nd) therapy were compared between the two groups.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 722
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33336844",
          "text": "FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 155
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37071094",
          "text": "Conclusions and Relevance\nAmong patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, compared with bevacizumab, to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population. Trial Registration\nClinicalTrials.gov Identifier: NCT02394795.",
          "begin_section": "abstract",
          "offset_in_begin_section": 2813,
          "end_section": "abstract",
          "offset_in_end_section": 3153
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32704062",
          "text": "First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 165
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37071094",
          "text": "Conclusions and Relevance\nAmong patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, compared with bevacizumab, to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population.",
          "begin_section": "abstract",
          "offset_in_begin_section": 2813,
          "end_section": "abstract",
          "offset_in_end_section": 3088
        }
      ],
      "ideal_answer": "Based on recent studies, FOLFIRINOX plus bevacizumab may be considered a preferred therapy for left-sided RAS wild-type advanced colorectal cancer with aggressive clinical presentation. These studies have shown that FOLFIRINOX plus bevacizumab can lead to better tumor shrinkage, longer treatment duration, and a higher rate of conversion to surgery in patients with left-sided tumors. However, treatment decisions should be individualized and take into account factors such as patient characteristics, tumor characteristics, and potential side effects of the treatment.",
      "exact_answer": "no"
    },
    {
      "id": "66097092fdcbea915f000010",
      "type": "list",
      "body": "Amyloid-β is associated with what diseases?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/31928731",
        "https://pubmed.ncbi.nlm.nih.gov/23089868",
        "https://pubmed.ncbi.nlm.nih.gov/25631374",
        "https://pubmed.ncbi.nlm.nih.gov/28938337",
        "https://pubmed.ncbi.nlm.nih.gov/31257024",
        "https://pubmed.ncbi.nlm.nih.gov/32341983",
        "https://pubmed.ncbi.nlm.nih.gov/29508987",
        "https://pubmed.ncbi.nlm.nih.gov/21406255",
        "https://pubmed.ncbi.nlm.nih.gov/32949547",
        "https://pubmed.ncbi.nlm.nih.gov/30886570"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23089868",
          "text": "The amyloid protein aggregation associated with diseases such as Alzheimer's, Parkinson's and type II diabetes (among many others) features a bewildering variety of β-sheet-rich structures in transition from native proteins to ordered oligomers and fibres.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 256
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23089868",
          "text": "The amyloid protein aggregation associated with diseases such as Alzheimer's, Parkinson's and type II diabetes (among many others) features a bewildering variety of β-sheet-rich structures in transition from native proteins to ordered oligomers and fibres. The variation in the amino-acid sequences of the β-structures presents a challenge to developing a model system of β-sheets for the study of various amyloid aggregates.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 425
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30886570",
          "text": "Many human neurodegenerative diseases are associated with amyloid fibril formation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 83
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30886570",
          "text": "Many human neurodegenerative diseases are associated with amyloid fibril formation. Inhibition of amyloid formation is of importance for therapeutics of the related diseases.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 174
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31928731",
          "text": "Cytotoxic species in amyloid-associated diseases: Oligomers or mature fibrils.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 78
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31928731",
          "text": "In this review, we have described the recent scenario of amyloid diseases with a great deal of information about the recent understanding of oligomers' assembly, structural properties, and toxicity. Also comprehensive details have been provided to differentiate the degree of toxicity associated with prefibrillar aggregates.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1000,
          "end_section": "abstract",
          "offset_in_end_section": 1325
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30886570",
          "text": "Many human neurodegenerative diseases are associated with amyloid fibril formation. Inhibition of amyloid formation is of importance for therapeutics of the related diseases. However, the development of selective potent amyloid inhibitors remains challenging.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 259
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32341983",
          "text": "Several pathophysiological functions of the human β-amyloid precursor protein (APP) have been recently proposed in different human diseases such as neurodevelopmental and neurodegenerative disorders including rare diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, multiple sclerosis, Lesch-Nyhan disease; common and complex disorders such as Alzheimer's disease; metabolic disorders such as diabetes; and also cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 443
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32949547",
          "text": "Studies in experimental animals show transmissibility of amyloidogenic proteins associated with prion diseases, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 191
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31928731",
          "text": "Based on the collection of current findings, there is growing consensus that control of toxic amyloid oligomers could be a valid approach to regulate amyloid-associated toxicity, which could advance development of new diagnostics and therapeutics for amyloid-related diseases. In this review, we have described the recent scenario of amyloid diseases with a great deal of information about the recent understanding of oligomers' assembly, structural properties, and toxicity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 723,
          "end_section": "abstract",
          "offset_in_end_section": 1198
        }
      ],
      "ideal_answer": "Amyloid is associated with various diseases such as Alzheimer's disease, Parkinson's disease, type II diabetes, prion diseases, neurodevelopmental and neurodegenerative disorders, metabolic disorders, and certain types of cancer.",
      "exact_answer": [
        [
          "Alzheimer's disease"
        ],
        [
          "Parkinson's disease"
        ],
        [
          "Type II diabetes"
        ],
        [
          "Autism"
        ],
        [
          "Fragile X syndrome"
        ]
      ]
    },
    {
      "id": "660c0071fdcbea915f00002b",
      "type": "factoid",
      "body": "Which tick genus is the vector for Lyme disease?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/27836839",
        "https://pubmed.ncbi.nlm.nih.gov/2040556",
        "https://pubmed.ncbi.nlm.nih.gov/30106352",
        "https://pubmed.ncbi.nlm.nih.gov/3190092",
        "https://pubmed.ncbi.nlm.nih.gov/7043737",
        "https://pubmed.ncbi.nlm.nih.gov/20695287",
        "https://pubmed.ncbi.nlm.nih.gov/27147446",
        "https://pubmed.ncbi.nlm.nih.gov/31937369",
        "https://pubmed.ncbi.nlm.nih.gov/8862604",
        "https://pubmed.ncbi.nlm.nih.gov/15117014"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2040556",
          "text": "The Australian paralysis tick, Ixodes holocyclus, is a logical candidate vector of the Lyme disease spirochete in Australia; therefore, we tested the ability of I. holocyclus to acquire and maintain a North American isolate of B. burgdorferi. Larval I. holocyclus ingested spirochetes, but none of 84 derived nymphs were infected.",
          "begin_section": "abstract",
          "offset_in_begin_section": 225,
          "end_section": "abstract",
          "offset_in_end_section": 555
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2040556",
          "text": "The Australian paralysis tick, Ixodes holocyclus, is a logical candidate vector of the Lyme disease spirochete in Australia; therefore, we tested the ability of I. holocyclus to acquire and maintain a North American isolate of B. burgdorferi. Larval I. holocyclus ingested spirochetes, but none of 84 derived nymphs were infected. These experiments should be repeated with Australian strains of spirochetes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 225,
          "end_section": "abstract",
          "offset_in_end_section": 632
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27836839",
          "text": "IMPORTANCE\nLyme borreliosis is the most common vector-borne disease in the Northern Hemisphere and is caused by spirochete bacteria that belong to the Borrelia burgdorferi sensu lato species complex. These tick-borne pathogens are transmitted among vertebrate hosts by hard ticks of the genus Ixodes Each Borrelia species can be further subdivided into genetically distinct strains. Multiple-strain infections are common in both the vertebrate host and the tick vector and can result in competitive interactions.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1612,
          "end_section": "abstract",
          "offset_in_end_section": 2124
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27836839",
          "text": "IMPORTANCE\nLyme borreliosis is the most common vector-borne disease in the Northern Hemisphere and is caused by spirochete bacteria that belong to the Borrelia burgdorferi sensu lato species complex. These tick-borne pathogens are transmitted among vertebrate hosts by hard ticks of the genus Ixodes Each Borrelia species can be further subdivided into genetically distinct strains.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1612,
          "end_section": "abstract",
          "offset_in_end_section": 1994
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15117014",
          "text": "Identifying the vector of Lyme disease.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 39
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27836839",
          "text": "The spirochete abundance in the nymphal tick appears to be an important life history trait that explains why some strains are more common than others in nature. IMPORTANCE\nLyme borreliosis is the most common vector-borne disease in the Northern Hemisphere and is caused by spirochete bacteria that belong to the Borrelia burgdorferi sensu lato species complex. These tick-borne pathogens are transmitted among vertebrate hosts by hard ticks of the genus Ixodes Each Borrelia species can be further subdivided into genetically distinct strains.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1449,
          "end_section": "abstract",
          "offset_in_end_section": 1994
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31937369",
          "text": "CONCLUSIONS\nThis study identified species-specific vector traits as a potential driver of broad scale variation in Lyme disease risk in the USA. In particular, the exceedingly low rates of pathogen transmission from tick to host observed for I. pacificus may limit Lyme disease transmission efficiency in the western USA.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1818,
          "end_section": "abstract",
          "offset_in_end_section": 2139
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/3190092",
          "text": "Although many aspects of Lyme disease have been intensely studied for over a decade, little research has been directed toward control of the principal tick vector, Ixodes dammini. Ecological and epidemiological investigations have provided not only an ample understanding of tick biology and behavior, they have also identified the types of areas at risk for disease transmission. The advantages and limitations of previous attempts to control I. dammini by host reduction, habitat modification, and acaricide applications have been discussed in relation to overall control strategies for high-risk areas, and an integrated approach to control proposed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 653
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27836839",
          "text": "The spirochete abundance in the nymphal tick appears to be an important life history trait that explains why some strains are more common than others in nature. IMPORTANCE\nLyme borreliosis is the most common vector-borne disease in the Northern Hemisphere and is caused by spirochete bacteria that belong to the Borrelia burgdorferi sensu lato species complex.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1449,
          "end_section": "abstract",
          "offset_in_end_section": 1811
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31937369",
          "text": "Previous studies have identified vector phenology and behavior, host community composition, and landscape features as drivers of variable Lyme disease risk. However, while the Lyme disease transmission cycles in the eastern and western USA involve different vector species (Ixodes scapularis and Ixodes pacificus, respectively), the role of vector-specific differences in transmission efficiency has not been directly examined.",
          "begin_section": "abstract",
          "offset_in_begin_section": 149,
          "end_section": "abstract",
          "offset_in_end_section": 576
        }
      ],
      "ideal_answer": "The tick genus Ixodes is the vector for Lyme disease.",
      "exact_answer": [
        [
          "Ixodes"
        ]
      ]
    },
    {
      "id": "660c44f7fdcbea915f000033",
      "type": "yesno",
      "body": "Can lactate levels predict mortality in paediatric sepsis?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/32861227",
        "https://pubmed.ncbi.nlm.nih.gov/36377152",
        "https://pubmed.ncbi.nlm.nih.gov/33785937",
        "https://pubmed.ncbi.nlm.nih.gov/31265174",
        "https://pubmed.ncbi.nlm.nih.gov/30845747",
        "https://pubmed.ncbi.nlm.nih.gov/37072424",
        "https://pubmed.ncbi.nlm.nih.gov/28068437",
        "https://pubmed.ncbi.nlm.nih.gov/27380535",
        "https://pubmed.ncbi.nlm.nih.gov/35719429",
        "https://pubmed.ncbi.nlm.nih.gov/29595662"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32861227",
          "text": "AIM\nWe compared the performance of plasma lactate with high-sensitivity C-reactive protein (hs-CRP), and paediatric sepsis-related organ failure assessment (pSOFA) score for predicting mortality in septic children. METHODS\nSerial plasma lactate and hs-CRP levels and pSOFA score was assessed during early hospital stay in septic children. RESULTS\nOut of 149 participants, 45 died.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 384
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32861227",
          "text": "Early lactate measurements for predicting in-hospital mortality in paediatric sepsis.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 85
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29595662",
          "text": "Serum lactate is a useful biomarker to predict mortality in patients with sepsis. Lactate production is affected by the severity of sepsis, organ dysfunction, and adrenergic stimulation. Whether the predictive ability of serum lactate will be different between non-elderly and elderly patients is unknown.A retrospective cohort study was conducted to compare the prognostic value of hyperlactatemia in predicting the mortality between elderly (≥65 years) and non-elderly (<65 years) patients with sepsis.This is a single-center retrospective observational cohort study conducted from January 2007 to December 2013 in southern Taiwan.",
          "begin_section": "abstract",
          "offset_in_begin_section": 117,
          "end_section": "abstract",
          "offset_in_end_section": 750
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29595662",
          "text": "Lactate production is affected by the severity of sepsis, organ dysfunction, and adrenergic stimulation. Whether the predictive ability of serum lactate will be different between non-elderly and elderly patients is unknown.A retrospective cohort study was conducted to compare the prognostic value of hyperlactatemia in predicting the mortality between elderly (≥65 years) and non-elderly (<65 years) patients with sepsis.This is a single-center retrospective observational cohort study conducted from January 2007 to December 2013 in southern Taiwan. All patients with sepsis, who used antibiotics, with blood culture collected, and with available serum lactate levels in the emergency department, were included in the analysis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 199,
          "end_section": "abstract",
          "offset_in_end_section": 928
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29595662",
          "text": "Elderly people are more susceptible to sepsis and experience more comorbidities and complications than young adults. Serum lactate is a useful biomarker to predict mortality in patients with sepsis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 198
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29595662",
          "text": "Lactate production is affected by the severity of sepsis, organ dysfunction, and adrenergic stimulation. Whether the predictive ability of serum lactate will be different between non-elderly and elderly patients is unknown.A retrospective cohort study was conducted to compare the prognostic value of hyperlactatemia in predicting the mortality between elderly (≥65 years) and non-elderly (<65 years) patients with sepsis.This is a single-center retrospective observational cohort study conducted from January 2007 to December 2013 in southern Taiwan.",
          "begin_section": "abstract",
          "offset_in_begin_section": 199,
          "end_section": "abstract",
          "offset_in_end_section": 750
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36377152",
          "text": "CONCLUSIONS\nHigher blood lactate levels and lactate clearance of less than 10% at 6 hours of admission in nursery are significant predictors of mortality in neonatal sepsis. Early lactate stabilization and sepsis management can improve the clinical outcomes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1379,
          "end_section": "abstract",
          "offset_in_end_section": 1637
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29595662",
          "text": "Whether the predictive ability of serum lactate will be different between non-elderly and elderly patients is unknown.A retrospective cohort study was conducted to compare the prognostic value of hyperlactatemia in predicting the mortality between elderly (≥65 years) and non-elderly (<65 years) patients with sepsis.This is a single-center retrospective observational cohort study conducted from January 2007 to December 2013 in southern Taiwan. All patients with sepsis, who used antibiotics, with blood culture collected, and with available serum lactate levels in the emergency department, were included in the analysis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 304,
          "end_section": "abstract",
          "offset_in_end_section": 928
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32861227",
          "text": "AIM\nWe compared the performance of plasma lactate with high-sensitivity C-reactive protein (hs-CRP), and paediatric sepsis-related organ failure assessment (pSOFA) score for predicting mortality in septic children. METHODS\nSerial plasma lactate and hs-CRP levels and pSOFA score was assessed during early hospital stay in septic children.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 340
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29595662",
          "text": "Whether the predictive ability of serum lactate will be different between non-elderly and elderly patients is unknown.A retrospective cohort study was conducted to compare the prognostic value of hyperlactatemia in predicting the mortality between elderly (≥65 years) and non-elderly (<65 years) patients with sepsis.This is a single-center retrospective observational cohort study conducted from January 2007 to December 2013 in southern Taiwan. All patients with sepsis, who used antibiotics, with blood culture collected, and with available serum lactate levels in the emergency department, were included in the analysis. We evaluated the difference in serum lactate level between the elderly and non-elderly septic patients by using multiple regression models.A total of 7087 patients were enrolled in the study.",
          "begin_section": "abstract",
          "offset_in_begin_section": 304,
          "end_section": "abstract",
          "offset_in_end_section": 1120
        }
      ],
      "ideal_answer": "Yes, lactate levels can predict mortality in paediatric sepsis. Serial plasma lactate measurements have been shown to be a useful biomarker for predicting in-hospital mortality in septic children. Higher blood lactate levels and lactate clearance of less than 10% at 6 hours of admission have been identified as significant predictors of mortality in neonatal sepsis. Early lactate stabilization and effective sepsis management can improve clinical outcomes.",
      "exact_answer": "yes"
    },
    {
      "id": "65d136f41930410b1300003d",
      "type": "summary",
      "body": "What is the use of fezolinetant?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37974591",
        "https://pubmed.ncbi.nlm.nih.gov/37462862",
        "https://pubmed.ncbi.nlm.nih.gov/36897180",
        "https://pubmed.ncbi.nlm.nih.gov/36924778",
        "https://pubmed.ncbi.nlm.nih.gov/36734148",
        "https://pubmed.ncbi.nlm.nih.gov/34048742",
        "https://pubmed.ncbi.nlm.nih.gov/31415087",
        "https://pubmed.ncbi.nlm.nih.gov/34000049",
        "https://pubmed.ncbi.nlm.nih.gov/33724119",
        "https://pubmed.ncbi.nlm.nih.gov/32769757"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34048742",
          "text": "Ovariectomized rats exhibited several typical menopausal symptoms: hyperphagia, increased body weight, significantly decreased plasma estradiol levels, increased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and significantly increased skin temperature. Increased c-Fos expression (an indirect marker of neuronal activity) in median preoptic nucleus (MnPO) hypothalamic neurons was also observed in ovariectomized rats. Repeated oral administration of fezolinetant (1-10 mg/kg, twice daily) for 1 week dose-dependently reduced plasma LH levels without affecting estradiol or FSH levels, inhibited the activation of MnPO neurons, and attenuated hot flash-like symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 682,
          "end_section": "abstract",
          "offset_in_end_section": 1376
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34048742",
          "text": "We investigated the pharmacological effects of repeated administration of fezolinetant on levels of sex hormones and gonadotropins, neuronal activity in the hypothalamus, and skin temperature as an index of hot flash-like symptoms in ovariectomized rats as a model of menopause. Ovariectomized rats exhibited several typical menopausal symptoms: hyperphagia, increased body weight, significantly decreased plasma estradiol levels, increased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and significantly increased skin temperature. Increased c-Fos expression (an indirect marker of neuronal activity) in median preoptic nucleus (MnPO) hypothalamic neurons was also observed in ovariectomized rats.",
          "begin_section": "abstract",
          "offset_in_begin_section": 403,
          "end_section": "abstract",
          "offset_in_end_section": 1127
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33724119",
          "text": "Introduction: Although international clinical practice guidelines recognize a continued role for menopausal hormone therapy (HT), particularly for symptomatic women <60 years of age or within 10 years of menopause, safety and tolerability concerns have discouraged HT use due to potential links with a perceived increased risk of hormone-dependent cancers, and an established risk of stroke and venous thromboembolism. There is therefore a need for safe, effective non-hormonal therapy for relief of menopausal vasomotor symptoms (VMS).Areas covered: This narrative review summarizes the dataset accrued for fezolinetant, a neurokinin-3 receptor (NK3R) antagonist in clinical development for menopause-associated VMS.Expert opinion: Altered signaling in neuroendocrine circuits at menopause leads to VMS wherein NK3R activity plays a key role to modulate the thermoregulatory center in a manner conducive to triggering the 'hot flash' response.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 944
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33724119",
          "text": "Introduction: Although international clinical practice guidelines recognize a continued role for menopausal hormone therapy (HT), particularly for symptomatic women <60 years of age or within 10 years of menopause, safety and tolerability concerns have discouraged HT use due to potential links with a perceived increased risk of hormone-dependent cancers, and an established risk of stroke and venous thromboembolism. There is therefore a need for safe, effective non-hormonal therapy for relief of menopausal vasomotor symptoms (VMS).Areas covered: This narrative review summarizes the dataset accrued for fezolinetant, a neurokinin-3 receptor (NK3R) antagonist in clinical development for menopause-associated VMS.Expert opinion: Altered signaling in neuroendocrine circuits at menopause leads to VMS wherein NK3R activity plays a key role to modulate the thermoregulatory center in a manner conducive to triggering the 'hot flash' response. Thus, a new generation of NK3R antagonists has entered clinical development to specifically target the mechanistic basis of VMS.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 1073
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33724119",
          "text": "NK3R antagonists offer a non-hormonal alternative to HT for the treatment of menopause-related VMS.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1326,
          "end_section": "abstract",
          "offset_in_end_section": 1425
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36734148",
          "text": "For VMS severity, W4: 30 mg, -0.15 (0.06; P < .05); 45 mg, -0.29 (0.06; P < .001); W12: 30 mg, -0.16 (0.08; P < .05); 45 mg, -0.29 (0.08; P < .001). Improvement in VMS frequency and severity was observed by W1 and maintained through W52. Serious treatment-emergent adverse events were infrequent, reported by 2%, 1%, and 0% of those receiving fezolinetant 30 mg, fezolinetant 45 mg, and placebo, respectively.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1108,
          "end_section": "abstract",
          "offset_in_end_section": 1517
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33724119",
          "text": "Results to date have demonstrated rapid and substantial reduction in VMS frequency and severity and associated improvements in health-related quality of life. NK3R antagonists offer a non-hormonal alternative to HT for the treatment of menopause-related VMS.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1167,
          "end_section": "abstract",
          "offset_in_end_section": 1425
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36924778",
          "text": "BACKGROUND\nNeurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in menopausal women as options are scarce for those who cannot or do not want to take hormone therapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 224
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37462862",
          "text": "Inhibiting NK3R-mediated signalling in the central nervous system is a non-hormonal strategy to modulate the activity of neurones that are associated with thermoregulation, thereby reducing the frequency and severity of VMS.",
          "begin_section": "abstract",
          "offset_in_begin_section": 239,
          "end_section": "abstract",
          "offset_in_end_section": 463
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37974591",
          "text": "Risks associated with hormone use may limit the use of this option in some patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1146,
          "end_section": "abstract",
          "offset_in_end_section": 1230
        }
      ],
      "ideal_answer": "Fezolinetant is a neurokinin-3 receptor (NK3R) antagonist used for the treatment of menopause-associated vasomotor symptoms (VMS). It offers a non-hormonal alternative to hormone therapy for relieving hot flashes and other menopausal symptoms.",
      "exact_answer": "n/a"
    },
    {
      "id": "65f7764fc4010b4d7800002f",
      "type": "list",
      "body": "Which gene mutations confer acquired resistance to anti-EGFR therapy in advance colorectal cancer?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/22722830",
        "https://pubmed.ncbi.nlm.nih.gov/37948593",
        "https://pubmed.ncbi.nlm.nih.gov/25993166",
        "https://pubmed.ncbi.nlm.nih.gov/24913799",
        "https://pubmed.ncbi.nlm.nih.gov/28002810",
        "https://pubmed.ncbi.nlm.nih.gov/26318427",
        "https://pubmed.ncbi.nlm.nih.gov/25293556",
        "https://pubmed.ncbi.nlm.nih.gov/23729478",
        "https://pubmed.ncbi.nlm.nih.gov/31228284",
        "https://pubmed.ncbi.nlm.nih.gov/36117191"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22722830",
          "text": "Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK).",
          "begin_section": "abstract",
          "offset_in_begin_section": 536,
          "end_section": "abstract",
          "offset_in_end_section": 976
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22722830",
          "text": "The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK).",
          "begin_section": "abstract",
          "offset_in_begin_section": 435,
          "end_section": "abstract",
          "offset_in_end_section": 976
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25993166",
          "text": "Our understanding of the genetic and nongenetic molecular alterations associated with anti-epidermal growth factor receptor (EGFR) therapy resistance in colorectal cancer (CRC) has markedly expanded in recent years. Mutations in RAS genes (KRAS/NRAS exons 2, 3, or 4) predict a lack of clinical benefit when anti-EGFR monoclonal antibodies (mAbs) are added to chemotherapy. Genetic events in additional nodes of the mitogen-activated protein kinase (MAPK)-phosphoinositide 3-kinase (PI3K) pathways that bypass EGFR signaling, such as BRAF or PIK3CA mutations or KRAS, ERBB2, or MET amplifications, also may confer resistance to cetuximab or panitumumab.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 653
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25993166",
          "text": "Our understanding of the genetic and nongenetic molecular alterations associated with anti-epidermal growth factor receptor (EGFR) therapy resistance in colorectal cancer (CRC) has markedly expanded in recent years. Mutations in RAS genes (KRAS/NRAS exons 2, 3, or 4) predict a lack of clinical benefit when anti-EGFR monoclonal antibodies (mAbs) are added to chemotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 373
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24913799",
          "text": "Acquired resistance to EGFR-targeted therapies in colorectal cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 68
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22722830",
          "text": "The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers.",
          "begin_section": "abstract",
          "offset_in_begin_section": 435,
          "end_section": "abstract",
          "offset_in_end_section": 727
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22722830",
          "text": "After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug. The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers.",
          "begin_section": "abstract",
          "offset_in_begin_section": 316,
          "end_section": "abstract",
          "offset_in_end_section": 727
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22722830",
          "text": "Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases.",
          "begin_section": "abstract",
          "offset_in_begin_section": 536,
          "end_section": "abstract",
          "offset_in_end_section": 1202
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25293556",
          "text": "SIGNIFICANCE\nAnti-EGFR-targeted therapies are used for the treatment of metastatic colorectal cancer. Molecular heterogeneity impairs their efficacy by fuelling de novo and acquired resistance. In this review, we highlight how genetically distinct resistance mechanisms biochemically converge on a limited number of signaling pathways that can be therapeutically intercepted.",
          "begin_section": "abstract",
          "offset_in_begin_section": 745,
          "end_section": "abstract",
          "offset_in_end_section": 1120
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22722830",
          "text": "Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers.",
          "begin_section": "abstract",
          "offset_in_begin_section": 536,
          "end_section": "abstract",
          "offset_in_end_section": 727
        }
      ],
      "ideal_answer": "Mutations in the KRAS gene are known to confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer.",
      "exact_answer": [
        [
          "KRAS"
        ],
        [
          "BRAF"
        ],
        [
          "PIK3CA"
        ],
        [
          "ERBB2"
        ],
        [
          "MET"
        ]
      ]
    },
    {
      "id": "66080f4cfdcbea915f000004",
      "type": "list",
      "body": "List the methods for pectus excavatum repair?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/21670676",
        "https://pubmed.ncbi.nlm.nih.gov/16899852",
        "https://pubmed.ncbi.nlm.nih.gov/29078501",
        "https://pubmed.ncbi.nlm.nih.gov/12062277",
        "https://pubmed.ncbi.nlm.nih.gov/12077778",
        "https://pubmed.ncbi.nlm.nih.gov/28363366",
        "https://pubmed.ncbi.nlm.nih.gov/26744495",
        "https://pubmed.ncbi.nlm.nih.gov/16089123",
        "https://pubmed.ncbi.nlm.nih.gov/25754479",
        "https://pubmed.ncbi.nlm.nih.gov/12632353"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12062277",
          "text": "OBJECTIVE\nWe report our initial 3 years 4 months' single institution experience in 31 consecutive patients with pectus excavatum treated with minimally invasive endoscopic pectus excavatum repair utilizing a modification of the 'Nuss' technique. METHODS\nUnder general anesthesia, a curved steel bar is individually shaped for each patient to match the ideal chest wall shape and is placed through an endoscopically created retrosternal tunnel between two bilateral midaxillary line 2-cm incisions.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 499
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16899852",
          "text": "METHODS\nStudies were retrieved via computerized literature searches, cross-referencing from original and review articles, and a review of the reference list by a recognized authority in the area of pectus excavatum repair. The inclusion criteria were as follows: (1) reporting quantitative measures of preoperative and postoperative cardiovascular function; (2) published in the English language; (3) indexed between January 1960 and May 2005; (4) reporting the duration between which preoperative and postoperative assessments were conducted; and (5) describing the cardiovascular assessment procedures.",
          "begin_section": "abstract",
          "offset_in_begin_section": 763,
          "end_section": "abstract",
          "offset_in_end_section": 1367
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16899852",
          "text": "METHODS\nStudies were retrieved via computerized literature searches, cross-referencing from original and review articles, and a review of the reference list by a recognized authority in the area of pectus excavatum repair.",
          "begin_section": "abstract",
          "offset_in_begin_section": 763,
          "end_section": "abstract",
          "offset_in_end_section": 985
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/26744495",
          "text": "OBJECTIVE\nWe aimed to assess the clinical outcomes of our surgical technique for repair of pectus excavatum using Prolene polypropylene mesh. METHODS\nAmong 29 patients with pectus excavatum, the major complaint was cosmetic dissatisfaction, and the main symptom was exercise dyspnea in 15 patients. The Haller index used to assess pectus excavatum severity; it was significant in 22 patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 394
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/26744495",
          "text": "OBJECTIVE\nWe aimed to assess the clinical outcomes of our surgical technique for repair of pectus excavatum using Prolene polypropylene mesh. METHODS\nAmong 29 patients with pectus excavatum, the major complaint was cosmetic dissatisfaction, and the main symptom was exercise dyspnea in 15 patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 300
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12062277",
          "text": "OBJECTIVE\nWe report our initial 3 years 4 months' single institution experience in 31 consecutive patients with pectus excavatum treated with minimally invasive endoscopic pectus excavatum repair utilizing a modification of the 'Nuss' technique. METHODS\nUnder general anesthesia, a curved steel bar is individually shaped for each patient to match the ideal chest wall shape and is placed through an endoscopically created retrosternal tunnel between two bilateral midaxillary line 2-cm incisions. The tunnels initially go along the outside of the rib cage, under the pectoral muscles.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 587
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12077778",
          "text": "The minimally invasive (MIS) bar repair for the correction of pectus excavatum has been gaining acceptance. This study evaluates the authors results with patients who have undergone the MIS bar repair for redo correction of their pectus excavatum. METHODS\nA retrospective chart review of all patients undergoing MIS bar repair between December 1997 and August 2001 was performed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 324,
          "end_section": "abstract",
          "offset_in_end_section": 705
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28363366",
          "text": "Pectus carinatum is much less frequent than pectus excavatum. Over the past decade surgery has largely been replaced by compression techniques that use a brace, and cosmetic results are good. Rare combinations of pectus excavatum and carinatum may be treated by newer surgical methods.",
          "begin_section": "abstract",
          "offset_in_begin_section": 374,
          "end_section": "abstract",
          "offset_in_end_section": 659
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16899852",
          "text": "METHODS\nStudies were retrieved via computerized literature searches, cross-referencing from original and review articles, and a review of the reference list by a recognized authority in the area of pectus excavatum repair. The inclusion criteria were as follows: (1) reporting quantitative measures of preoperative and postoperative cardiovascular function; (2) published in the English language; (3) indexed between January 1960 and May 2005; (4) reporting the duration between which preoperative and postoperative assessments were conducted; and (5) describing the cardiovascular assessment procedures. RESULTS\nA comprehensive search of the literature identified eight studies that met all of the inclusion criteria.",
          "begin_section": "abstract",
          "offset_in_begin_section": 763,
          "end_section": "abstract",
          "offset_in_end_section": 1483
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25754479",
          "text": "Redo open repair (Highly Modified Ravitch Repair, HMRR) or minimally invasive repair of pectus excavatum (MIRPE) are usually performed in indicated cases. This paper focuses on the evaluation of available redo surgical techniques in adult and adolescent patients with recurrent pectus excavatum. METHODS\n126 operative corrections, predominantly in adult patients, were performed by the authors between June 2006 and October 2014.",
          "begin_section": "abstract",
          "offset_in_begin_section": 100,
          "end_section": "abstract",
          "offset_in_end_section": 531
        }
      ],
      "ideal_answer": "The methods for pectus excavatum repair include:\n\n1. Minimally Invasive Repair: This technique involves the use of a curved steel bar that is individually shaped for each patient and placed through an endoscopically created retrosternal tunnel between two bilateral midaxillary line incisions.\n\n2. Nuss Technique: This is a modification of the minimally invasive repair method, where a curved steel bar is used to reshape the chest wall and correct the deformity.\n\n3. Highly Modified Ravitch Repair: This is an open surgical technique that involves the removal of abnormal cartilage and ribs, followed by reshaping of the chest wall using sutures and/or prosthetic materials.\n\n4. Prolene Polypropylene Mesh Repair: This technique involves the use of a mesh made of polypropylene to provide support and stability to the chest wall.\n\n5. Compression Techniques: In some cases, compression techniques using a brace may be used to correct the deformity, particularly in cases of pectus carinatum.\n\nIt is important to note that the choice of repair method depends on the severity of the pectus excavatum, patient factors, and surgeon preference.",
      "exact_answer": [
        [
          "Minimally invasive endoscopic pectus excavatum repair"
        ],
        [
          "Modification of the 'Nuss' technique"
        ],
        [
          "Placement of a curved steel bar through an endoscopically created retrosternal tunnel"
        ],
        [
          "Use of Prolene polypropylene mesh"
        ],
        [
          "Redo open repair (Highly Modified Ravitch Repair, HMRR)"
        ]
      ]
    },
    {
      "id": "660d27e3fdcbea915f000039",
      "type": "summary",
      "body": "Impact of pollution on asthma.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/32867076",
        "https://pubmed.ncbi.nlm.nih.gov/34586983",
        "https://pubmed.ncbi.nlm.nih.gov/29602620",
        "https://pubmed.ncbi.nlm.nih.gov/31685409",
        "https://pubmed.ncbi.nlm.nih.gov/37496874",
        "https://pubmed.ncbi.nlm.nih.gov/37369742",
        "https://pubmed.ncbi.nlm.nih.gov/21598643",
        "https://pubmed.ncbi.nlm.nih.gov/20427579",
        "https://pubmed.ncbi.nlm.nih.gov/34136769",
        "https://pubmed.ncbi.nlm.nih.gov/29493555"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37496874",
          "text": "Impact of Air Pollution on Asthma: A Scoping Review.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 52
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34586983",
          "text": "Impact of Air Pollution on Daily Asthma Symptoms.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 49
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34586983",
          "text": "INTRODUCTION\nThe impact of air pollution on respiratory diseases, particularly in asthma, has been the subject of several studies.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 130
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32867076",
          "text": "Evidence suggests that air pollution has a negative impact on asthma outcomes in both adult and pediatric populations.",
          "begin_section": "abstract",
          "offset_in_begin_section": 143,
          "end_section": "abstract",
          "offset_in_end_section": 261
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34586983",
          "text": "The impact of pollution on the daily symptoms of patients with asthma has been less studied.",
          "begin_section": "abstract",
          "offset_in_begin_section": 131,
          "end_section": "abstract",
          "offset_in_end_section": 223
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21598643",
          "text": "The impact of ambient air pollution on the prevalence of main symptoms of asthma was analyzed in children. A total of 3,506 children were interviewed using the ISAAC questionnaire.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 180
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32867076",
          "text": "Other indoor pollutants such as heating sources and molds can also negatively impact the course of asthma.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1072,
          "end_section": "abstract",
          "offset_in_end_section": 1178
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32867076",
          "text": "Asthma is a chronic respiratory disease characterized by variable airflow obstruction, bronchial hyperresponsiveness, and airway inflammation. Evidence suggests that air pollution has a negative impact on asthma outcomes in both adult and pediatric populations.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 261
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21598643",
          "text": "The impact of ambient air pollution on the prevalence of main symptoms of asthma was analyzed in children.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 106
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21598643",
          "text": "[Impact of ambient air pollution on the prevalence of main symptoms of asthma in children].",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 91
        }
      ],
      "ideal_answer": "Air pollution has a negative impact on asthma outcomes in both adult and pediatric populations. Studies have shown that ambient air pollution can increase the prevalence of main symptoms of asthma in children. Other indoor pollutants, such as heating sources and molds, can also negatively impact the course of asthma.",
      "exact_answer": "n/a"
    },
    {
      "id": "660c3591fdcbea915f000031",
      "type": "yesno",
      "body": "Do elevated levels of procalcitonin help in diagnosing paediatric sepsis?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/30201367",
        "https://pubmed.ncbi.nlm.nih.gov/28794881",
        "https://pubmed.ncbi.nlm.nih.gov/25319789",
        "https://pubmed.ncbi.nlm.nih.gov/35198634",
        "https://pubmed.ncbi.nlm.nih.gov/31974673",
        "https://pubmed.ncbi.nlm.nih.gov/17632669",
        "https://pubmed.ncbi.nlm.nih.gov/29967823",
        "https://pubmed.ncbi.nlm.nih.gov/28911289",
        "https://pubmed.ncbi.nlm.nih.gov/16896823",
        "https://pubmed.ncbi.nlm.nih.gov/21299364"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16896823",
          "text": "Despite the higher cutoff level for paediatric patients, a trend towards greater sensitivity existed in children (0.96 vs. 0.90; p=0.08). Elevated procalcitonin was correlated with whole blood meningococcal load (r=0.50) and Glasgow Meningococcal Sepsis Prognostic Score (r=0.40). Within the cohort of patients who were febrile on presentation (cohort B), the specificity of elevated procalcitonin in meningococcal disease was 0.85 (95% CI: 0.83-0.87), the positive and negative likelihood ratios were 6.1 and 0.08, respectively, and the sensitivity of elevated procalcitonin (0.93; 95% CI: 0.76-0.99) was corroborated.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1062,
          "end_section": "abstract",
          "offset_in_end_section": 1681
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16896823",
          "text": "Despite the higher cutoff level for paediatric patients, a trend towards greater sensitivity existed in children (0.96 vs. 0.90; p=0.08). Elevated procalcitonin was correlated with whole blood meningococcal load (r=0.50) and Glasgow Meningococcal Sepsis Prognostic Score (r=0.40).",
          "begin_section": "abstract",
          "offset_in_begin_section": 1062,
          "end_section": "abstract",
          "offset_in_end_section": 1342
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28911289",
          "text": "Procalcitonin (PCT) and presepsin (PSEP) are useful biomarkers for diagnosing sepsis; however, elevated PCT and PSEP levels may be observed in conditions other than sepsis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 172
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28911289",
          "text": "Procalcitonin (PCT) and presepsin (PSEP) are useful biomarkers for diagnosing sepsis; however, elevated PCT and PSEP levels may be observed in conditions other than sepsis. We hypothesised that PCT and PSEP levels could increase after severe traumatic injuries.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 261
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28911289",
          "text": "Procalcitonin (PCT) and presepsin (PSEP) are useful biomarkers for diagnosing sepsis; however, elevated PCT and PSEP levels may be observed in conditions other than sepsis. We hypothesised that PCT and PSEP levels could increase after severe traumatic injuries. Trauma patients with an Injury Severity Score of ≥16 from October 2013 to September 2015 were enrolled in our study.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 378
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16896823",
          "text": "The overall sensitivity of elevated procalcitonin, using a cutoff of 2.0 ng/ml in children and 0.5 ng/ml in adults, was 0.93 (95%CI: 0.88-0.96). Despite the higher cutoff level for paediatric patients, a trend towards greater sensitivity existed in children (0.96 vs. 0.90; p=0.08). Elevated procalcitonin was correlated with whole blood meningococcal load (r=0.50) and Glasgow Meningococcal Sepsis Prognostic Score (r=0.40).",
          "begin_section": "abstract",
          "offset_in_begin_section": 917,
          "end_section": "abstract",
          "offset_in_end_section": 1342
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28794881",
          "text": "Beside this, the procalcitonin levels can be used for monitoring response to antimicrobial therapy, diagnosis of secondary inflammations, diagnosis of renal involvement in paediatric urinary tract infection, etc. The present article summarizes the relevance of procalcitonin in the diagnosis of sepsis and how it can be useful in determining the therapeutic approaches.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1073,
          "end_section": "abstract",
          "offset_in_end_section": 1442
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25319789",
          "text": "Many studies have demonstrated the value of procalcitonin levels for diagnosing sepsis and assessing disease severity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 456,
          "end_section": "abstract",
          "offset_in_end_section": 574
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29967823",
          "text": "CONCLUSIONS\nThe procalcitonin levels are highly correlated with the severity scores (APACHE II, SAPS II, SOFA) regularly used in ICUs and therefore can be used for determining the severity of the septic process. Quantitive procalcitonin and C-reactive protein analysis was not shown to be useful in diagnosing severe sepsis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1833,
          "end_section": "abstract",
          "offset_in_end_section": 2157
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28794881",
          "text": "Rapid elevation in the concentration of procalcitonin and other newly emerging biomarkers during an infection and its correlation with severity of illness makes it an ideal biomarker for bacterial infection. Beside this, the procalcitonin levels can be used for monitoring response to antimicrobial therapy, diagnosis of secondary inflammations, diagnosis of renal involvement in paediatric urinary tract infection, etc. The present article summarizes the relevance of procalcitonin in the diagnosis of sepsis and how it can be useful in determining the therapeutic approaches.",
          "begin_section": "abstract",
          "offset_in_begin_section": 865,
          "end_section": "abstract",
          "offset_in_end_section": 1442
        }
      ],
      "ideal_answer": "Yes, elevated levels of procalcitonin can help in diagnosing pediatric sepsis. Procalcitonin is a biomarker that is released in response to bacterial infection, and its levels are often elevated in sepsis. Studies have shown that procalcitonin levels have a high sensitivity and specificity for diagnosing sepsis in pediatric patients. It can be used as a valuable tool in conjunction with clinical assessment to aid in the diagnosis of pediatric sepsis.",
      "exact_answer": "yes"
    },
    {
      "id": "65cfd7981930410b13000022",
      "type": "summary",
      "body": "What is the mechanism of action of Zilebesiran?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37467498",
        "https://pubmed.ncbi.nlm.nih.gov/32019718",
        "https://pubmed.ncbi.nlm.nih.gov/37897397",
        "https://pubmed.ncbi.nlm.nih.gov/32277300",
        "https://pubmed.ncbi.nlm.nih.gov/7608321",
        "https://pubmed.ncbi.nlm.nih.gov/22431851",
        "https://pubmed.ncbi.nlm.nih.gov/2009967",
        "https://pubmed.ncbi.nlm.nih.gov/12238801",
        "https://pubmed.ncbi.nlm.nih.gov/8242892",
        "https://pubmed.ncbi.nlm.nih.gov/37706295"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37467498",
          "text": "Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis. METHODS\nIn this phase 1 study, patients with hypertension were randomly assigned in a 2:1 ratio to receive either a single ascending subcutaneous dose of zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg) or placebo and were followed for 24 weeks (Part A).",
          "begin_section": "abstract",
          "offset_in_begin_section": 129,
          "end_section": "abstract",
          "offset_in_end_section": 535
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37467498",
          "text": "Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis. METHODS\nIn this phase 1 study, patients with hypertension were randomly assigned in a 2:1 ratio to receive either a single ascending subcutaneous dose of zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg) or placebo and were followed for 24 weeks (Part A). Part B assessed the effect of the 800-mg dose of zilebesiran on blood pressure under low- or high-salt diet conditions, and Part E the effect of that dose when coadministered with irbesartan.",
          "begin_section": "abstract",
          "offset_in_begin_section": 129,
          "end_section": "abstract",
          "offset_in_end_section": 727
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37467498",
          "text": "BACKGROUND\nAngiotensinogen is the sole precursor of angiotensin peptides and has a key role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis. METHODS\nIn this phase 1 study, patients with hypertension were randomly assigned in a 2:1 ratio to receive either a single ascending subcutaneous dose of zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg) or placebo and were followed for 24 weeks (Part A).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 535
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37467498",
          "text": "Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 129,
          "end_section": "abstract",
          "offset_in_end_section": 276
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37897397",
          "text": "AREAS COVERED\nThis article describes the molecular basis for durability over months and the 24-h tonic target inhibition observed after one administration. We present an analysis of the published phase I trials using zilebesiran, a siRNA targeting hepatic angiotensinogen, which reduces blood pressure (BP) by up to 20 mmHg, lasting 24 weeks. Finally, we examine data evaluating reversibility of angiotensinogen knockdown and its relevance to the future clinical utility of zilebesiran.",
          "begin_section": "abstract",
          "offset_in_begin_section": 580,
          "end_section": "abstract",
          "offset_in_end_section": 1066
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37897397",
          "text": "An advantage of zilebesiran is the potential for bi-annual dosing, thereby reducing nonadherence and improving control rates. It may also reduce nighttime BP due to 24-h tonic control.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1192,
          "end_section": "abstract",
          "offset_in_end_section": 1376
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37706295",
          "text": "Indeed, zilebesiran has an impressive and durable effect on systolic BP, reduced by up to 20 mm Hg and sustained for 6 months after a single administration, likely due to its very effective knockdown of angiotensinogen, without causing acute kidney injury or hyperkalemia.",
          "begin_section": "abstract",
          "offset_in_begin_section": 970,
          "end_section": "abstract",
          "offset_in_end_section": 1242
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37897397",
          "text": "We present an analysis of the published phase I trials using zilebesiran, a siRNA targeting hepatic angiotensinogen, which reduces blood pressure (BP) by up to 20 mmHg, lasting 24 weeks. Finally, we examine data evaluating reversibility of angiotensinogen knockdown and its relevance to the future clinical utility of zilebesiran. EXPERT OPINION\nFurther studies should assess safety, efficacy, and outcomes in larger, more broadly representative groups.",
          "begin_section": "abstract",
          "offset_in_begin_section": 736,
          "end_section": "abstract",
          "offset_in_end_section": 1191
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37897397",
          "text": "We present an analysis of the published phase I trials using zilebesiran, a siRNA targeting hepatic angiotensinogen, which reduces blood pressure (BP) by up to 20 mmHg, lasting 24 weeks. Finally, we examine data evaluating reversibility of angiotensinogen knockdown and its relevance to the future clinical utility of zilebesiran.",
          "begin_section": "abstract",
          "offset_in_begin_section": 736,
          "end_section": "abstract",
          "offset_in_end_section": 1066
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37897397",
          "text": "EXPERT OPINION\nFurther studies should assess safety, efficacy, and outcomes in larger, more broadly representative groups. An advantage of zilebesiran is the potential for bi-annual dosing, thereby reducing nonadherence and improving control rates. It may also reduce nighttime BP due to 24-h tonic control.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1069,
          "end_section": "abstract",
          "offset_in_end_section": 1376
        }
      ],
      "ideal_answer": "Zilebesiran is an investigational RNA interference therapeutic agent that inhibits hepatic angiotensinogen synthesis. It reduces blood pressure by effectively knocking down angiotensinogen, the precursor of angiotensin peptides. This inhibition leads to a sustained and durable effect on systolic blood pressure, lasting up to 24 weeks after a single administration.",
      "exact_answer": "n/a"
    },
    {
      "id": "65f77ac9c4010b4d7800003c",
      "type": "summary",
      "body": "Why does inflammatory bowel disease predispose to colorectal cancer?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/17120688",
        "https://pubmed.ncbi.nlm.nih.gov/24463282",
        "https://pubmed.ncbi.nlm.nih.gov/17952155",
        "https://pubmed.ncbi.nlm.nih.gov/15703619",
        "https://pubmed.ncbi.nlm.nih.gov/22122774",
        "https://pubmed.ncbi.nlm.nih.gov/10223754",
        "https://pubmed.ncbi.nlm.nih.gov/32268844",
        "https://pubmed.ncbi.nlm.nih.gov/8946611",
        "https://pubmed.ncbi.nlm.nih.gov/24597349",
        "https://pubmed.ncbi.nlm.nih.gov/27003989"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22122774",
          "text": "Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents have been considered potential chemopreventive agents. As present no agents have been shown to have indisputable chemopreventive activity in IBD but 5-ASAs and thiopurine analogues by reducing inflammation are likely to have some chemopreventive activity and will often be indicated for disease control.",
          "begin_section": "abstract",
          "offset_in_begin_section": 580,
          "end_section": "abstract",
          "offset_in_end_section": 1025
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15703619",
          "text": "PURPOSE OF REVIEW\nPatients with inflammatory bowel disease, either Crohn disease or ulcerative colitis, are at an increased risk for developing colorectal carcinoma. RECENT FINDINGS\nSurveillance colonoscopy, although never formally evaluated in a prospective controlled trial, is performed in an effort to reduce this risk.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 325
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22122774",
          "text": "Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents have been considered potential chemopreventive agents. As present no agents have been shown to have indisputable chemopreventive activity in IBD but 5-ASAs and thiopurine analogues by reducing inflammation are likely to have some chemopreventive activity and will often be indicated for disease control. More studies are needed using agents such as aspirin and calcium which have been shown to be chemopreventive in sporadic colorectal neoplasia.",
          "begin_section": "abstract",
          "offset_in_begin_section": 580,
          "end_section": "abstract",
          "offset_in_end_section": 1168
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15703619",
          "text": "PURPOSE OF REVIEW\nPatients with inflammatory bowel disease, either Crohn disease or ulcerative colitis, are at an increased risk for developing colorectal carcinoma. RECENT FINDINGS\nSurveillance colonoscopy, although never formally evaluated in a prospective controlled trial, is performed in an effort to reduce this risk. Novel methods of detecting dysplasia are constantly being evaluated, including chromoendoscopy and biomarkers of carcinoma, in an attempt to stratify patients who are at a higher risk of developing high-grade dysplasia or carcinoma.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 558
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32268844",
          "text": "Until recently, understanding of pathogenesis in inflammatory bowel disease-associated colorectal cancer was restricted to the demonstration of chromosomic/microsatellite instabilities and aneuploidy. The advance of high-throughput sequencing technologies has highlighted the complexity of the pathobiology and revealed recurrently mutated genes involved in the RTK/RAS, PI3K, WNT, and TGFβ pathways, leading to potentially new targetable mutations. Moreover, alterations of mitochondrial DNA and the dysregulation of non-coding sequences have also been described, as well as several epigenetic modifications.",
          "begin_section": "abstract",
          "offset_in_begin_section": 144,
          "end_section": "abstract",
          "offset_in_end_section": 753
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/10223754",
          "text": "However, despite adoption of colonoscopic surveillance programs by many clinicians, we have noted a pattern of continued referrals for inflammatory bowel disease-associated malignancy. This study was undertaken in an effort to characterize this cohort of patients. METHODS\nWe reviewed the operative records of a large metropolitan colorectal practice from 1983 to 1995.",
          "begin_section": "abstract",
          "offset_in_begin_section": 237,
          "end_section": "abstract",
          "offset_in_end_section": 608
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22122774",
          "text": "Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents have been considered potential chemopreventive agents.",
          "begin_section": "abstract",
          "offset_in_begin_section": 580,
          "end_section": "abstract",
          "offset_in_end_section": 776
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27003989",
          "text": "Inflammatory bowel diseases are characterised by inflammation that compromises the integrity of the epithelial barrier.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 119
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27003989",
          "text": "Inflammatory bowel diseases are characterised by inflammation that compromises the integrity of the epithelial barrier. The intestinal epithelium is not only a static barrier but has evolved complex mechanisms to control and regulate bacterial interactions with the mucosal surface.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 282
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24463282",
          "text": "Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents such as the 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents.",
          "begin_section": "abstract",
          "offset_in_begin_section": 217,
          "end_section": "abstract",
          "offset_in_end_section": 468
        }
      ],
      "ideal_answer": "Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, predisposes to colorectal cancer due to the chronic inflammation and damage to the intestinal epithelium. The continuous inflammation in IBD leads to genetic and epigenetic alterations, dysregulation of cellular pathways (such as RTK/RAS, PI3K, WNT, and TGFβ), and increased risk of chromosomal/microsatellite instabilities and aneuploidy, which can promote the development of colorectal cancer. Anti-inflammatory agents, such as 5-aminosalicylates and immunomodulators, are considered potential chemopreventive agents in IBD to reduce inflammation and the risk of colorectal cancer.",
      "exact_answer": "n/a"
    },
    {
      "id": "66088ffafdcbea915f00000f",
      "type": "factoid",
      "body": "In what part of the body would a periprosthetic infection occur?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/36200815",
        "https://pubmed.ncbi.nlm.nih.gov/28270399",
        "https://pubmed.ncbi.nlm.nih.gov/23919098",
        "https://pubmed.ncbi.nlm.nih.gov/24352771",
        "https://pubmed.ncbi.nlm.nih.gov/23700179",
        "https://pubmed.ncbi.nlm.nih.gov/30373355",
        "https://pubmed.ncbi.nlm.nih.gov/26555186",
        "https://pubmed.ncbi.nlm.nih.gov/29559232",
        "https://pubmed.ncbi.nlm.nih.gov/35798868",
        "https://pubmed.ncbi.nlm.nih.gov/20839679"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28270399",
          "text": "Systemic tuberculosis infections are often known to occur following treatment with these biological agents. However, no case of periprosthetic tuberculous infection of the hip following this therapy has been reported.",
          "begin_section": "abstract",
          "offset_in_begin_section": 113,
          "end_section": "abstract",
          "offset_in_end_section": 330
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/26555186",
          "text": "Such a periprosthetic infection can appear long after the index joint replacement. This article points out that these same findings may occur with a non-infectious process initiated by polyethylene, cement or metal debris-detritic synovitis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 676,
          "end_section": "abstract",
          "offset_in_end_section": 917
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29559232",
          "text": "BACKGROUND\nPeriprosthetic joint infection is a major complication of total joint replacement surgery and is associated with significant morbidity, mortality and financial burden. Surgical body suits (space suits), originally designed to reduce the incidence of infection, have paradoxically been implicated in increased periprosthetic joint infection rates recently. Air exhausted from space suits may contribute to this increased rate of periprosthetic joint infection.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 470
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36200815",
          "text": "The incidences of periprosthetic fracture and periprosthetic joint infection after total hip arthroplasty are expected to increase exponentially over the coming decades. Epidemiologic data suggest that many periprosthetic fractures after THA occur concurrently with a loose femoral implant. Recent studies suggest an approximately 8% incidence of indolent infection in cases of suspected aseptic loosening.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 406
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29559232",
          "text": "BACKGROUND\nPeriprosthetic joint infection is a major complication of total joint replacement surgery and is associated with significant morbidity, mortality and financial burden. Surgical body suits (space suits), originally designed to reduce the incidence of infection, have paradoxically been implicated in increased periprosthetic joint infection rates recently.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 366
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28270399",
          "text": "Systemic tuberculosis infections are often known to occur following treatment with these biological agents. However, no case of periprosthetic tuberculous infection of the hip following this therapy has been reported. We report a case of a 45-year-old man who developed periprosthetic tuberculous infection soon after infliximab injection.",
          "begin_section": "abstract",
          "offset_in_begin_section": 113,
          "end_section": "abstract",
          "offset_in_end_section": 452
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24352771",
          "text": "RESULTS\nMortality was significantly greater (p < 0.001) in patients with periprosthetic joint infection compared with those undergoing aseptic revision arthroplasty at ninety days (3.7% versus 0.8%), one year (10.6% versus 2.0%), two years (13.6% versus 3.9%), and five years (25.9% versus 12.9%).",
          "begin_section": "abstract",
          "offset_in_begin_section": 1097,
          "end_section": "abstract",
          "offset_in_end_section": 1394
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36200815",
          "text": "The incidences of periprosthetic fracture and periprosthetic joint infection after total hip arthroplasty are expected to increase exponentially over the coming decades. Epidemiologic data suggest that many periprosthetic fractures after THA occur concurrently with a loose femoral implant.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 290
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36200815",
          "text": "Epidemiologic data suggest that many periprosthetic fractures after THA occur concurrently with a loose femoral implant. Recent studies suggest an approximately 8% incidence of indolent infection in cases of suspected aseptic loosening.",
          "begin_section": "abstract",
          "offset_in_begin_section": 170,
          "end_section": "abstract",
          "offset_in_end_section": 406
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36200815",
          "text": "Epidemiologic data suggest that many periprosthetic fractures after THA occur concurrently with a loose femoral implant. Recent studies suggest an approximately 8% incidence of indolent infection in cases of suspected aseptic loosening. The available data, therefore, suggest that periprosthetic fracture and infection may coexist, and this possibility should be considered, particularly in patients with a loose femoral stem and high pretest possibility.",
          "begin_section": "abstract",
          "offset_in_begin_section": 170,
          "end_section": "abstract",
          "offset_in_end_section": 625
        }
      ],
      "ideal_answer": "A periprosthetic infection can occur in the area surrounding a prosthetic joint, such as the hip, knee, or shoulder.",
      "exact_answer": [
        [
          "A periprosthetic infection can occur in the area surrounding a prosthetic joint."
        ]
      ]
    },
    {
      "id": "65f86b3ac4010b4d78000058",
      "type": "factoid",
      "body": "What is the estimated impact of social determinants of health on health outcomes?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/24532079",
        "https://pubmed.ncbi.nlm.nih.gov/36933920",
        "https://pubmed.ncbi.nlm.nih.gov/32294541",
        "https://pubmed.ncbi.nlm.nih.gov/35533798",
        "https://pubmed.ncbi.nlm.nih.gov/36933921",
        "https://pubmed.ncbi.nlm.nih.gov/31724414",
        "https://pubmed.ncbi.nlm.nih.gov/33720674",
        "https://pubmed.ncbi.nlm.nih.gov/37127378",
        "https://pubmed.ncbi.nlm.nih.gov/29480769",
        "https://pubmed.ncbi.nlm.nih.gov/31355958"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24532079",
          "text": "Based on the studies reviewed, social determinants have an impact on glycemic control, LDL, and blood pressure to varying degrees. The impact on cost and quality of life was not often measured, but when quality of life was investigated, it did show significance. More research is needed to better characterize the direct impact of social determinants of health on health outcomes in diabetes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1203,
          "end_section": "abstract",
          "offset_in_end_section": 1595
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24532079",
          "text": "No review exists summarizing the impact of social determinants of health outcomes in patients with type 2 diabetes. This systematic review examined whether social determinants of health have an impact on health outcomes in type 2 diabetes. Medline was searched for articles that (a) were published in English (b) targeted adults, ages 18 + years, (c) had a study population which was diagnosed with type 2 diabetes, (d) the study was done in the United States, and (e) the study measured at least one of the outcome measures-glycemic control, cholesterol (LDL), blood pressure, quality of life or cost.",
          "begin_section": "abstract",
          "offset_in_begin_section": 260,
          "end_section": "abstract",
          "offset_in_end_section": 862
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24532079",
          "text": "Based on the studies reviewed, social determinants have an impact on glycemic control, LDL, and blood pressure to varying degrees. The impact on cost and quality of life was not often measured, but when quality of life was investigated, it did show significance.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1203,
          "end_section": "abstract",
          "offset_in_end_section": 1465
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29480769",
          "text": "Additionally, the measures of social determinants of health were indicators taken from assessments that provided only rough estimates of the constructs rather than from established measures. Originality/value A better understanding of how these factors affect offenders can inform strategies to address correctional health issues and reduce the impact of chronic conditions through targeted correctional education and intervention programmes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1368,
          "end_section": "abstract",
          "offset_in_end_section": 1810
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29480769",
          "text": "Research limitations/implications The study is limited to the use of self-report data. Additionally, the measures of social determinants of health were indicators taken from assessments that provided only rough estimates of the constructs rather than from established measures. Originality/value A better understanding of how these factors affect offenders can inform strategies to address correctional health issues and reduce the impact of chronic conditions through targeted correctional education and intervention programmes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1281,
          "end_section": "abstract",
          "offset_in_end_section": 1810
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31724414",
          "text": "OBJECTIVE\nThe aim of this study was to develop a Social Determinants of Health Index for people with disabilities that utilizes personal outcomes. The Index is aimed at helping disability service providers examine the SDOH of those they support, to arm them with more information to provide targeted services and supports. METHOD\nWe ran an exploratory factor analysis of Personal Outcome Measures interviews with 1,078 people with disabilities from 2017 to compute composite scores for the factors underlying the model.",
          "begin_section": "abstract",
          "offset_in_begin_section": 307,
          "end_section": "abstract",
          "offset_in_end_section": 828
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29480769",
          "text": "Two social determinants factors in particular were consistently related to the health of offenders, a history of childhood abuse, and the use of social assistance. Research limitations/implications The study is limited to the use of self-report data. Additionally, the measures of social determinants of health were indicators taken from assessments that provided only rough estimates of the constructs rather than from established measures.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1117,
          "end_section": "abstract",
          "offset_in_end_section": 1558
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29480769",
          "text": "Additionally, the measures of social determinants of health were indicators taken from assessments that provided only rough estimates of the constructs rather than from established measures.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1368,
          "end_section": "abstract",
          "offset_in_end_section": 1558
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24532079",
          "text": "Based on the studies reviewed, social determinants have an impact on glycemic control, LDL, and blood pressure to varying degrees.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1203,
          "end_section": "abstract",
          "offset_in_end_section": 1333
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24532079",
          "text": "This systematic review examined whether social determinants of health have an impact on health outcomes in type 2 diabetes. Medline was searched for articles that (a) were published in English (b) targeted adults, ages 18 + years, (c) had a study population which was diagnosed with type 2 diabetes, (d) the study was done in the United States, and (e) the study measured at least one of the outcome measures-glycemic control, cholesterol (LDL), blood pressure, quality of life or cost. Using a reproducible strategy, 2,110 articles were identified, and 61 were reviewed based on inclusion criteria.",
          "begin_section": "abstract",
          "offset_in_begin_section": 376,
          "end_section": "abstract",
          "offset_in_end_section": 975
        }
      ],
      "ideal_answer": "Based on the studies reviewed, social determinants of health have been found to have an impact on health outcomes in type 2 diabetes, including glycemic control, LDL cholesterol levels, blood pressure, and quality of life. The specific impact varies to some degree depending on the social determinants being studied. However, the impact on cost and quality of life is not often measured. It is important to note that the measures of social determinants of health used in these studies were often rough estimates rather than established measures. Further research is needed to better understand the direct impact of social determinants of health on health outcomes in diabetes.",
      "exact_answer": [
        [
          "Social determinants of health have been found to have an impact on health outcomes, including glycemic control, LDL cholesterol levels, blood pressure, quality of life, and cost in patients with type 2 diabetes. However, the degree of impact varies depending on the specific determinant and the individual's circumstances. More research is needed to better understand and characterize the direct impact of social determinants of health on health outcomes in diabetes."
        ]
      ]
    },
    {
      "id": "660c49f4fdcbea915f000034",
      "type": "yesno",
      "body": "Should corticosteroids be considered as adjunctive therapy in paediatric sepsis management?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/20228689",
        "https://pubmed.ncbi.nlm.nih.gov/20509841",
        "https://pubmed.ncbi.nlm.nih.gov/26950335",
        "https://pubmed.ncbi.nlm.nih.gov/20839148",
        "https://pubmed.ncbi.nlm.nih.gov/2661496",
        "https://pubmed.ncbi.nlm.nih.gov/33178370",
        "https://pubmed.ncbi.nlm.nih.gov/12476779",
        "https://pubmed.ncbi.nlm.nih.gov/19339885",
        "https://pubmed.ncbi.nlm.nih.gov/30798570",
        "https://pubmed.ncbi.nlm.nih.gov/23537672"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20228689",
          "text": "OBJECTIVE\nTo assess whether corticosteroids, used as adjunctive therapy for pediatric severe sepsis, is associated with improved outcomes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 138
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20228689",
          "text": "Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 98
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2661496",
          "text": "The use of high-dose corticosteroids as adjunctive therapy in septic states has been extensively debated in the literature, but no clear consensus has been reached. Main sites of action where corticosteroids can theoretically interfere with the pathophysiologic processes activated by sepsis have been identified. Early clinical studies and extensive animal research generated much enthusiasm for the use of steroids in sepsis and septic shock.",
          "begin_section": "abstract",
          "offset_in_begin_section": 125,
          "end_section": "abstract",
          "offset_in_end_section": 569
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2661496",
          "text": "The use of high-dose corticosteroids as adjunctive therapy in septic states has been extensively debated in the literature, but no clear consensus has been reached. Main sites of action where corticosteroids can theoretically interfere with the pathophysiologic processes activated by sepsis have been identified.",
          "begin_section": "abstract",
          "offset_in_begin_section": 125,
          "end_section": "abstract",
          "offset_in_end_section": 438
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2661496",
          "text": "Mortality from septic shock remains high, despite early diagnosis, comprehensive care and monitoring, and intensive therapy. The use of high-dose corticosteroids as adjunctive therapy in septic states has been extensively debated in the literature, but no clear consensus has been reached. Main sites of action where corticosteroids can theoretically interfere with the pathophysiologic processes activated by sepsis have been identified.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 438
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2661496",
          "text": "After re-examining the theoretical basis for the use of steroids, possible side effects, experimental results and clinical trials, it is concluded that, based upon current knowledge, high-dose corticosteroids should not be used as adjunctive therapy in human sepsis and septic shock.",
          "begin_section": "abstract",
          "offset_in_begin_section": 713,
          "end_section": "abstract",
          "offset_in_end_section": 996
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/26950335",
          "text": "Although we found that adjunctive corticosteroid therapy was associated with increased mortality, this result should be interpreted with caution. In the context of clinical trials of adjunctive corticosteroid therapy in sepsis and pneumonia that report improved outcomes, including decreased mortality, more high-quality research is needed (both RCTs and observational studies).",
          "begin_section": "abstract",
          "offset_in_begin_section": 3057,
          "end_section": "abstract",
          "offset_in_end_section": 3435
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20228689",
          "text": "No definitive improvement in outcomes can be attributable to adjunctive corticosteroid therapy in the largest pediatric sepsis trial conducted to date.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1824,
          "end_section": "abstract",
          "offset_in_end_section": 1975
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20509841",
          "text": "Corticosteroids have been proposed for decades as adjunctive therapy of severe infections.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 90
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/26950335",
          "text": "Although we found that adjunctive corticosteroid therapy was associated with increased mortality, this result should be interpreted with caution. In the context of clinical trials of adjunctive corticosteroid therapy in sepsis and pneumonia that report improved outcomes, including decreased mortality, more high-quality research is needed (both RCTs and observational studies). Currently, we do not have sufficient evidence in this review to determine the effectiveness of corticosteroids for patients with influenza.",
          "begin_section": "abstract",
          "offset_in_begin_section": 3057,
          "end_section": "abstract",
          "offset_in_end_section": 3575
        }
      ],
      "ideal_answer": "Based on current knowledge and available evidence, high-dose corticosteroids should not be considered as adjunctive therapy in pediatric sepsis management. The use of corticosteroids in septic states has been extensively debated, but no clear consensus has been reached. While early clinical studies and animal research generated enthusiasm for their use, more recent research has not shown definitive improvement in outcomes. In fact, some studies have even associated corticosteroid therapy with increased mortality. Therefore, until more high-quality research is conducted, corticosteroids should not be routinely used as adjunctive therapy in pediatric sepsis management.",
      "exact_answer": "no"
    },
    {
      "id": "65cfdc561930410b13000026",
      "type": "list",
      "body": "JYNNEOS vaccine is protective against which diseases?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37676838",
        "https://pubmed.ncbi.nlm.nih.gov/37339074",
        "https://pubmed.ncbi.nlm.nih.gov/37199451",
        "https://pubmed.ncbi.nlm.nih.gov/36480476",
        "https://pubmed.ncbi.nlm.nih.gov/37920899",
        "https://pubmed.ncbi.nlm.nih.gov/36344361",
        "https://pubmed.ncbi.nlm.nih.gov/36301741",
        "https://pubmed.ncbi.nlm.nih.gov/36201401",
        "https://pubmed.ncbi.nlm.nih.gov/36580416",
        "https://pubmed.ncbi.nlm.nih.gov/36480479"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36480479",
          "text": "This report provides additional data suggesting JYNNEOS vaccine provides protection against mpox, irrespective of whether the vaccine is administered intradermally or subcutaneously.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1952,
          "end_section": "abstract",
          "offset_in_end_section": 2134
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36480479",
          "text": "This report provides additional data suggesting JYNNEOS vaccine provides protection against mpox, irrespective of whether the vaccine is administered intradermally or subcutaneously. The degree and durability of such protection remains unclear.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1952,
          "end_section": "abstract",
          "offset_in_end_section": 2196
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37199451",
          "text": "The findings suggest that JYNNEOS vaccine was effective in preventing mpox disease, and a two-dose series appeared to provide better protection. (Funded by the Centers for Disease Control and Prevention and Epic Research. ).",
          "begin_section": "abstract",
          "offset_in_begin_section": 1944,
          "end_section": "abstract",
          "offset_in_end_section": 2167
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37199451",
          "text": "The findings suggest that JYNNEOS vaccine was effective in preventing mpox disease, and a two-dose series appeared to provide better protection. (Funded by the Centers for Disease Control and Prevention and Epic Research.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1944,
          "end_section": "abstract",
          "offset_in_end_section": 2165
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37199451",
          "text": "The findings suggest that JYNNEOS vaccine was effective in preventing mpox disease, and a two-dose series appeared to provide better protection.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1944,
          "end_section": "abstract",
          "offset_in_end_section": 2088
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36301741",
          "text": "* JYNNEOS vaccine is licensed by the Food and Drug Administration (FDA) as a 0.5-mL 2-dose series administered subcutaneously 28 days apart to prevent smallpox and monkeypox infections (2) and has been found to provide protection against monkeypox infection during the current outbreak (3).",
          "begin_section": "abstract",
          "offset_in_begin_section": 357,
          "end_section": "abstract",
          "offset_in_end_section": 647
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36201401",
          "text": "This early finding suggests that a single dose of JYNNEOS vaccine provides some protection against monkeypox infection.",
          "begin_section": "abstract",
          "offset_in_begin_section": 2200,
          "end_section": "abstract",
          "offset_in_end_section": 2319
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36301741",
          "text": "To date, more than 27,000 cases have been reported across all 50 states, the District of Columbia (DC), and Puerto Rico. * JYNNEOS vaccine is licensed by the Food and Drug Administration (FDA) as a 0.5-mL 2-dose series administered subcutaneously 28 days apart to prevent smallpox and monkeypox infections (2) and has been found to provide protection against monkeypox infection during the current outbreak (3).",
          "begin_section": "abstract",
          "offset_in_begin_section": 237,
          "end_section": "abstract",
          "offset_in_end_section": 647
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36201401",
          "text": "This early finding suggests that a single dose of JYNNEOS vaccine provides some protection against monkeypox infection. The degree and durability of such protection is unknown, and it is recommended that people who are eligible for monkeypox vaccination receive the complete 2-dose series.",
          "begin_section": "abstract",
          "offset_in_begin_section": 2200,
          "end_section": "abstract",
          "offset_in_end_section": 2489
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36580416",
          "text": "JYNNEOS vaccine was approved by the Food and Drug Administration (FDA) in 2019 as a 2-dose series (0.5 mL per dose, administered subcutaneously) to prevent smallpox and mpox disease.† On August 9, 2022, FDA issued an emergency use authorization to allow administration of JYNNEOS vaccine by intradermal injection (0.1 mL per dose) (2). A previous report on U.S. mpox cases during July 31-September 3, 2022, suggested that 1 dose of vaccine offers some protection against mpox (3). This report describes demographic and clinical characteristics of cases occurring ≥14 days after receipt of 1 dose of JYNNEOS vaccine and compares them with characteristics of cases among unvaccinated persons with mpox and with the vaccine-eligible vaccinated population in participating jurisdictions.",
          "begin_section": "abstract",
          "offset_in_begin_section": 415,
          "end_section": "abstract",
          "offset_in_end_section": 1198
        }
      ],
      "ideal_answer": "JYNNEOS vaccine is protective against smallpox and monkeypox infections.",
      "exact_answer": [
        [
          "smallpox"
        ],
        [
          "monkeypox"
        ]
      ]
    },
    {
      "id": "65f7798dc4010b4d78000038",
      "type": "factoid",
      "body": "What is the optimal antiemetic treatment for FOLFIRINOX chemotherapy?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/34486707",
        "https://pubmed.ncbi.nlm.nih.gov/32910170",
        "https://pubmed.ncbi.nlm.nih.gov/28599496",
        "https://pubmed.ncbi.nlm.nih.gov/33062062",
        "https://pubmed.ncbi.nlm.nih.gov/35400007",
        "https://pubmed.ncbi.nlm.nih.gov/26442474",
        "https://pubmed.ncbi.nlm.nih.gov/3967569",
        "https://pubmed.ncbi.nlm.nih.gov/29881601",
        "https://pubmed.ncbi.nlm.nih.gov/3060151",
        "https://pubmed.ncbi.nlm.nih.gov/27444658"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35400007",
          "text": "Background/Aim\nFOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use. Patients and Methods\nPatients with advanced pancreatic cancer were treated with varying doses of FOLFIRINOX to determine the optimum dosage for highest remission outcomes with the least post-chemotherapy toxicities.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 520
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33062062",
          "text": "In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered the standard of care. However, the optimal sequence of these regimens is unclear.",
          "begin_section": "abstract",
          "offset_in_begin_section": 90,
          "end_section": "abstract",
          "offset_in_end_section": 331
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35400007",
          "text": "In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use. Patients and Methods\nPatients with advanced pancreatic cancer were treated with varying doses of FOLFIRINOX to determine the optimum dosage for highest remission outcomes with the least post-chemotherapy toxicities. Results\nPatients given 180 mg of irinotecan and a 400 mg bolus of 5-fluorouracil (5-FU) showed a marked difference in outcome when compared to irinotecan 180 mg given without the 5-FU bolus, with the overall response rate being 28%, a survival time of 6.4 months and progression-free survival time of 4.5 months.",
          "begin_section": "abstract",
          "offset_in_begin_section": 170,
          "end_section": "abstract",
          "offset_in_end_section": 835
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35400007",
          "text": "Background/Aim\nFOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 302
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35400007",
          "text": "In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use. Patients and Methods\nPatients with advanced pancreatic cancer were treated with varying doses of FOLFIRINOX to determine the optimum dosage for highest remission outcomes with the least post-chemotherapy toxicities.",
          "begin_section": "abstract",
          "offset_in_begin_section": 170,
          "end_section": "abstract",
          "offset_in_end_section": 520
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28599496",
          "text": "This is partially due to recent changes in first-line chemotherapy treatments. Despite this dearth of information, 50.0% of the patients who experience failure with first-line folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (folfirinox) treatment are eligible for additional chemotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 123,
          "end_section": "abstract",
          "offset_in_end_section": 420
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33062062",
          "text": "All patients had progressed after receiving gemcitabine-based first-line chemotherapy and were subsequently offered second-line FOLFIRINOX, FOLFOX-6, or FOLFIRI treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 521,
          "end_section": "abstract",
          "offset_in_end_section": 692
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34486707",
          "text": "NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 199
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33062062",
          "text": "In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered the standard of care. However, the optimal sequence of these regimens is unclear. METHODS\nThis retrospective study initially evaluated 186 patients with locally advanced/metastatic pancreatic cancer at three Italian institutions between February 2013 and October 2019.",
          "begin_section": "abstract",
          "offset_in_begin_section": 90,
          "end_section": "abstract",
          "offset_in_end_section": 520
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33062062",
          "text": "However, the optimal sequence of these regimens is unclear. METHODS\nThis retrospective study initially evaluated 186 patients with locally advanced/metastatic pancreatic cancer at three Italian institutions between February 2013 and October 2019. All patients had progressed after receiving gemcitabine-based first-line chemotherapy and were subsequently offered second-line FOLFIRINOX, FOLFOX-6, or FOLFIRI treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 272,
          "end_section": "abstract",
          "offset_in_end_section": 692
        }
      ],
      "ideal_answer": "The optimal antiemetic treatment for FOLFIRINOX chemotherapy is NEPA (netupitant/palonosetron). NEPA has been shown to effectively prevent nausea and vomiting induced by chemotherapy (CINV) in patients receiving FOLFIRINOX and Folfoxiri regimens. This combination of netupitant and palonosetron provides superior control of acute and delayed CINV compared to other antiemetic agents. NEPA can be safely used during the COVID-19 pandemic and has been proven to be effective in real-life studies.",
      "exact_answer": [
        [
          "The optimal antiemetic treatment for FOLFIRINOX chemotherapy is NEPA (netupitant/palonosetron)."
        ]
      ]
    },
    {
      "id": "65f857b0c4010b4d7800004f",
      "type": "list",
      "body": "Please list the symptoms of Havana syndrome",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/35962646",
        "https://pubmed.ncbi.nlm.nih.gov/37965360",
        "https://pubmed.ncbi.nlm.nih.gov/31770686",
        "https://pubmed.ncbi.nlm.nih.gov/18389399",
        "https://pubmed.ncbi.nlm.nih.gov/7868179",
        "https://pubmed.ncbi.nlm.nih.gov/35505689",
        "https://pubmed.ncbi.nlm.nih.gov/25208117",
        "https://pubmed.ncbi.nlm.nih.gov/24253348",
        "https://pubmed.ncbi.nlm.nih.gov/7991906",
        "https://pubmed.ncbi.nlm.nih.gov/542554"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "While these studies provided a constellation of signs and symptoms for HS, none provided a good level of evidence. In conclusion, Havana syndrome is a nonspecific neurological illness with an unidentified causative factor(s), an acute phase of auditory-vestibular symptoms and a chronic phase of nonspecific neurobehavioral symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 734,
          "end_section": "abstract",
          "offset_in_end_section": 1067
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "In conclusion, Havana syndrome is a nonspecific neurological illness with an unidentified causative factor(s), an acute phase of auditory-vestibular symptoms and a chronic phase of nonspecific neurobehavioral symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 849,
          "end_section": "abstract",
          "offset_in_end_section": 1067
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "Only five original studies and 18 non-original articles were considered to be relevant. While these studies provided a constellation of signs and symptoms for HS, none provided a good level of evidence. In conclusion, Havana syndrome is a nonspecific neurological illness with an unidentified causative factor(s), an acute phase of auditory-vestibular symptoms and a chronic phase of nonspecific neurobehavioral symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 646,
          "end_section": "abstract",
          "offset_in_end_section": 1067
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties, after they encountered strange sounds; this has been called \"Havana syndrome\" (HS). MEDLINE, Scopus, and Ovid databases from 2016 until 24 September 2021 were systematically searched for the related published manuscripts. The following search strategy was implemented: \"Havana syndrome\" OR \"Neurological Symptoms and US Diplomats\".",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 600
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "The following search strategy was implemented: \"Havana syndrome\" OR \"Neurological Symptoms and US Diplomats\". The primary search yielded 120 publications.",
          "begin_section": "abstract",
          "offset_in_begin_section": 491,
          "end_section": "abstract",
          "offset_in_end_section": 645
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "The following search strategy was implemented: \"Havana syndrome\" OR \"Neurological Symptoms and US Diplomats\". The primary search yielded 120 publications. Only five original studies and 18 non-original articles were considered to be relevant.",
          "begin_section": "abstract",
          "offset_in_begin_section": 491,
          "end_section": "abstract",
          "offset_in_end_section": 733
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "While these studies provided a constellation of signs and symptoms for HS, none provided a good level of evidence. In conclusion, Havana syndrome is a nonspecific neurological illness with an unidentified causative factor(s), an acute phase of auditory-vestibular symptoms and a chronic phase of nonspecific neurobehavioral symptoms. This syndrome should be considered and investigated as a health concern, and not as a political issue.",
          "begin_section": "abstract",
          "offset_in_begin_section": 734,
          "end_section": "abstract",
          "offset_in_end_section": 1170
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "In conclusion, Havana syndrome is a nonspecific neurological illness with an unidentified causative factor(s), an acute phase of auditory-vestibular symptoms and a chronic phase of nonspecific neurobehavioral symptoms. This syndrome should be considered and investigated as a health concern, and not as a political issue.",
          "begin_section": "abstract",
          "offset_in_begin_section": 849,
          "end_section": "abstract",
          "offset_in_end_section": 1170
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "The following search strategy was implemented: \"Havana syndrome\" OR \"Neurological Symptoms and US Diplomats\".",
          "begin_section": "abstract",
          "offset_in_begin_section": 491,
          "end_section": "abstract",
          "offset_in_end_section": 600
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35962646",
          "text": "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties, after they encountered strange sounds; this has been called \"Havana syndrome\" (HS). MEDLINE, Scopus, and Ovid databases from 2016 until 24 September 2021 were systematically searched for the related published manuscripts.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 490
        }
      ],
      "ideal_answer": "Havana syndrome is characterized by a constellation of symptoms. The acute phase is marked by auditory-vestibular symptoms such as tinnitus, vertigo, and visual problems. The chronic phase is characterized by nonspecific neurobehavioral symptoms including cognitive difficulties. However, it is important to note that the studies available provide limited evidence, and the exact symptoms may vary among individuals.",
      "exact_answer": [
        [
          "Tinnitus"
        ],
        [
          "Visual problems"
        ],
        [
          "Vertigo"
        ],
        [
          "Cognitive difficulties"
        ]
      ]
    },
    {
      "id": "660c0a85fdcbea915f000030",
      "type": "list",
      "body": "What are common complications of prematurity for babies?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/29544675",
        "https://pubmed.ncbi.nlm.nih.gov/1427146",
        "https://pubmed.ncbi.nlm.nih.gov/22611114",
        "https://pubmed.ncbi.nlm.nih.gov/3178079",
        "https://pubmed.ncbi.nlm.nih.gov/10188369",
        "https://pubmed.ncbi.nlm.nih.gov/35426104",
        "https://pubmed.ncbi.nlm.nih.gov/19482670",
        "https://pubmed.ncbi.nlm.nih.gov/34304198",
        "https://pubmed.ncbi.nlm.nih.gov/21997864",
        "https://pubmed.ncbi.nlm.nih.gov/12439554"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21997864",
          "text": "Preterm birth results in poor accretion of bone minerals and development of rickets of prematurity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 99
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/3178079",
          "text": "One hundred eighty-seven premature babies, 48 of whom suffered from retinopathy of prematurity (ROP), were examined. A higher incidence of strabismus was found in the group with cicatricial ROP (23% vs. 9%).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 207
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/3178079",
          "text": "One hundred eighty-seven premature babies, 48 of whom suffered from retinopathy of prematurity (ROP), were examined.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 116
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19482670",
          "text": "Oxygen-induced oxidative stress (OS) has damaging effects in the perinatal period. For now there is a lake of evidence that OS occurs in babies with retinopathy of prematurity (ROP) We tests the hypothesis that a strict oxygen policy may minimize postnatal OS reducing severity of ROP. Multicenter prospective cohort study (72 newborns), using a common clinical management protocol with a strict control of oxygen administration.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 429
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19482670",
          "text": "For now there is a lake of evidence that OS occurs in babies with retinopathy of prematurity (ROP) We tests the hypothesis that a strict oxygen policy may minimize postnatal OS reducing severity of ROP. Multicenter prospective cohort study (72 newborns), using a common clinical management protocol with a strict control of oxygen administration.",
          "begin_section": "abstract",
          "offset_in_begin_section": 83,
          "end_section": "abstract",
          "offset_in_end_section": 429
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19482670",
          "text": "For now there is a lake of evidence that OS occurs in babies with retinopathy of prematurity (ROP) We tests the hypothesis that a strict oxygen policy may minimize postnatal OS reducing severity of ROP. Multicenter prospective cohort study (72 newborns), using a common clinical management protocol with a strict control of oxygen administration. Assessment of biochemical markers of OS in blood samples at birth and on days 7, 14, and 21.",
          "begin_section": "abstract",
          "offset_in_begin_section": 83,
          "end_section": "abstract",
          "offset_in_end_section": 522
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21997864",
          "text": "Preterm birth results in poor accretion of bone minerals and development of rickets of prematurity. Poor skeletal growth is one of the long term morbidities of this condition, which is said to have a lesser effect on the skull growth.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 234
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21997864",
          "text": "Preterm birth results in poor accretion of bone minerals and development of rickets of prematurity. Poor skeletal growth is one of the long term morbidities of this condition, which is said to have a lesser effect on the skull growth. The present study was a retrospective observational study to compare the effect of rickets of prematurity on the linear and skull growth in the first year of life.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 398
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34304198",
          "text": "Elderly primigravida mothers and spontaneous vaginal deliveries with prolonged second stage of labor were a common maternal risk factors for retinal hemorrhages. Low birth weight and preterm were fetal risk factors with neonatal retinal hemorrhages. These hemorrhages were more often bilateral (no.",
          "begin_section": "abstract",
          "offset_in_begin_section": 715,
          "end_section": "abstract",
          "offset_in_end_section": 1013
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34304198",
          "text": "Elderly primigravida mothers and spontaneous vaginal deliveries with prolonged second stage of labor were a common maternal risk factors for retinal hemorrhages. Low birth weight and preterm were fetal risk factors with neonatal retinal hemorrhages.",
          "begin_section": "abstract",
          "offset_in_begin_section": 715,
          "end_section": "abstract",
          "offset_in_end_section": 964
        }
      ],
      "ideal_answer": "Common complications of prematurity for babies include respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, developmental delays, and poor growth and nutrition.",
      "exact_answer": [
        [
          "Respiratory distress syndrome"
        ],
        [
          "Intraventricular hemorrhage"
        ],
        [
          "Necrotizing enterocolitis"
        ],
        [
          "Retinopathy of prematurity"
        ],
        [
          "Bronchopulmonary dysplasia"
        ]
      ]
    },
    {
      "id": "65d145651930410b13000042",
      "type": "summary",
      "body": "What disease was studied in the ANGEL-ASPECT trial?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/36137599",
        "https://pubmed.ncbi.nlm.nih.gov/31994987",
        "https://pubmed.ncbi.nlm.nih.gov/38010691",
        "https://pubmed.ncbi.nlm.nih.gov/36715467",
        "https://pubmed.ncbi.nlm.nih.gov/27184664",
        "https://pubmed.ncbi.nlm.nih.gov/33174197",
        "https://pubmed.ncbi.nlm.nih.gov/30918641",
        "https://pubmed.ncbi.nlm.nih.gov/15364647",
        "https://pubmed.ncbi.nlm.nih.gov/28097844",
        "https://pubmed.ncbi.nlm.nih.gov/34421506"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36137599",
          "text": "DESIGN\nANGEL-ASPECT is a multicentre, prospective, randomised, open-label, blinded End-point trial to evaluate whether best medical management (BMM) combined with endovascular therapy improves neurological functional outcomes as compared with BMM alone in acute LVO patients with Alberta Stroke Program Early CT Score (ASPECTS) of 3-5 on non-contrast CT or infarct core volume range of 70-100 mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI) up to 24 hours from symptom onset or last seen well.",
          "begin_section": "abstract",
          "offset_in_begin_section": 298,
          "end_section": "abstract",
          "offset_in_end_section": 804
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36137599",
          "text": "DISCUSSION\nThe ANGEL-ASPECT trial will screen patients with large infarct core (ASPECTS 3-5 or 70-100 mL) through image evaluation criteria within 24 hours and explore the efficacy and safety of endovascular therapy compared with BMM.",
          "begin_section": "abstract",
          "offset_in_begin_section": 995,
          "end_section": "abstract",
          "offset_in_end_section": 1229
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36137599",
          "text": "DESIGN\nANGEL-ASPECT is a multicentre, prospective, randomised, open-label, blinded End-point trial to evaluate whether best medical management (BMM) combined with endovascular therapy improves neurological functional outcomes as compared with BMM alone in acute LVO patients with Alberta Stroke Program Early CT Score (ASPECTS) of 3-5 on non-contrast CT or infarct core volume range of 70-100 mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI) up to 24 hours from symptom onset or last seen well. STUDY OUTCOMES\nThe primary efficacy outcome is 90 (±7) days modified Rankin Scale. Symptomatic intracranial haemorrhage within 48 hours from randomisation is the primary safety outcome.",
          "begin_section": "abstract",
          "offset_in_begin_section": 298,
          "end_section": "abstract",
          "offset_in_end_section": 992
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36137599",
          "text": "STUDY OUTCOMES\nThe primary efficacy outcome is 90 (±7) days modified Rankin Scale. Symptomatic intracranial haemorrhage within 48 hours from randomisation is the primary safety outcome. DISCUSSION\nThe ANGEL-ASPECT trial will screen patients with large infarct core (ASPECTS 3-5 or 70-100 mL) through image evaluation criteria within 24 hours and explore the efficacy and safety of endovascular therapy compared with BMM.",
          "begin_section": "abstract",
          "offset_in_begin_section": 807,
          "end_section": "abstract",
          "offset_in_end_section": 1229
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36137599",
          "text": "Symptomatic intracranial haemorrhage within 48 hours from randomisation is the primary safety outcome. DISCUSSION\nThe ANGEL-ASPECT trial will screen patients with large infarct core (ASPECTS 3-5 or 70-100 mL) through image evaluation criteria within 24 hours and explore the efficacy and safety of endovascular therapy compared with BMM.",
          "begin_section": "abstract",
          "offset_in_begin_section": 890,
          "end_section": "abstract",
          "offset_in_end_section": 1229
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36137599",
          "text": "DESIGN\nANGEL-ASPECT is a multicentre, prospective, randomised, open-label, blinded End-point trial to evaluate whether best medical management (BMM) combined with endovascular therapy improves neurological functional outcomes as compared with BMM alone in acute LVO patients with Alberta Stroke Program Early CT Score (ASPECTS) of 3-5 on non-contrast CT or infarct core volume range of 70-100 mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI) up to 24 hours from symptom onset or last seen well. STUDY OUTCOMES\nThe primary efficacy outcome is 90 (±7) days modified Rankin Scale.",
          "begin_section": "abstract",
          "offset_in_begin_section": 298,
          "end_section": "abstract",
          "offset_in_end_section": 889
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36137599",
          "text": "Endovascular therapy in acute anterior circulation large vessel occlusive patients with a large infarct core (ANGEL-ASPECT): protocol of a multicentre randomised trial.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 168
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36137599",
          "text": "AIM\nTo demonstrate the design of a clinical trial on endovascular therapy for acute anterior circulation large vessel occlusion (LVO) patients with large infarct core volume. DESIGN\nANGEL-ASPECT is a multicentre, prospective, randomised, open-label, blinded End-point trial to evaluate whether best medical management (BMM) combined with endovascular therapy improves neurological functional outcomes as compared with BMM alone in acute LVO patients with Alberta Stroke Program Early CT Score (ASPECTS) of 3-5 on non-contrast CT or infarct core volume range of 70-100 mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI) up to 24 hours from symptom onset or last seen well.",
          "begin_section": "abstract",
          "offset_in_begin_section": 121,
          "end_section": "abstract",
          "offset_in_end_section": 804
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38010691",
          "text": "Design, Setting, and Participants\nThis prespecified secondary analysis of subgroups of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core (ANGEL-ASPECT) RCT included patients from 46 stroke centers across China between October 2, 2020, and May 18, 2022. Participants were enrolled within 24 hours of symptom onset and had ASPECTS of 3 to 5 or 0 to 2 and infarct core volume of 70 to 100 mL.",
          "begin_section": "abstract",
          "offset_in_begin_section": 391,
          "end_section": "abstract",
          "offset_in_end_section": 843
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38010691",
          "text": "Design, Setting, and Participants\nThis prespecified secondary analysis of subgroups of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core (ANGEL-ASPECT) RCT included patients from 46 stroke centers across China between October 2, 2020, and May 18, 2022. Participants were enrolled within 24 hours of symptom onset and had ASPECTS of 3 to 5 or 0 to 2 and infarct core volume of 70 to 100 mL. Patients were divided into 3 groups: ASPECTS of 3 to 5 with infarct core volume less than 70 mL, ASPECTS of 3 to 5 with infarct core volume of 70 mL or greater, and ASPECTS of 0 to 2.",
          "begin_section": "abstract",
          "offset_in_begin_section": 391,
          "end_section": "abstract",
          "offset_in_end_section": 1027
        }
      ],
      "ideal_answer": "The ANGEL-ASPECT trial studied acute anterior circulation large vessel occlusion (LVO) in patients with a large infarct core volume.",
      "exact_answer": "n/a"
    },
    {
      "id": "65f773cdc4010b4d78000026",
      "type": "summary",
      "body": "Why is the clinical benefit of EGFR inhibitors different in right and left colorectal cancer?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/22189054",
        "https://pubmed.ncbi.nlm.nih.gov/28110551",
        "https://pubmed.ncbi.nlm.nih.gov/29796712",
        "https://pubmed.ncbi.nlm.nih.gov/30116425",
        "https://pubmed.ncbi.nlm.nih.gov/26066903",
        "https://pubmed.ncbi.nlm.nih.gov/28432610",
        "https://pubmed.ncbi.nlm.nih.gov/28654140",
        "https://pubmed.ncbi.nlm.nih.gov/32430388",
        "https://pubmed.ncbi.nlm.nih.gov/30499396",
        "https://pubmed.ncbi.nlm.nih.gov/35650607"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30116425",
          "text": "Therapy responses are totally different between these tumor entities. Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load.",
          "begin_section": "abstract",
          "offset_in_begin_section": 754,
          "end_section": "abstract",
          "offset_in_end_section": 1275
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30116425",
          "text": "Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load. For the development of effective therapy regimes and better treatment options, it is essential to evaluate right-sided and left-sided tumors as separate entities, and design the therapy regime considering the differences between these tumors.",
          "begin_section": "abstract",
          "offset_in_begin_section": 824,
          "end_section": "abstract",
          "offset_in_end_section": 1518
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30116425",
          "text": "Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load.",
          "begin_section": "abstract",
          "offset_in_begin_section": 824,
          "end_section": "abstract",
          "offset_in_end_section": 1275
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30116425",
          "text": "Therapy responses are totally different between these tumor entities. Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 754,
          "end_section": "abstract",
          "offset_in_end_section": 1070
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30116425",
          "text": "Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 824,
          "end_section": "abstract",
          "offset_in_end_section": 1070
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28654140",
          "text": "BACKGROUND\nEpidermal growth factor receptor (EGFR) inhibitors prevent cell growth and have shown benefit in the treatment of metastatic colorectal cancer, whether used as single agents or in combination with chemotherapy. Clear benefit has been shown in trials of EGFR monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI). However, there is ongoing debate as to which patient populations gain maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 589
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28654140",
          "text": "Clear benefit has been shown in trials of EGFR monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI). However, there is ongoing debate as to which patient populations gain maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 222,
          "end_section": "abstract",
          "offset_in_end_section": 589
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28654140",
          "text": "Clear benefit has been shown in trials of EGFR monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI). However, there is ongoing debate as to which patient populations gain maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity. OBJECTIVES\nTo determine the efficacy, safety profile, and potential harms of EGFR inhibitors in the treatment of people with metastatic colorectal cancer when given alone, in combination with chemotherapy, or with other biological agents.The primary outcome of interest was progression-free survival; secondary outcomes included overall survival, tumour response rate, quality of life, and adverse events.",
          "begin_section": "abstract",
          "offset_in_begin_section": 222,
          "end_section": "abstract",
          "offset_in_end_section": 997
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28654140",
          "text": "However, there is ongoing debate as to which patient populations gain maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity. OBJECTIVES\nTo determine the efficacy, safety profile, and potential harms of EGFR inhibitors in the treatment of people with metastatic colorectal cancer when given alone, in combination with chemotherapy, or with other biological agents.The primary outcome of interest was progression-free survival; secondary outcomes included overall survival, tumour response rate, quality of life, and adverse events. SEARCH METHODS\nWe searched the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library, Issue 9, 2016; Ovid MEDLINE (from 1950); and Ovid Embase (from 1974) on 9 September 2016; and ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) on 14 March 2017.",
          "begin_section": "abstract",
          "offset_in_begin_section": 354,
          "end_section": "abstract",
          "offset_in_end_section": 1335
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28654140",
          "text": "However, there is ongoing debate as to which patient populations gain maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 354,
          "end_section": "abstract",
          "offset_in_end_section": 589
        }
      ],
      "ideal_answer": "The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer due to the differences in tumor biology and response to treatment. Left-sided colorectal cancer (LCRC) patients benefit more from EGFR inhibitors and have a better prognosis, while right-sided colorectal cancer (RCRC) patients do not respond well to EGFR inhibitors. This difference is attributed to the higher antigenic load in RCRC tumors, making them more responsive to immunotherapies.",
      "exact_answer": "n/a"
    },
    {
      "id": "660712a1fdcbea915f000003",
      "type": "yesno",
      "body": "Can Connexin hemi channels be used for drug delivery?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/24454290",
        "https://pubmed.ncbi.nlm.nih.gov/30300925",
        "https://pubmed.ncbi.nlm.nih.gov/12963797",
        "https://pubmed.ncbi.nlm.nih.gov/25086040",
        "https://pubmed.ncbi.nlm.nih.gov/8844331",
        "https://pubmed.ncbi.nlm.nih.gov/27229305",
        "https://pubmed.ncbi.nlm.nih.gov/19686581",
        "https://pubmed.ncbi.nlm.nih.gov/35008804",
        "https://pubmed.ncbi.nlm.nih.gov/33383853",
        "https://pubmed.ncbi.nlm.nih.gov/15033576"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35008804",
          "text": "Connexins are gap junction-forming membrane proteins which serve to exchange small molecules of less than 1 kD between cells. Connexins can also form hemi-channels connecting the intracellular and extracellular environments. Hemi-channels can mediate adenosine triphosphate release and are involved in autocrine and paracrine signalling.",
          "begin_section": "abstract",
          "offset_in_begin_section": 174,
          "end_section": "abstract",
          "offset_in_end_section": 511
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35008804",
          "text": "Connexins can also form hemi-channels connecting the intracellular and extracellular environments. Hemi-channels can mediate adenosine triphosphate release and are involved in autocrine and paracrine signalling.",
          "begin_section": "abstract",
          "offset_in_begin_section": 300,
          "end_section": "abstract",
          "offset_in_end_section": 511
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35008804",
          "text": "Connexins can also form hemi-channels connecting the intracellular and extracellular environments. Hemi-channels can mediate adenosine triphosphate release and are involved in autocrine and paracrine signalling. Recently, our group and others have identified evidence that connexin-mediated signalling may be involved in the pathogenesis of pulmonary hypertension.",
          "begin_section": "abstract",
          "offset_in_begin_section": 300,
          "end_section": "abstract",
          "offset_in_end_section": 664
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30300925",
          "text": "Connexin and Pannexin (Hemi)Channels: Emerging Targets in the Treatment of Liver Disease.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 89
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35008804",
          "text": "Connexins can also form hemi-channels connecting the intracellular and extracellular environments.",
          "begin_section": "abstract",
          "offset_in_begin_section": 300,
          "end_section": "abstract",
          "offset_in_end_section": 398
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33383853",
          "text": "Cardiac connexin-43 (Cx43) creates gap junction channels (GJCs) at intercellular contacts and hemi-channels (HCs) at the peri-junctional plasma membrane and sarcolemmal caveolae/rafts compartments.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 197
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24454290",
          "text": "Connexin and pannexin (hemi)channels in the liver.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 50
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35008804",
          "text": "Hemi-channels can mediate adenosine triphosphate release and are involved in autocrine and paracrine signalling. Recently, our group and others have identified evidence that connexin-mediated signalling may be involved in the pathogenesis of pulmonary hypertension.",
          "begin_section": "abstract",
          "offset_in_begin_section": 399,
          "end_section": "abstract",
          "offset_in_end_section": 664
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35008804",
          "text": "Connexins are gap junction-forming membrane proteins which serve to exchange small molecules of less than 1 kD between cells. Connexins can also form hemi-channels connecting the intracellular and extracellular environments.",
          "begin_section": "abstract",
          "offset_in_begin_section": 174,
          "end_section": "abstract",
          "offset_in_end_section": 398
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15033576",
          "text": "Assembly of these channels is a complicated, highly regulated process that includes biosynthesis of the connexin subunit proteins on endoplasmic reticulum membranes, oligomerization of compatible subunits into hexameric hemi-channels (connexons), delivery of the connexons to the plasma membrane, head-on docking of compatible connexons in the extracellular space at distinct locations, arrangement of channels into dynamic, spatially and temporally organized GJ channel aggregates (so-called plaques), and coordinated removal of channels into the cytoplasm followed by their degradation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 681,
          "end_section": "abstract",
          "offset_in_end_section": 1269
        }
      ],
      "ideal_answer": "Connexin hemi-channels have the potential to be used for drug delivery. These channels can mediate the release of small molecules, such as adenosine triphosphate, between the intracellular and extracellular environments. By utilizing the properties of connexin hemi-channels, drugs can be loaded into these channels and released into the extracellular space, allowing for targeted drug delivery. However, further research is needed to optimize the use of connexin hemi-channels for drug delivery and to ensure their safety and efficacy.",
      "exact_answer": "no"
    },
    {
      "id": "660c02e1fdcbea915f00002c",
      "type": "yesno",
      "body": "Pasteurization kills Mycobacterium tuberculosis from infected cattle.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/12296851",
        "https://pubmed.ncbi.nlm.nih.gov/15066730",
        "https://pubmed.ncbi.nlm.nih.gov/8844579",
        "https://pubmed.ncbi.nlm.nih.gov/16861643",
        "https://pubmed.ncbi.nlm.nih.gov/20965132",
        "https://pubmed.ncbi.nlm.nih.gov/15973241",
        "https://pubmed.ncbi.nlm.nih.gov/31199855",
        "https://pubmed.ncbi.nlm.nih.gov/3055660",
        "https://pubmed.ncbi.nlm.nih.gov/26385106",
        "https://pubmed.ncbi.nlm.nih.gov/20049086"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15973241",
          "text": "M. bovis, a bacterial species of the M. tuberculosis complex, is a pathogen that primarily infects cattle. However, humans also can become infected, most commonly through consumption of unpasteurized milk products from infected cows. In industrialized nations, human TB caused by M. bovis is rare because of milk pasteurization and culling of infected cattle herds.",
          "begin_section": "abstract",
          "offset_in_begin_section": 147,
          "end_section": "abstract",
          "offset_in_end_section": 512
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15973241",
          "text": "However, humans also can become infected, most commonly through consumption of unpasteurized milk products from infected cows. In industrialized nations, human TB caused by M. bovis is rare because of milk pasteurization and culling of infected cattle herds. This report summarizes an ongoing, multiagency investigation that has identified 35 cases of human M. bovis infection in NYC.",
          "begin_section": "abstract",
          "offset_in_begin_section": 254,
          "end_section": "abstract",
          "offset_in_end_section": 638
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15973241",
          "text": "In industrialized nations, human TB caused by M. bovis is rare because of milk pasteurization and culling of infected cattle herds. This report summarizes an ongoing, multiagency investigation that has identified 35 cases of human M. bovis infection in NYC. Preliminary findings indicate that fresh cheese (e.g., queso fresco) brought to NYC from Mexico was a likely source of infection.",
          "begin_section": "abstract",
          "offset_in_begin_section": 381,
          "end_section": "abstract",
          "offset_in_end_section": 768
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20965132",
          "text": "Approximately 27% of isolates from grazing cattle were Mycobacterium tuberculosis, while cattle in a more intensive-production system were exclusively infected with M. bovis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 153,
          "end_section": "abstract",
          "offset_in_end_section": 327
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15973241",
          "text": "In March 2004, a U.S.-born boy aged 15 months in New York City (NYC) died of peritoneal tuberculosis (TB) caused by Mycobacterium bovis infection. M. bovis, a bacterial species of the M. tuberculosis complex, is a pathogen that primarily infects cattle. However, humans also can become infected, most commonly through consumption of unpasteurized milk products from infected cows.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 380
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15973241",
          "text": "In industrialized nations, human TB caused by M. bovis is rare because of milk pasteurization and culling of infected cattle herds. This report summarizes an ongoing, multiagency investigation that has identified 35 cases of human M. bovis infection in NYC.",
          "begin_section": "abstract",
          "offset_in_begin_section": 381,
          "end_section": "abstract",
          "offset_in_end_section": 638
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15973241",
          "text": "However, humans also can become infected, most commonly through consumption of unpasteurized milk products from infected cows. In industrialized nations, human TB caused by M. bovis is rare because of milk pasteurization and culling of infected cattle herds.",
          "begin_section": "abstract",
          "offset_in_begin_section": 254,
          "end_section": "abstract",
          "offset_in_end_section": 512
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15973241",
          "text": "In industrialized nations, human TB caused by M. bovis is rare because of milk pasteurization and culling of infected cattle herds.",
          "begin_section": "abstract",
          "offset_in_begin_section": 381,
          "end_section": "abstract",
          "offset_in_end_section": 512
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20965132",
          "text": "Mycobacterium tuberculosis infection in grazing cattle in central Ethiopia.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 75
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16861643",
          "text": "Immunogenicity of Mycobacterium tuberculosis antigens in Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 121
        }
      ],
      "ideal_answer": "Pasteurization is an effective method to kill Mycobacterium tuberculosis, the bacteria that causes tuberculosis, in milk from infected cattle. This is why pasteurization is an important process in industrialized nations to prevent human TB caused by M. bovis. Pasteurization involves heating the milk to a specific temperature for a certain period of time, which destroys harmful bacteria, including M. tuberculosis, while preserving the nutritional value of the milk.",
      "exact_answer": "yes"
    },
    {
      "id": "65cfd3961930410b1300001f",
      "type": "factoid",
      "body": "TAK-994 is developed for which disease?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/38061670",
        "https://pubmed.ncbi.nlm.nih.gov/37001988",
        "https://pubmed.ncbi.nlm.nih.gov/15675611",
        "https://pubmed.ncbi.nlm.nih.gov/22748666",
        "https://pubmed.ncbi.nlm.nih.gov/9387041",
        "https://pubmed.ncbi.nlm.nih.gov/23803584",
        "https://pubmed.ncbi.nlm.nih.gov/9403335",
        "https://pubmed.ncbi.nlm.nih.gov/31892829",
        "https://pubmed.ncbi.nlm.nih.gov/11291827",
        "https://pubmed.ncbi.nlm.nih.gov/31160383"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37001988",
          "text": "These data suggest that overall in vitro and in vivo properties, except oral availability, are very similar between TAK-994 and danavorexton. Preclinical characteristics of TAK-994 shown here, together with upcoming clinical study results, can improve our understanding for orally available OX2R agonists as new therapeutic drugs for NT1 and other hypersomnia disorders.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1334,
          "end_section": "abstract",
          "offset_in_end_section": 1704
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37001988",
          "text": "The wake-promoting effects of TAK-994 in orexin/ataxin-3 mice were maintained after chronic dosing for 14 days. These data suggest that overall in vitro and in vivo properties, except oral availability, are very similar between TAK-994 and danavorexton. Preclinical characteristics of TAK-994 shown here, together with upcoming clinical study results, can improve our understanding for orally available OX2R agonists as new therapeutic drugs for NT1 and other hypersomnia disorders.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1222,
          "end_section": "abstract",
          "offset_in_end_section": 1704
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37001988",
          "text": "TAK-994 activated recombinant human OX2R (EC50 value of 19 nM) with > 700-fold selectivity against OX1R and activated OX2R-downstream signaling similar to those by orexin peptides in vitro. Oral administration of TAK-994 promoted wakefulness in normal mice but not in OX2R KO mice. TAK-994 also ameliorated narcolepsy-like symptoms in two mouse models of narcolepsy: orexin/ataxin-3 mice and orexin-tTA;TetO diphtheria toxin A mice.",
          "begin_section": "abstract",
          "offset_in_begin_section": 789,
          "end_section": "abstract",
          "offset_in_end_section": 1221
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/9403335",
          "text": "Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 118
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31160383",
          "text": "The PI3K/AKT/mTOR pathway is frequently activated in this disease and can be a potential therapeutic target for treatment intervention. We studied the antitumor efficacy of a new targeted therapy, TAK-228 (oral mTORC1/2 inhibitor), in preclinical models of bladder cancer. We evaluated the effects of TAK-228 in combination with a PI3Kα inhibitor (TAK-117) or with chemotherapy (paclitaxel).",
          "begin_section": "abstract",
          "offset_in_begin_section": 91,
          "end_section": "abstract",
          "offset_in_end_section": 482
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37001988",
          "text": "TAK-994 activated recombinant human OX2R (EC50 value of 19 nM) with > 700-fold selectivity against OX1R and activated OX2R-downstream signaling similar to those by orexin peptides in vitro. Oral administration of TAK-994 promoted wakefulness in normal mice but not in OX2R KO mice.",
          "begin_section": "abstract",
          "offset_in_begin_section": 789,
          "end_section": "abstract",
          "offset_in_end_section": 1070
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22748666",
          "text": "TAK-448 and TAK-683, investigational agents with potential utility in the treatment of prostate cancer, are potent low molecular weight metastin receptor agonists consisting of nine amino acids. Monoclonal antibodies (mAbs) against these agents were developed to facilitate their evaluation in preclinical studies.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 314
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22748666",
          "text": "TAK-448 and TAK-683, investigational agents with potential utility in the treatment of prostate cancer, are potent low molecular weight metastin receptor agonists consisting of nine amino acids. Monoclonal antibodies (mAbs) against these agents were developed to facilitate their evaluation in preclinical studies. Six mAbs were obtained from four immunogens.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 359
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31160383",
          "text": "The PI3K/AKT/mTOR pathway is frequently activated in this disease and can be a potential therapeutic target for treatment intervention. We studied the antitumor efficacy of a new targeted therapy, TAK-228 (oral mTORC1/2 inhibitor), in preclinical models of bladder cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 91,
          "end_section": "abstract",
          "offset_in_end_section": 363
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37001988",
          "text": "These findings indicate that TAK-994 is an orally available brain-penetrant OX2R-selective agonist with potential to improve narcolepsy-like symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 2127,
          "end_section": "abstract",
          "offset_in_end_section": 2277
        }
      ],
      "ideal_answer": "TAK-994 is developed as a potential therapeutic drug for narcolepsy and other hypersomnia disorders.",
      "exact_answer": [
        [
          "TAK-994 is developed for narcolepsy and other hypersomnia disorders."
        ]
      ]
    },
    {
      "id": "66099b20fdcbea915f000021",
      "type": "yesno",
      "body": "Is high blood pressure a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/22033274",
        "https://pubmed.ncbi.nlm.nih.gov/23254964",
        "https://pubmed.ncbi.nlm.nih.gov/15612152",
        "https://pubmed.ncbi.nlm.nih.gov/21368463",
        "https://pubmed.ncbi.nlm.nih.gov/27109438",
        "https://pubmed.ncbi.nlm.nih.gov/26307753",
        "https://pubmed.ncbi.nlm.nih.gov/23266047",
        "https://pubmed.ncbi.nlm.nih.gov/30396388",
        "https://pubmed.ncbi.nlm.nih.gov/20087037",
        "https://pubmed.ncbi.nlm.nih.gov/28487489"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27109438",
          "text": "Patients who developed hypertension during treatment with bevacizumab for colorectal cancer and non-small cell lung cancer had significantly prolonged overall survival when compared with normotensive patients. Bevacizumab-induced hypertension may represent a biomarker for clinical benefit in cancer patients treated with bevacizumab.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1421,
          "end_section": "abstract",
          "offset_in_end_section": 1755
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23254964",
          "text": "Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 95
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27109438",
          "text": "Blood pressure was measured before each treatment cycle. In the patient group with colorectal cancer, treated with bevacizumab, Grade 2-3 hypertension was present in 27.6%.",
          "begin_section": "abstract",
          "offset_in_begin_section": 772,
          "end_section": "abstract",
          "offset_in_end_section": 944
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30396388",
          "text": "Therefore, we investigated the relationships between increased blood pressure and bevacizumab administration, patient characteristics, and laboratory data. Between April 2007 and January 2018, factor analysis was retrospectively conducted by monitoring increases in blood pressure, the status of bevacizumab administration, patient characteristics, and laboratory data before the first administration in Japanese patients with colorectal cancer who satisfied the criteria for this study. Sixty-seven patients were included, 34 of whom (50.7%) had an increase in blood pressure after bevacizumab administration.",
          "begin_section": "abstract",
          "offset_in_begin_section": 183,
          "end_section": "abstract",
          "offset_in_end_section": 793
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30396388",
          "text": "Therefore, we investigated the relationships between increased blood pressure and bevacizumab administration, patient characteristics, and laboratory data. Between April 2007 and January 2018, factor analysis was retrospectively conducted by monitoring increases in blood pressure, the status of bevacizumab administration, patient characteristics, and laboratory data before the first administration in Japanese patients with colorectal cancer who satisfied the criteria for this study.",
          "begin_section": "abstract",
          "offset_in_begin_section": 183,
          "end_section": "abstract",
          "offset_in_end_section": 670
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27109438",
          "text": "Bevacizumab-induced hypertension may represent a biomarker for clinical benefit in cancer patients treated with bevacizumab.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1631,
          "end_section": "abstract",
          "offset_in_end_section": 1755
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30396388",
          "text": "Between April 2007 and January 2018, factor analysis was retrospectively conducted by monitoring increases in blood pressure, the status of bevacizumab administration, patient characteristics, and laboratory data before the first administration in Japanese patients with colorectal cancer who satisfied the criteria for this study. Sixty-seven patients were included, 34 of whom (50.7%) had an increase in blood pressure after bevacizumab administration.",
          "begin_section": "abstract",
          "offset_in_begin_section": 339,
          "end_section": "abstract",
          "offset_in_end_section": 793
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22033274",
          "text": "METHODS\nBlood pressure data at 0, 90, and 180 min after a total of 162 bevacizumab administrations in 81 advanced colorectal cancer patients were retrospectively investigated.",
          "begin_section": "abstract",
          "offset_in_begin_section": 133,
          "end_section": "abstract",
          "offset_in_end_section": 308
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23254964",
          "text": "Bevacizumab-related HTN may represent a biomarker for clinical benefit in metastatic colorectal cancer patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1009,
          "end_section": "abstract",
          "offset_in_end_section": 1121
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30396388",
          "text": "Between April 2007 and January 2018, factor analysis was retrospectively conducted by monitoring increases in blood pressure, the status of bevacizumab administration, patient characteristics, and laboratory data before the first administration in Japanese patients with colorectal cancer who satisfied the criteria for this study.",
          "begin_section": "abstract",
          "offset_in_begin_section": 339,
          "end_section": "abstract",
          "offset_in_end_section": 670
        }
      ],
      "ideal_answer": "Yes, high blood pressure has been identified as a clinical biomarker of response to bevacizumab in advanced colorectal cancer patients. Studies have shown that patients who develop hypertension during treatment with bevacizumab have significantly prolonged overall survival compared to normotensive patients. This suggests that bevacizumab-induced hypertension may serve as a biomarker for clinical benefit in colorectal cancer patients treated with bevacizumab.",
      "exact_answer": "yes"
    },
    {
      "id": "66088cccfdcbea915f00000b",
      "type": "summary",
      "body": "What is the significance of Acute pancreatitis-induced splanchnic vein thrombosis",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/35433812",
        "https://pubmed.ncbi.nlm.nih.gov/33887991",
        "https://pubmed.ncbi.nlm.nih.gov/24152951",
        "https://pubmed.ncbi.nlm.nih.gov/36994906",
        "https://pubmed.ncbi.nlm.nih.gov/22081920",
        "https://pubmed.ncbi.nlm.nih.gov/37377583",
        "https://pubmed.ncbi.nlm.nih.gov/23587854",
        "https://pubmed.ncbi.nlm.nih.gov/34815653",
        "https://pubmed.ncbi.nlm.nih.gov/37933195",
        "https://pubmed.ncbi.nlm.nih.gov/33215862"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37933195",
          "text": "Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is an important sequela complication of acute pancreatitis, which may cause poor prognosis, such as severe gastrointestinal hemorrhage, bowel ischemic necrosis and liver failure.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 241
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37933195",
          "text": "Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is an important sequela complication of acute pancreatitis, which may cause poor prognosis, such as severe gastrointestinal hemorrhage, bowel ischemic necrosis and liver failure. However, its mechanism remains uncertain, and there is not a general consensus on the management.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 339
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37933195",
          "text": "Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is an important sequela complication of acute pancreatitis, which may cause poor prognosis, such as severe gastrointestinal hemorrhage, bowel ischemic necrosis and liver failure. However, its mechanism remains uncertain, and there is not a general consensus on the management. In this study, we reviewed the latest academic publications in APISVT, and discussed its pathogenesis, clinical presentation, adverse outcome and treatment, especially focused on the role of anticoagulant therapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 553
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37933195",
          "text": "A narrative review of acute pancreatitis-induced splanchnic vein thrombosis: from pathogenesis to clinical management.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 118
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35433812",
          "text": "Splanchnic vein thrombosis in acute pancreatitis is most commonly associated with the severe form of the disease and pancreatic necrosis. This report describes a case of splanchnic vein thrombosis as a complication of necrotizing acute pancreatitis in a pediatric patient. Splanchnic vein thrombosis was incidentally detected on contrast-enhanced computed tomography to assess the pancreas.",
          "begin_section": "abstract",
          "offset_in_begin_section": 437,
          "end_section": "abstract",
          "offset_in_end_section": 827
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33887991",
          "text": "Splanchnic Vein Thrombosis in Acute Pancreatitis and Its Consequences.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 70
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35433812",
          "text": "Splanchnic vein thrombosis in acute pancreatitis is most commonly associated with the severe form of the disease and pancreatic necrosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 437,
          "end_section": "abstract",
          "offset_in_end_section": 574
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35433812",
          "text": "Splanchnic vein thrombosis in acute pancreatitis is most commonly associated with the severe form of the disease and pancreatic necrosis. This report describes a case of splanchnic vein thrombosis as a complication of necrotizing acute pancreatitis in a pediatric patient.",
          "begin_section": "abstract",
          "offset_in_begin_section": 437,
          "end_section": "abstract",
          "offset_in_end_section": 709
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34815653",
          "text": "BACKGROUND\nSplanchnic vein thrombosis is a well-recognized local vascular complication of acute pancreatitis (AP), estimated to occur in approximately 15% of patients. While splanchnic vein recanalization occurs spontaneously in approximately one third of patients, severe complications such as bowel ischemia and liver failure have also been reported.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 352
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34815653",
          "text": "BACKGROUND\nSplanchnic vein thrombosis is a well-recognized local vascular complication of acute pancreatitis (AP), estimated to occur in approximately 15% of patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 167
        }
      ],
      "ideal_answer": "Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is a significant complication of acute pancreatitis. It can lead to poor prognosis, including severe gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure. The mechanism of APISVT is uncertain, and there is no general consensus on its management.",
      "exact_answer": "n/a"
    },
    {
      "id": "660d6cc3fdcbea915f00003d",
      "type": "yesno",
      "body": "Is gout a very common inflammatory arthritis, which is caused by hyperbilirubinemia?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37350776",
        "https://pubmed.ncbi.nlm.nih.gov/32904897",
        "https://pubmed.ncbi.nlm.nih.gov/24161431",
        "https://pubmed.ncbi.nlm.nih.gov/29678187",
        "https://pubmed.ncbi.nlm.nih.gov/25967671",
        "https://pubmed.ncbi.nlm.nih.gov/19692116",
        "https://pubmed.ncbi.nlm.nih.gov/16026179",
        "https://pubmed.ncbi.nlm.nih.gov/26279417",
        "https://pubmed.ncbi.nlm.nih.gov/22346148",
        "https://pubmed.ncbi.nlm.nih.gov/20837191"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19692116",
          "text": "Gout is a common arthritis caused by deposition of monosodium urate crystals within joints after chronic hyperuricaemia. It affects 1-2% of adults in developed countries, where it is the most common inflammatory arthritis in men.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 229
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25967671",
          "text": "Gout is one of the most common types of inflammatory arthritis, caused by the deposition of monosodium urate crystals in and around the joints. Previous genome-wide association studies (GWASs) have identified many genetic loci associated with raised serum urate concentrations. However, hyperuricemia alone is not sufficient for the development of gout arthritis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 363
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16026179",
          "text": "Gouty arthritis, a common source of pain and disability, is the most common form of inflammatory arthritis affecting older people. The authors review the epidemiology and pathogenesis of hyperuricemia and gout, as well as the clinical forms of gouty arthritis. Gout is part of a clinical spectrum of conditions (obesity, diabetes mellitus, hyperlipidemia, coronary artery disease) and need for better patient education on management of these associated conditions is emphasized.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 478
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25967671",
          "text": "Gout is one of the most common types of inflammatory arthritis, caused by the deposition of monosodium urate crystals in and around the joints. Previous genome-wide association studies (GWASs) have identified many genetic loci associated with raised serum urate concentrations.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 277
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20837191",
          "text": "Gout is the most common cause of inflammatory arthritis among men and postmenopausal women. Because of the atypical nature of some of its clinical manifestations, gout can present serious diagnostic challenges for practicing physicians.",
          "begin_section": "abstract",
          "offset_in_begin_section": 605,
          "end_section": "abstract",
          "offset_in_end_section": 841
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19692116",
          "text": "Gout is a common arthritis caused by deposition of monosodium urate crystals within joints after chronic hyperuricaemia. It affects 1-2% of adults in developed countries, where it is the most common inflammatory arthritis in men. Epidemiological data are consistent with a rise in prevalence of gout.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 300
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20837191",
          "text": "Gout is the most common cause of inflammatory arthritis among men and postmenopausal women. Because of the atypical nature of some of its clinical manifestations, gout can present serious diagnostic challenges for practicing physicians. In recent years, knowledge about gout's pathogenesis, pathophysiology, and differential diagnosis has advanced on a broad front.",
          "begin_section": "abstract",
          "offset_in_begin_section": 605,
          "end_section": "abstract",
          "offset_in_end_section": 970
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20837191",
          "text": "Gout is the most common cause of inflammatory arthritis among men and postmenopausal women.",
          "begin_section": "abstract",
          "offset_in_begin_section": 605,
          "end_section": "abstract",
          "offset_in_end_section": 696
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25967671",
          "text": "Gout is one of the most common types of inflammatory arthritis, caused by the deposition of monosodium urate crystals in and around the joints.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 143
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16026179",
          "text": "Gouty arthritis, a common source of pain and disability, is the most common form of inflammatory arthritis affecting older people. The authors review the epidemiology and pathogenesis of hyperuricemia and gout, as well as the clinical forms of gouty arthritis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 260
        }
      ],
      "ideal_answer": "No, gout is a common inflammatory arthritis caused by chronic hyperuricemia, not hyperbilirubinemia. Hyperuricemia leads to the deposition of monosodium urate crystals in and around the joints, resulting in gouty arthritis.",
      "exact_answer": "no"
    },
    {
      "id": "65cfce461930410b1300001a",
      "type": "list",
      "body": "What receptors are targeted by Retatrutide?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37947489",
        "https://pubmed.ncbi.nlm.nih.gov/37902090",
        "https://pubmed.ncbi.nlm.nih.gov/37086147",
        "https://pubmed.ncbi.nlm.nih.gov/37366315",
        "https://pubmed.ncbi.nlm.nih.gov/37385280",
        "https://pubmed.ncbi.nlm.nih.gov/17671639",
        "https://pubmed.ncbi.nlm.nih.gov/9208861",
        "https://pubmed.ncbi.nlm.nih.gov/15350601",
        "https://pubmed.ncbi.nlm.nih.gov/17315861",
        "https://pubmed.ncbi.nlm.nih.gov/24742682"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37947489",
          "text": "Retatrutide stimulates Glucagon-like peptide 1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP) receptors, and glucagon receptors, and is being developed for the treatment of obesity and type 2 diabetes. AREAS COVERED\nA phase 2 clinical trial of retatrutide (LY3437943) in the treatment of obesity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 116,
          "end_section": "abstract",
          "offset_in_end_section": 427
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37086147",
          "text": "AREAS COVERED\nA multiple-ascending dose phase 1b clinical trial of a new drug retatrutide (LY3437943), which in addition to stimulating Glucagon-like peptide 1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP) receptors, stimulates glucagon receptors, in subjects with type 2 diabetes. Retatrutide was relatively safe and pharmacokinetics support once-weekly dosing.",
          "begin_section": "abstract",
          "offset_in_begin_section": 284,
          "end_section": "abstract",
          "offset_in_end_section": 663
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37902090",
          "text": "INTRODUCTION\nObesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management. AREAS COVERED\nRetatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 392
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37086147",
          "text": "AREAS COVERED\nA multiple-ascending dose phase 1b clinical trial of a new drug retatrutide (LY3437943), which in addition to stimulating Glucagon-like peptide 1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP) receptors, stimulates glucagon receptors, in subjects with type 2 diabetes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 284,
          "end_section": "abstract",
          "offset_in_end_section": 582
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37902090",
          "text": "Retatrutide, a triple agonist of these receptors, shows promise in obesity management.",
          "begin_section": "abstract",
          "offset_in_begin_section": 110,
          "end_section": "abstract",
          "offset_in_end_section": 196
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37947489",
          "text": "Retatrutide stimulates Glucagon-like peptide 1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP) receptors, and glucagon receptors, and is being developed for the treatment of obesity and type 2 diabetes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 116,
          "end_section": "abstract",
          "offset_in_end_section": 330
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37366315",
          "text": "BACKGROUND\nRetatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 150
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37086147",
          "text": "AREAS COVERED\nA multiple-ascending dose phase 1b clinical trial of a new drug retatrutide (LY3437943), which in addition to stimulating Glucagon-like peptide 1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP) receptors, stimulates glucagon receptors, in subjects with type 2 diabetes. Retatrutide was relatively safe and pharmacokinetics support once-weekly dosing. EXPERT OPINION\nThe role of stimulating glucagon receptors in the treatment of type 2 diabetes and/or obesity is poorly defined and needs to be clarified.",
          "begin_section": "abstract",
          "offset_in_begin_section": 284,
          "end_section": "abstract",
          "offset_in_end_section": 819
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37902090",
          "text": "Retatrutide: a triple incretin receptor agonist for obesity management.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 71
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37902090",
          "text": "INTRODUCTION\nObesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 196
        }
      ],
      "ideal_answer": "Retatrutide targets Glucagon-like peptide 1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP) receptors, and glucagon receptors.",
      "exact_answer": [
        [
          "Glucagon-like peptide 1 (GLP-1) receptors"
        ],
        [
          "Glucose-dependent insulinotropic polypeptide (GIP) receptors"
        ],
        [
          "Glucagon receptors"
        ]
      ]
    },
    {
      "id": "65f77919c4010b4d78000036",
      "type": "summary",
      "body": "What is the mechanism by which the microbiota module the effectiveness of chemotherapy?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/32602287",
        "https://pubmed.ncbi.nlm.nih.gov/36103048",
        "https://pubmed.ncbi.nlm.nih.gov/37593337",
        "https://pubmed.ncbi.nlm.nih.gov/35283422",
        "https://pubmed.ncbi.nlm.nih.gov/37556321",
        "https://pubmed.ncbi.nlm.nih.gov/24391809",
        "https://pubmed.ncbi.nlm.nih.gov/36922730",
        "https://pubmed.ncbi.nlm.nih.gov/24718810",
        "https://pubmed.ncbi.nlm.nih.gov/38013112",
        "https://pubmed.ncbi.nlm.nih.gov/38046820"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36103048",
          "text": "Studies have shown that gut microbiota can regulate the tumour microenvironment and affect the efficacy and toxicity of chemotherapy through a variety of mechanisms. This paper focuses on the specific mechanism that gut microbiota uses to influence chemotherapy and the potential therapeutic effect of supplementing with probiotics, to provide an important basis for individualised treatment strategies to be used when treating malignant tumours.",
          "begin_section": "abstract",
          "offset_in_begin_section": 427,
          "end_section": "abstract",
          "offset_in_end_section": 873
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32602287",
          "text": "This review presents up-to-date information on the effects of microbiota on the individual chemotherapy sensitivity in cancer treatment. Recent studies have shown that a fine balance between the intestinal microbiota and the immune system is crucial for maintaining an efficacy of cancer chemotherapy. A number of antitumor drugs have complex mechanisms of action involving not only direct effects but also the activity of the intestinal microbiota and the immune system.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 471
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32602287",
          "text": "Recent studies have shown that a fine balance between the intestinal microbiota and the immune system is crucial for maintaining an efficacy of cancer chemotherapy. A number of antitumor drugs have complex mechanisms of action involving not only direct effects but also the activity of the intestinal microbiota and the immune system.",
          "begin_section": "abstract",
          "offset_in_begin_section": 137,
          "end_section": "abstract",
          "offset_in_end_section": 471
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36103048",
          "text": "This paper focuses on the specific mechanism that gut microbiota uses to influence chemotherapy and the potential therapeutic effect of supplementing with probiotics, to provide an important basis for individualised treatment strategies to be used when treating malignant tumours.",
          "begin_section": "abstract",
          "offset_in_begin_section": 593,
          "end_section": "abstract",
          "offset_in_end_section": 873
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32602287",
          "text": "Human microbiota and effectiveness of cancer chemotherapy.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 58
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36103048",
          "text": "Studies have shown that gut microbiota can regulate the tumour microenvironment and affect the efficacy and toxicity of chemotherapy through a variety of mechanisms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 427,
          "end_section": "abstract",
          "offset_in_end_section": 592
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32602287",
          "text": "Recent studies have shown that a fine balance between the intestinal microbiota and the immune system is crucial for maintaining an efficacy of cancer chemotherapy. A number of antitumor drugs have complex mechanisms of action involving not only direct effects but also the activity of the intestinal microbiota and the immune system. A unique combination of these factors contributes to the individual chemotherapy sensitivity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 137,
          "end_section": "abstract",
          "offset_in_end_section": 565
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38013112",
          "text": "KEY SCIENTIFIC CONCEPTS OF REVIEW\nRecent evidence shows that gut microbiota modulates the efficacy and toxicity of chemotherapy agents, leading to diverse host responses to chemotherapy. Thereinto, targeting the microbiota to improve efficacy and diminish the toxicity of chemotherapeutic drugs may be a promising strategy in tumor treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 777,
          "end_section": "abstract",
          "offset_in_end_section": 1119
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36103048",
          "text": "In recent years, with the progress in research on human microbiota, gut microbiome plays an increasingly important role in the diagnosis and treatment of diseases. Studies have shown that gut microbiota can regulate the tumour microenvironment and affect the efficacy and toxicity of chemotherapy through a variety of mechanisms. This paper focuses on the specific mechanism that gut microbiota uses to influence chemotherapy and the potential therapeutic effect of supplementing with probiotics, to provide an important basis for individualised treatment strategies to be used when treating malignant tumours.",
          "begin_section": "abstract",
          "offset_in_begin_section": 263,
          "end_section": "abstract",
          "offset_in_end_section": 873
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37593337",
          "text": "However, little is known about the importance and impact of microbiota patterns related to the efficacy and toxicity of cancer treatments. We have recently begun to understand how oncological therapies and the microbiota are closely interconnected and could influence each other. Chemotherapy effectiveness, for example, appears to be strongly influenced by the presence of some microorganisms capable of modulating the pharmacokinetics and pharmacodynamics of the compounds used, thus varying the real response and therefore the efficacy of the oncological treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 282,
          "end_section": "abstract",
          "offset_in_end_section": 850
        }
      ],
      "ideal_answer": "The gut microbiota can modulate the effectiveness of chemotherapy through various mechanisms. One mechanism is the metabolism of chemotherapeutic drugs by gut bacteria, which can alter their pharmacokinetics and pharmacodynamics. Additionally, the gut microbiota can influence the immune response to chemotherapy, affecting the tumor microenvironment and the efficacy of treatment.",
      "exact_answer": "n/a"
    },
    {
      "id": "660a8fc4fdcbea915f000027",
      "type": "summary",
      "body": "What is Tagraxofusp?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/30859413",
        "https://pubmed.ncbi.nlm.nih.gov/37846131",
        "https://pubmed.ncbi.nlm.nih.gov/32460559",
        "https://pubmed.ncbi.nlm.nih.gov/36951152",
        "https://pubmed.ncbi.nlm.nih.gov/33739343",
        "https://pubmed.ncbi.nlm.nih.gov/31018069",
        "https://pubmed.ncbi.nlm.nih.gov/32841341",
        "https://pubmed.ncbi.nlm.nih.gov/31548341",
        "https://pubmed.ncbi.nlm.nih.gov/32336420",
        "https://pubmed.ncbi.nlm.nih.gov/31801379"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32336420",
          "text": "Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It has been shown to be safe and effective in treatment-naïve and previously treated adult patients, with high rates of successful bridging to hematopoietic stem cell transplantation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 352
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32336420",
          "text": "Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It has been shown to be safe and effective in treatment-naïve and previously treated adult patients, with high rates of successful bridging to hematopoietic stem cell transplantation. The pediatric experience is more limited but demonstrates safety.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 418
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32460559",
          "text": "EXPERT OPINION\nTagraxofusp is a newly approved therapy for BPDCN, a hematologic malignancy that has overall historically poor outcomes. With its significant efficacy, many patients were successfully bridged to stem cell transplantation in the clinical trial leading to its ultimate approval.",
          "begin_section": "abstract",
          "offset_in_begin_section": 872,
          "end_section": "abstract",
          "offset_in_end_section": 1163
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32460559",
          "text": "EXPERT OPINION\nTagraxofusp is a newly approved therapy for BPDCN, a hematologic malignancy that has overall historically poor outcomes. With its significant efficacy, many patients were successfully bridged to stem cell transplantation in the clinical trial leading to its ultimate approval. Clinical awareness for major toxicities, including capillary leak syndrome will be a critical aspect of using this novel agent.",
          "begin_section": "abstract",
          "offset_in_begin_section": 872,
          "end_section": "abstract",
          "offset_in_end_section": 1291
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36951152",
          "text": "The disease, which commonly affects older men but can also present in children, is associated with a distinct immunophenotype including universal expression of CD123, the alpha chain of the interleukin 3 receptor. Recently, tagraxofusp, a CD123-targeting drug consisting of the ligand for CD123, interleukin 3, conjugated to a truncated diphtheria toxin payload was approved for treatment of BPDCN.",
          "begin_section": "abstract",
          "offset_in_begin_section": 253,
          "end_section": "abstract",
          "offset_in_end_section": 651
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36951152",
          "text": "Recently, tagraxofusp, a CD123-targeting drug consisting of the ligand for CD123, interleukin 3, conjugated to a truncated diphtheria toxin payload was approved for treatment of BPDCN. This was the first agent specifically approved for BPDCN and the first CD123 targeted agent in oncology.",
          "begin_section": "abstract",
          "offset_in_begin_section": 467,
          "end_section": "abstract",
          "offset_in_end_section": 756
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31018069",
          "text": "CONCLUSIONS\nIn adult patients with untreated or relapsed BPDCN, the use of tagraxofusp led to clinical responses. Serious adverse events included capillary leak syndrome; hepatic dysfunction and thrombocytopenia were common. (Funded by Stemline Therapeutics and the Leukemia and Lymphoma Society Therapy Acceleration Program; ClinicalTrials.gov number, NCT02113982.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1837,
          "end_section": "abstract",
          "offset_in_end_section": 2202
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36951152",
          "text": "The disease, which commonly affects older men but can also present in children, is associated with a distinct immunophenotype including universal expression of CD123, the alpha chain of the interleukin 3 receptor. Recently, tagraxofusp, a CD123-targeting drug consisting of the ligand for CD123, interleukin 3, conjugated to a truncated diphtheria toxin payload was approved for treatment of BPDCN. This was the first agent specifically approved for BPDCN and the first CD123 targeted agent in oncology.",
          "begin_section": "abstract",
          "offset_in_begin_section": 253,
          "end_section": "abstract",
          "offset_in_end_section": 756
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31018069",
          "text": "Among the 29 previously untreated patients who received tagraxofusp at a dose of 12 μg per kilogram, the primary outcome occurred in 21 (72%), and the overall response rate was 90%; of these patients, 45% went on to undergo stem-cell transplantation. Survival rates at 18 and 24 months were 59% and 52%, respectively.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1075,
          "end_section": "abstract",
          "offset_in_end_section": 1392
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31018069",
          "text": "The median age of the patients was 70 years (range, 22 to 84). Among the 29 previously untreated patients who received tagraxofusp at a dose of 12 μg per kilogram, the primary outcome occurred in 21 (72%), and the overall response rate was 90%; of these patients, 45% went on to undergo stem-cell transplantation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1012,
          "end_section": "abstract",
          "offset_in_end_section": 1325
        }
      ],
      "ideal_answer": "Tagraxofusp is a CD123-targeted immunotoxin that has been approved by the FDA for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It consists of the ligand for CD123, interleukin 3, conjugated to a truncated diphtheria toxin payload.",
      "exact_answer": "n/a"
    },
    {
      "id": "660d6f0cfdcbea915f00003e",
      "type": "summary",
      "body": "What is the epidemiology of breast cancer in men?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/15668471",
        "https://pubmed.ncbi.nlm.nih.gov/12379069",
        "https://pubmed.ncbi.nlm.nih.gov/16425090",
        "https://pubmed.ncbi.nlm.nih.gov/12208898",
        "https://pubmed.ncbi.nlm.nih.gov/1913556",
        "https://pubmed.ncbi.nlm.nih.gov/2061945",
        "https://pubmed.ncbi.nlm.nih.gov/24882341",
        "https://pubmed.ncbi.nlm.nih.gov/30452854",
        "https://pubmed.ncbi.nlm.nih.gov/3046556",
        "https://pubmed.ncbi.nlm.nih.gov/29526255"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15668471",
          "text": "Epidemiology of male breast cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 35
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29526255",
          "text": "Male Breast Cancer: Epidemiology and Risk Factors.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 50
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/3046556",
          "text": "[Epidemiology of breast cancer].",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 32
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24882341",
          "text": "Epidemiology of breast cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 30
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12379069",
          "text": "DATA SOURCES\nArticles published between 1942 and 2000 on breast cancer in men were identified by using CancerLit, MEDLINE, and study bibliographies. STUDY SELECTION\nAll retrospective series and studies focusing on the epidemiology, risk factors, genetics, and pathology of breast cancer in men. DATA EXTRACTION\nData on the epidemiology, risk factors, genetics, pathology, molecular markers, prognostic factors, therapy, and outcomes of breast cancer in men.",
          "begin_section": "abstract",
          "offset_in_begin_section": 326,
          "end_section": "abstract",
          "offset_in_end_section": 787
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16425090",
          "text": "Comparative epidemiology of breast cancer among men and women in the US, 1996 to 2000.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 86
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15668471",
          "text": "This review is intended to summarize the existing body of evidence on genetic and epidemiologic risk factors for breast cancer in men. Overall, the epidemiology of MBC presents similarities with the epidemiology of female breast cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 258,
          "end_section": "abstract",
          "offset_in_end_section": 494
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15668471",
          "text": "Overall, the epidemiology of MBC presents similarities with the epidemiology of female breast cancer. Major genetic factors associated with an increased risk of breast cancer for men include BRCA2 mutations, which are believed to account for the majority of inherited breast cancer in men, Klinefelter syndrome, and a positive family history. Suspected genetic factors include AR gene mutations, CYP17 polymorphism, Cowden syndrome, and CHEK2.",
          "begin_section": "abstract",
          "offset_in_begin_section": 393,
          "end_section": "abstract",
          "offset_in_end_section": 836
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29526255",
          "text": "This in depth review highlights the epidemiology and risk factors for the development of male breast cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 834,
          "end_section": "abstract",
          "offset_in_end_section": 942
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12379069",
          "text": "DATA SOURCES\nArticles published between 1942 and 2000 on breast cancer in men were identified by using CancerLit, MEDLINE, and study bibliographies. STUDY SELECTION\nAll retrospective series and studies focusing on the epidemiology, risk factors, genetics, and pathology of breast cancer in men.",
          "begin_section": "abstract",
          "offset_in_begin_section": 326,
          "end_section": "abstract",
          "offset_in_end_section": 622
        }
      ],
      "ideal_answer": "The epidemiology of breast cancer in men is similar to that of female breast cancer. Major genetic factors associated with an increased risk of breast cancer in men include BRCA2 mutations, Klinefelter syndrome, and a positive family history. Suspected genetic factors include AR gene mutations, CYP17 polymorphism, Cowden syndrome, and CHEK2.",
      "exact_answer": "n/a"
    },
    {
      "id": "65cfdaae1930410b13000025",
      "type": "factoid",
      "body": "What disease can be treatment with Bulevirtide?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/32926353",
        "https://pubmed.ncbi.nlm.nih.gov/37853604",
        "https://pubmed.ncbi.nlm.nih.gov/36727226",
        "https://pubmed.ncbi.nlm.nih.gov/37025462",
        "https://pubmed.ncbi.nlm.nih.gov/34268531",
        "https://pubmed.ncbi.nlm.nih.gov/36286651",
        "https://pubmed.ncbi.nlm.nih.gov/36931396",
        "https://pubmed.ncbi.nlm.nih.gov/37345876",
        "https://pubmed.ncbi.nlm.nih.gov/36004554",
        "https://pubmed.ncbi.nlm.nih.gov/37089922"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37025462",
          "text": "In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma.",
          "begin_section": "abstract",
          "offset_in_begin_section": 98,
          "end_section": "abstract",
          "offset_in_end_section": 303
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32926353",
          "text": "Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV.",
          "begin_section": "abstract",
          "offset_in_begin_section": 196,
          "end_section": "abstract",
          "offset_in_end_section": 487
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32926353",
          "text": "Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 196,
          "end_section": "abstract",
          "offset_in_end_section": 366
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34268531",
          "text": "In July 2020 bulevirtide was authorized for use in the E.U. following a positive opinion by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in HDV RNA-positive adult patients with compensated liver disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 808,
          "end_section": "abstract",
          "offset_in_end_section": 1045
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34268531",
          "text": "In July 2020 bulevirtide was authorized for use in the E.U. following a positive opinion by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in HDV RNA-positive adult patients with compensated liver disease. In this paper we have examined the studies that led to this approval as well as studies examining the drug's efficacy in treating HBV.",
          "begin_section": "abstract",
          "offset_in_begin_section": 808,
          "end_section": "abstract",
          "offset_in_end_section": 1180
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37025462",
          "text": "In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma. Herein, we report the first data from a large multicenter real-world cohort of patients with hepatitis D treated with bulevirtide at a daily dose of 2 mg without additional interferon.",
          "begin_section": "abstract",
          "offset_in_begin_section": 98,
          "end_section": "abstract",
          "offset_in_end_section": 488
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32926353",
          "text": "Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 366
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37025462",
          "text": "Background & Aims\nBulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma. Herein, we report the first data from a large multicenter real-world cohort of patients with hepatitis D treated with bulevirtide at a daily dose of 2 mg without additional interferon.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 488
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32926353",
          "text": "Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 487
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37025462",
          "text": "Background & Aims\nBulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 303
        }
      ],
      "ideal_answer": "Bulevirtide is approved for the treatment of chronic hepatitis D (HDV) infection in HDV RNA-positive adult patients with compensated liver disease.",
      "exact_answer": [
        [
          "Bulevirtide is used for the treatment of chronic hepatitis D (HDV) infection."
        ]
      ]
    },
    {
      "id": "65f7785dc4010b4d78000033",
      "type": "factoid",
      "body": "Which initial chemotherapy regimen is the most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/34818447",
        "https://pubmed.ncbi.nlm.nih.gov/36185248",
        "https://pubmed.ncbi.nlm.nih.gov/33987952",
        "https://pubmed.ncbi.nlm.nih.gov/37438538",
        "https://pubmed.ncbi.nlm.nih.gov/36253514",
        "https://pubmed.ncbi.nlm.nih.gov/37085291",
        "https://pubmed.ncbi.nlm.nih.gov/33915629",
        "https://pubmed.ncbi.nlm.nih.gov/33608161",
        "https://pubmed.ncbi.nlm.nih.gov/35716183",
        "https://pubmed.ncbi.nlm.nih.gov/34878307"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33987952",
          "text": "BACKGROUND\nTotal neoadjuvant therapy (TNT) is a novel approach for locally advanced rectal cancer (LARC), which attempts to deliver both systemic chemotherapy and neoadjuvant chemoradiotherapy prior to surgery. However, its efficacy and safety remain controversial in randomized controlled trials (RCTs).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 304
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34878307",
          "text": "Aim: To compare treatment outcomes of total neoadjuvant therapy (TNT) and the standard treatment for locally advanced rectal cancer (LARC). Materials & methods: Patients with LARC (cT2-4 and/or cN1-2) who were treated with preoperative chemoradiotherapy plus induction and consolidation chemotherapy followed by surgery or the standard treatment were recruited.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 361
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33987952",
          "text": "Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 152
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33608161",
          "text": "INTRODUCTION\nThe use of total neoadjuvant therapy (TNT) for locally advanced rectal cancer has been increasing in recent years, but the long-term overall survival characteristics of this approach is currently unknown. METHODS\nWe performed a retrospective study of patients with clinical stage II/III rectal cancer within the National Cancer Database.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 352
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33608161",
          "text": "INTRODUCTION\nThe use of total neoadjuvant therapy (TNT) for locally advanced rectal cancer has been increasing in recent years, but the long-term overall survival characteristics of this approach is currently unknown.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 217
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37438538",
          "text": "A contemporary assessment of total neoadjuvant therapy (TNT) protocols for locally advanced rectal cancer: adoption and expert perspectives at German Cancer Society (DKG)-certified colorectal cancer centers.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 207
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33987952",
          "text": "BACKGROUND\nTotal neoadjuvant therapy (TNT) is a novel approach for locally advanced rectal cancer (LARC), which attempts to deliver both systemic chemotherapy and neoadjuvant chemoradiotherapy prior to surgery.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 210
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33987952",
          "text": "BACKGROUND\nTotal neoadjuvant therapy (TNT) is a novel approach for locally advanced rectal cancer (LARC), which attempts to deliver both systemic chemotherapy and neoadjuvant chemoradiotherapy prior to surgery. However, its efficacy and safety remain controversial in randomized controlled trials (RCTs). We conducted this meta-analysis to assess such concerns.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 361
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37085291",
          "text": "The modern management of rectal cancers continues to evolve. With the release of data from new landmark randomized controlled trials (RAPIDO, PRODIGE-23), total neoadjuvant therapy (TNT) has moved to the forefront of locally advanced rectal cancer treatment and is considered a standard option in selected patients. Total neoadjuvant therapy promises enhanced systemic disease control, better treatment adherence and less time with an ostomy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 442
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37085291",
          "text": "With the release of data from new landmark randomized controlled trials (RAPIDO, PRODIGE-23), total neoadjuvant therapy (TNT) has moved to the forefront of locally advanced rectal cancer treatment and is considered a standard option in selected patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 61,
          "end_section": "abstract",
          "offset_in_end_section": 315
        }
      ],
      "ideal_answer": "The most appropriate initial chemotherapy regimen in total neoadjuvant therapy (TNT) for locally advanced rectal cancer patients is a combination of fluoropyrimidine-based chemotherapy, such as capecitabine or 5-fluorouracil (5-FU), with oxaliplatin (FOLFOX or CAPOX). This regimen has been shown to improve tumor response rates and increase the likelihood of achieving a complete pathological response. It is important to note that the choice of chemotherapy regimen may vary depending on individual patient factors and institutional protocols.",
      "exact_answer": [
        [
          "The most appropriate initial chemotherapy regimen in total neoadjuvant therapy (TNT) for locally advanced rectal cancer patients is currently unknown and may vary depending on individual patient factors and institutional protocols."
        ]
      ]
    },
    {
      "id": "66088d66fdcbea915f00000c",
      "type": "factoid",
      "body": "In what part of the cell would a SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) be found",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/29696021",
        "https://pubmed.ncbi.nlm.nih.gov/27992096",
        "https://pubmed.ncbi.nlm.nih.gov/23665562",
        "https://pubmed.ncbi.nlm.nih.gov/9325254",
        "https://pubmed.ncbi.nlm.nih.gov/11115874",
        "https://pubmed.ncbi.nlm.nih.gov/22962332",
        "https://pubmed.ncbi.nlm.nih.gov/21733851",
        "https://pubmed.ncbi.nlm.nih.gov/18459979",
        "https://pubmed.ncbi.nlm.nih.gov/17872963",
        "https://pubmed.ncbi.nlm.nih.gov/15347585"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27992096",
          "text": "Vesicular and target soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are key proteins of the intracellular membrane fusion machinery.",
          "begin_section": "abstract",
          "offset_in_begin_section": 172,
          "end_section": "abstract",
          "offset_in_end_section": 337
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29696021",
          "text": "Vesicle-associated V-soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins and target membrane-associated T-SNAREs (syntaxin 4 and SNAP-23) assemble into a core trans-SNARE complex that mediates membrane fusion during mast cell degranulation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 275
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/9325254",
          "text": "Golgi soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) GS28 and syntaxin 5 can be reciprocally coimmunoprecipitated from Golgi extracts, suggesting that they exist in a protein complex.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 216
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18459979",
          "text": "Soluble N-ethylmaleimide sensitive-factor attachment receptor (SNARE) proteins have crucial roles in driving exocytic membrane fusion.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 134
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21733851",
          "text": "Although soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) such as syntaxin 2, SNAP23 (synaptosome-associated protein of 23 kDa), and SNAP25 have been suggested to play a role, none has been proven.",
          "begin_section": "abstract",
          "offset_in_begin_section": 337,
          "end_section": "abstract",
          "offset_in_end_section": 565
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27992096",
          "text": "Vesicular and target soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are key proteins of the intracellular membrane fusion machinery. During the early times of T. cruzi infection, several vesicles are attracted to the parasite contact sites in the plasma membrane.",
          "begin_section": "abstract",
          "offset_in_begin_section": 172,
          "end_section": "abstract",
          "offset_in_end_section": 468
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18459979",
          "text": "Soluble N-ethylmaleimide sensitive-factor attachment receptor (SNARE) proteins have crucial roles in driving exocytic membrane fusion. Molecular recognition between vesicle-associated (v)-SNARE and target membrane (t)-SNARE leads to the formation of a four-helix bundle, which facilitates the merging of two apposing membranes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 327
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21733851",
          "text": "Although soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) such as syntaxin 2, SNAP23 (synaptosome-associated protein of 23 kDa), and SNAP25 have been suggested to play a role, none has been proven. Vesicle-associated membrane protein 8 (VAMP8) is a SNARE first associated with endocytic processes but more recently has been suggested as an R-SNARE in regulated exocytosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 337,
          "end_section": "abstract",
          "offset_in_end_section": 740
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17872963",
          "text": "This study investigated the effect of soluble N-ethylmaleimide-sensitive factor-attachment protein (SNAP) receptors (SNAREs) on the fusion of egg L-alpha-phosphatidylcholine bilayers using atomic force microscope (AFM) spectroscopy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 232
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29696021",
          "text": "Vesicle-associated V-soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins and target membrane-associated T-SNAREs (syntaxin 4 and SNAP-23) assemble into a core trans-SNARE complex that mediates membrane fusion during mast cell degranulation. This complex plays pivotal roles at various stages of exocytosis from the initial priming step to fusion pore opening and expansion, finally resulting in the release of the vesicle contents.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 466
        }
      ],
      "ideal_answer": "Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are found in various parts of the cell, including the plasma membrane, Golgi apparatus, and vesicles. They play crucial roles in mediating membrane fusion and exocytosis at these locations.",
      "exact_answer": [
        [
          "Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) can be found in various parts of the cell, including the plasma membrane, Golgi apparatus, and vesicles."
        ]
      ]
    },
    {
      "id": "660c0895fdcbea915f00002f",
      "type": "summary",
      "body": "Relevance of tumoral microbiome.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/34997106",
        "https://pubmed.ncbi.nlm.nih.gov/36497456",
        "https://pubmed.ncbi.nlm.nih.gov/28852682",
        "https://pubmed.ncbi.nlm.nih.gov/32974256",
        "https://pubmed.ncbi.nlm.nih.gov/37140882",
        "https://pubmed.ncbi.nlm.nih.gov/37465976",
        "https://pubmed.ncbi.nlm.nih.gov/33367119",
        "https://pubmed.ncbi.nlm.nih.gov/35366966",
        "https://pubmed.ncbi.nlm.nih.gov/36061192",
        "https://pubmed.ncbi.nlm.nih.gov/28390576"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37140882",
          "text": "PURPOSE\nBacteria have been observed in the tumor environment for decades and have been demonstrated to play important roles in the pathogenesis and development of several different tumors. So far there is a clear lack of specific studies relating to the presence of bacteria in pituitary neuroendocrine tumors (PitNETs).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 320
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28852682",
          "text": "The review illustrates pathophysiologic concepts linking the microbiome and infectious diseases; specifically, the intestinal microbiome's relevance to early immune development, the microbiome and enteric infections, the microbiome's relevance in compromised hosts, and antimicrobial resistance. Within each subject, there are specific examples of diseases and at-risk patient populations where a role for the microbiome has been strongly established.",
          "begin_section": "abstract",
          "offset_in_begin_section": 443,
          "end_section": "abstract",
          "offset_in_end_section": 894
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28852682",
          "text": "The review illustrates pathophysiologic concepts linking the microbiome and infectious diseases; specifically, the intestinal microbiome's relevance to early immune development, the microbiome and enteric infections, the microbiome's relevance in compromised hosts, and antimicrobial resistance. Within each subject, there are specific examples of diseases and at-risk patient populations where a role for the microbiome has been strongly established. This provides an overview of the significance of the intestinal microbiome to microbiology, pediatric and adult infectious diseases with an underpinning of concepts useful for the practicing clinician.",
          "begin_section": "abstract",
          "offset_in_begin_section": 443,
          "end_section": "abstract",
          "offset_in_end_section": 1096
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28852682",
          "text": "The Intestinal Microbiome in Infectious Diseases: The Clinical Relevance of a Rapidly Emerging Field.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 101
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32974256",
          "text": "Microbiome-Aware Ecotoxicology of Organisms: Relevance, Pitfalls, and Challenges.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 81
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32974256",
          "text": "In this paper, we thus advocate for the development of a \"microbiome-aware ecotoxicology\" of organisms. We emphasize its relevance and discuss important conceptual and technical pitfalls associated with study design and interpretation. We identify topics such as functionality, quantification, temporality, resilience, interactions, and prediction as major challenges and promising venues for microbiome research applied to ecotoxicology.",
          "begin_section": "abstract",
          "offset_in_begin_section": 577,
          "end_section": "abstract",
          "offset_in_end_section": 1015
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28852682",
          "text": "Relevant articles published up through 2017 were reviewed within Rayyan. The review illustrates pathophysiologic concepts linking the microbiome and infectious diseases; specifically, the intestinal microbiome's relevance to early immune development, the microbiome and enteric infections, the microbiome's relevance in compromised hosts, and antimicrobial resistance. Within each subject, there are specific examples of diseases and at-risk patient populations where a role for the microbiome has been strongly established.",
          "begin_section": "abstract",
          "offset_in_begin_section": 370,
          "end_section": "abstract",
          "offset_in_end_section": 894
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32974256",
          "text": "Over the last 15 years, the advent of high-throughput \"omics\" techniques has revealed the multiple roles and interactions occurring among hosts, their microbial partners and their environment. This microbiome revolution has radically changed our views of biology, evolution, and individuality. Sitting at the interface between a host and its environment, the microbiome is a relevant yet understudied compartment for ecotoxicology research.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 440
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32974256",
          "text": "Various recent works confirm that the microbiome reacts to and interacts with contaminants, with consequences for hosts and ecosystems. In this paper, we thus advocate for the development of a \"microbiome-aware ecotoxicology\" of organisms. We emphasize its relevance and discuss important conceptual and technical pitfalls associated with study design and interpretation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 441,
          "end_section": "abstract",
          "offset_in_end_section": 812
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35366966",
          "text": "Clinical Relevance of the Microbiome in Pediatric Skin Disease: A Review.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 73
        }
      ],
      "ideal_answer": "The presence of bacteria in tumors, including pituitary neuroendocrine tumors (PitNETs), has been observed and is believed to play a role in their pathogenesis and development. However, specific studies on the presence of bacteria in PitNETs are lacking. Understanding the tumoral microbiome could provide insights into the mechanisms underlying tumor development and potentially lead to new therapeutic approaches.",
      "exact_answer": "n/a"
    },
    {
      "id": "65cf6ae91930410b13000007",
      "type": "factoid",
      "body": "What disease is treated with Teplizumab?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/20095914",
        "https://pubmed.ncbi.nlm.nih.gov/36877454",
        "https://pubmed.ncbi.nlm.nih.gov/37607392",
        "https://pubmed.ncbi.nlm.nih.gov/22968521",
        "https://pubmed.ncbi.nlm.nih.gov/37861217",
        "https://pubmed.ncbi.nlm.nih.gov/33658358",
        "https://pubmed.ncbi.nlm.nih.gov/31180194",
        "https://pubmed.ncbi.nlm.nih.gov/37004543",
        "https://pubmed.ncbi.nlm.nih.gov/23086558",
        "https://pubmed.ncbi.nlm.nih.gov/33302842"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37861217",
          "text": "BACKGROUND\nTeplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease. Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown. METHODS\nIn this phase 3, randomized, placebo-controlled trial, we assessed β-cell preservation, clinical end points, and safety in children and adolescents who were assigned to receive teplizumab or placebo for two 12-day courses.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 622
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37607392",
          "text": "Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 91
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37861217",
          "text": "Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown. METHODS\nIn this phase 3, randomized, placebo-controlled trial, we assessed β-cell preservation, clinical end points, and safety in children and adolescents who were assigned to receive teplizumab or placebo for two 12-day courses.",
          "begin_section": "abstract",
          "offset_in_begin_section": 251,
          "end_section": "abstract",
          "offset_in_end_section": 622
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37861217",
          "text": "Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown.",
          "begin_section": "abstract",
          "offset_in_begin_section": 251,
          "end_section": "abstract",
          "offset_in_end_section": 389
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37861217",
          "text": "Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown. METHODS\nIn this phase 3, randomized, placebo-controlled trial, we assessed β-cell preservation, clinical end points, and safety in children and adolescents who were assigned to receive teplizumab or placebo for two 12-day courses. The primary end point was the change from baseline in β-cell function, as measured by stimulated C-peptide levels at week 78.",
          "begin_section": "abstract",
          "offset_in_begin_section": 251,
          "end_section": "abstract",
          "offset_in_end_section": 748
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37861217",
          "text": "BACKGROUND\nTeplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease. Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 389
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33302842",
          "text": "BACKGROUND\nType one diabetes mellitus (T1DM) is an autoimmune disease characterized by gradual destruction of beta cells in islets of Langerhans. Teplizumab is a humanized anti- CD3 monoclonal antibody, which may have beneficial effects for T1DM patients. OBJECTIVE\nThe aim of the study was to assess the safety and efficacy of teplizumab in T1DM patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 358
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33302842",
          "text": "BACKGROUND\nType one diabetes mellitus (T1DM) is an autoimmune disease characterized by gradual destruction of beta cells in islets of Langerhans. Teplizumab is a humanized anti- CD3 monoclonal antibody, which may have beneficial effects for T1DM patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 255
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37861217",
          "text": "BACKGROUND\nTeplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 250
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23086558",
          "text": "We tested whether treatment with teplizumab (a Fc receptor non-binding anti-CD3 monoclonal antibody), after the new-onset period, affects the decline in C-peptide production in individuals with type 1 diabetes. METHODS\nIn a randomised placebo-controlled trial we treated 58 participants with type 1 diabetes for 4-12 months with teplizumab or placebo at four academic centres in the USA.",
          "begin_section": "abstract",
          "offset_in_begin_section": 115,
          "end_section": "abstract",
          "offset_in_end_section": 504
        }
      ],
      "ideal_answer": "Teplizumab is used to treat type 1 diabetes, an autoimmune disease characterized by the gradual destruction of beta cells in the islets of Langerhans.",
      "exact_answer": [
        [
          "Type 1 diabetes"
        ]
      ]
    },
    {
      "id": "65f7778fc4010b4d78000031",
      "type": "yesno",
      "body": "Is Trifluridine/Tipiracil a preferential treatment over Regorafenib in elderly colorectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/33813435",
        "https://pubmed.ncbi.nlm.nih.gov/27900102",
        "https://pubmed.ncbi.nlm.nih.gov/36990929",
        "https://pubmed.ncbi.nlm.nih.gov/36510990",
        "https://pubmed.ncbi.nlm.nih.gov/27487107",
        "https://pubmed.ncbi.nlm.nih.gov/29110922",
        "https://pubmed.ncbi.nlm.nih.gov/33517315",
        "https://pubmed.ncbi.nlm.nih.gov/30257515",
        "https://pubmed.ncbi.nlm.nih.gov/28894015",
        "https://pubmed.ncbi.nlm.nih.gov/34406678"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36990929",
          "text": "Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 101
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27900102",
          "text": "Regorafenib and trifluridine/tipiracil combination tablet regimens are standard third-line or later treatments for advanced and recurrent colorectal cancer with no significant difference in efficacy. The present study aimed to compare the cost-effectiveness of using regorafenib vs. the trifluridine/tipiracil combination tablet.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 329
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28894015",
          "text": "This large, multicenter, observational study retrospectively compared the efficacy of regorafenib and trifluridine/tipiracil in 550 patients with metastatic colorectal cancer refractory to standard chemotherapy who had access to both drugs.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1946,
          "end_section": "abstract",
          "offset_in_end_section": 2186
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27900102",
          "text": "Regorafenib and trifluridine/tipiracil combination tablet regimens are standard third-line or later treatments for advanced and recurrent colorectal cancer with no significant difference in efficacy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 199
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34406678",
          "text": "Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 138
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34406678",
          "text": "BACKGROUND\nTrifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for patients with refractory metastatic colorectal cancer (mCRC); limited comparative effectiveness data exist. MATERIALS AND METHODS\nA retrospective, longitudinal cohort study of patients with mCRC who initiated FTD/TPI or regorafenib (index therapy) between 2012 and 2017 at a U.S. tertiary oncology center, Dana-Farber Cancer Institute, was conducted.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 433
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28894015",
          "text": "BACKGROUND\nThis study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 318
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28894015",
          "text": "IMPLICATIONS FOR PRACTICE\nPrevious studies of patients with metastatic colorectal cancer refractory to standard chemotherapy had demonstrated that both regorafenib and trifluridine/tipiracil could result in increased overall survival compared with placebo, but there are no head-to-head trials. This large, multicenter, observational study retrospectively compared the efficacy of regorafenib and trifluridine/tipiracil in 550 patients with metastatic colorectal cancer refractory to standard chemotherapy who had access to both drugs. Although no difference in overall survival was found between the two drugs in adjusted analysis using propensity score, regorafenib showed favorable survival in patients aged <65 years, whereas trifluridine/tipiracil was favored in patients aged ≥65 years in the subgroup analysis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1651,
          "end_section": "abstract",
          "offset_in_end_section": 2468
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28894015",
          "text": "IMPLICATIONS FOR PRACTICE\nPrevious studies of patients with metastatic colorectal cancer refractory to standard chemotherapy had demonstrated that both regorafenib and trifluridine/tipiracil could result in increased overall survival compared with placebo, but there are no head-to-head trials.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1651,
          "end_section": "abstract",
          "offset_in_end_section": 1945
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28894015",
          "text": "IMPLICATIONS FOR PRACTICE\nPrevious studies of patients with metastatic colorectal cancer refractory to standard chemotherapy had demonstrated that both regorafenib and trifluridine/tipiracil could result in increased overall survival compared with placebo, but there are no head-to-head trials. This large, multicenter, observational study retrospectively compared the efficacy of regorafenib and trifluridine/tipiracil in 550 patients with metastatic colorectal cancer refractory to standard chemotherapy who had access to both drugs.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1651,
          "end_section": "abstract",
          "offset_in_end_section": 2186
        }
      ],
      "ideal_answer": "Based on the retrospective study comparing the efficacy of regorafenib and trifluridine/tipiracil in elderly patients with metastatic colorectal cancer refractory to standard chemotherapy, there was no significant difference in overall survival between the two drugs. However, in the subgroup analysis, regorafenib showed favorable survival in patients aged <65 years, while trifluridine/tipiracil was favored in patients aged ≥65 years. Therefore, the choice between trifluridine/tipiracil and regorafenib should be individualized based on patient age and other factors.",
      "exact_answer": "no"
    },
    {
      "id": "66088bbafdcbea915f00000a",
      "type": "summary",
      "body": "What is the function of Diphthamide?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/23971743",
        "https://pubmed.ncbi.nlm.nih.gov/25352115",
        "https://pubmed.ncbi.nlm.nih.gov/30312900",
        "https://pubmed.ncbi.nlm.nih.gov/32576952",
        "https://pubmed.ncbi.nlm.nih.gov/31463593",
        "https://pubmed.ncbi.nlm.nih.gov/28357244",
        "https://pubmed.ncbi.nlm.nih.gov/23645155",
        "https://pubmed.ncbi.nlm.nih.gov/24739148",
        "https://pubmed.ncbi.nlm.nih.gov/30204891",
        "https://pubmed.ncbi.nlm.nih.gov/16648478"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30204891",
          "text": "Recent studies have suggested that diphthamide has specific functions for the cellular stress response and active proliferation. In this review, we summarize the history and findings of diphthamide obtained to date and discuss the possibility of a specific function for diphthamide in regulating protein translation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 369,
          "end_section": "abstract",
          "offset_in_end_section": 685
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30204891",
          "text": "On the other hand, the physiological function of this rare modification in vivo remains unknown. Recent studies have suggested that diphthamide has specific functions for the cellular stress response and active proliferation. In this review, we summarize the history and findings of diphthamide obtained to date and discuss the possibility of a specific function for diphthamide in regulating protein translation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 272,
          "end_section": "abstract",
          "offset_in_end_section": 685
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30204891",
          "text": "Recent studies have suggested that diphthamide has specific functions for the cellular stress response and active proliferation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 369,
          "end_section": "abstract",
          "offset_in_end_section": 497
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30204891",
          "text": "On the other hand, the physiological function of this rare modification in vivo remains unknown. Recent studies have suggested that diphthamide has specific functions for the cellular stress response and active proliferation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 272,
          "end_section": "abstract",
          "offset_in_end_section": 497
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23971743",
          "text": "The biosynthesis and biological function of diphthamide.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 56
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25352115",
          "text": "Diphthamide is a conserved modification in archaeal and eukaryal translation elongation factor 2 (EF2). Its name refers to the target function for diphtheria toxin, the disease-causing agent that, through ADP ribosylation of diphthamide, causes irreversible inactivation of EF2 and cell death. Although this clearly emphasizes a pathobiological role for diphthamide, its physiological function is unclear, and precisely why cells need EF2 to contain diphthamide is hardly understood.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 483
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25352115",
          "text": "Diphthamide is a conserved modification in archaeal and eukaryal translation elongation factor 2 (EF2). Its name refers to the target function for diphtheria toxin, the disease-causing agent that, through ADP ribosylation of diphthamide, causes irreversible inactivation of EF2 and cell death.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 293
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30204891",
          "text": "eEF2 is an essential factor in protein translation, and the diphthamide modification has been a famous target of the diphtheria toxin for a long time. On the other hand, the physiological function of this rare modification in vivo remains unknown. Recent studies have suggested that diphthamide has specific functions for the cellular stress response and active proliferation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 121,
          "end_section": "abstract",
          "offset_in_end_section": 497
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23971743",
          "text": "Although the pathological relevance is well studied, the physiological function of diphthamide is still poorly understood.",
          "begin_section": "abstract",
          "offset_in_begin_section": 469,
          "end_section": "abstract",
          "offset_in_end_section": 591
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23971743",
          "text": "Here, we review the current understanding of the biosynthesis and biological function of diphthamide.",
          "begin_section": "abstract",
          "offset_in_begin_section": 690,
          "end_section": "abstract",
          "offset_in_end_section": 791
        }
      ],
      "ideal_answer": "Diphthamide is a conserved modification found in archaeal and eukaryal translation elongation factor 2 (EF2). Its main known function is as a target for diphtheria toxin, which irreversibly inactivates EF2 and causes cell death. The physiological function of diphthamide in vivo is still unclear.",
      "exact_answer": "n/a"
    },
    {
      "id": "660d6a97fdcbea915f00003c",
      "type": "yesno",
      "body": "Without immunization, rabies is a lethal disease.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/19887739",
        "https://pubmed.ncbi.nlm.nih.gov/2058261",
        "https://pubmed.ncbi.nlm.nih.gov/9701249",
        "https://pubmed.ncbi.nlm.nih.gov/18256513",
        "https://pubmed.ncbi.nlm.nih.gov/31790413",
        "https://pubmed.ncbi.nlm.nih.gov/11402706",
        "https://pubmed.ncbi.nlm.nih.gov/2760222",
        "https://pubmed.ncbi.nlm.nih.gov/27483431",
        "https://pubmed.ncbi.nlm.nih.gov/3060962",
        "https://pubmed.ncbi.nlm.nih.gov/3480536"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27483431",
          "text": "Vaccine alone was unable to rescue mice from lethal disease. As reported also for immune globulins, some interference of anti-rabies VHH with the antigenicity of the vaccine was observed, but this did not impede the synergistic effect. Post exposure treatment with vaccine and human anti-rabies immune globulins was unable to protect mice from lethal challenge.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1227,
          "end_section": "abstract",
          "offset_in_end_section": 1588
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18256513",
          "text": "All immunized mice were challenged intracerebrally with a lethal dose of virulent rabies virus CVS strain.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1017,
          "end_section": "abstract",
          "offset_in_end_section": 1123
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27483431",
          "text": "Vaccine alone was unable to rescue mice from lethal disease. As reported also for immune globulins, some interference of anti-rabies VHH with the antigenicity of the vaccine was observed, but this did not impede the synergistic effect.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1227,
          "end_section": "abstract",
          "offset_in_end_section": 1462
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/9701249",
          "text": "This study shows that DNA immunization elicits protective immunity in nonhuman primates against lethal challenge with a human viral pathogen of the central nervous system. Our findings indicate that DNA vaccines may have a promising future in human rabies immunization.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1201,
          "end_section": "abstract",
          "offset_in_end_section": 1470
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27483431",
          "text": "Post-exposure prophylaxis (PEP) against rabies infection consists of a combination of passive immunisation with plasma-derived human or equine immune globulins and active immunisation with vaccine delivered shortly after exposure. Since anti-rabies immune globulins are expensive and scarce, there is a need for cheaper alternatives that can be produced more consistently. Previously, we generated potent virus-neutralising VHH, also called Nanobodies, against the rabies glycoprotein that are effectively preventing lethal disease in an in vivo mouse model.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 558
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/9701249",
          "text": "Furthermore, serum samples from DNA- or HDCV-vaccinated monkeys neutralized a global spectrum of rabies virus variants in vitro. This study shows that DNA immunization elicits protective immunity in nonhuman primates against lethal challenge with a human viral pathogen of the central nervous system.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1072,
          "end_section": "abstract",
          "offset_in_end_section": 1372
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27483431",
          "text": "The PEP combination therapy of systemic anti-rabies VHH and intramuscular vaccine significantly delayed the onset of disease compared to treatment with anti-rabies VHH alone, prolonged median survival time (35 versus 14 days) and decreased mortality (60% versus 19% survival rate), when treated 24 hours after rabies virus challenge. Vaccine alone was unable to rescue mice from lethal disease. As reported also for immune globulins, some interference of anti-rabies VHH with the antigenicity of the vaccine was observed, but this did not impede the synergistic effect.",
          "begin_section": "abstract",
          "offset_in_begin_section": 893,
          "end_section": "abstract",
          "offset_in_end_section": 1462
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31790413",
          "text": "Intramuscular challenge with a lethal dose of rabies virus was used to determine protection status at six (raccoons) and 11 (skunks) months post-vaccination.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1056,
          "end_section": "abstract",
          "offset_in_end_section": 1213
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/3480536",
          "text": "Moreover, mice or raccoons immunized with RNP alone resisted lethal peripheral challenge with homologous or heterologous virus strains. These results indicate that the RNP of rabies virus plays a crucial role in induction of protective immunity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 624,
          "end_section": "abstract",
          "offset_in_end_section": 869
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31790413",
          "text": "Intramuscular challenge with a lethal dose of rabies virus was used to determine protection status at six (raccoons) and 11 (skunks) months post-vaccination. In addition to fecal samples, blood was collected at various time points to permit quantitative assessment of rabies antibody responses arising from immunization. Feces were analyzed by headspace gas chromatography with mass spectrometric detection and the chromatographic responses were grouped according to cluster analysis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1056,
          "end_section": "abstract",
          "offset_in_end_section": 1540
        }
      ],
      "ideal_answer": "Without immunization, rabies is a lethal disease. Immunization, through the administration of a vaccine, is crucial in preventing and protecting against rabies infection. The vaccine stimulates the immune system to produce antibodies that can neutralize the rabies virus, providing immunity and preventing the development of the disease.",
      "exact_answer": "yes"
    },
    {
      "id": "65cfaf7e1930410b13000016",
      "type": "factoid",
      "body": "What is the target of Divarasib?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/38052910",
        "https://pubmed.ncbi.nlm.nih.gov/37611121",
        "https://pubmed.ncbi.nlm.nih.gov/37774359",
        "https://pubmed.ncbi.nlm.nih.gov/23988437",
        "https://pubmed.ncbi.nlm.nih.gov/33391070",
        "https://pubmed.ncbi.nlm.nih.gov/23085982",
        "https://pubmed.ncbi.nlm.nih.gov/16604317",
        "https://pubmed.ncbi.nlm.nih.gov/36475349",
        "https://pubmed.ncbi.nlm.nih.gov/29664927",
        "https://pubmed.ncbi.nlm.nih.gov/24489793"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37611121",
          "text": "METHODS\nIn a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation. The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 124,
          "end_section": "abstract",
          "offset_in_end_section": 506
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38052910",
          "text": "Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients with KRAS G12C-positive CRC (n = 29) from arm C of an ongoing phase 1b trial. The primary objective was to evaluate safety. Secondary objectives included preliminary antitumor activity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 397,
          "end_section": "abstract",
          "offset_in_end_section": 683
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37611121",
          "text": "The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed. RESULTS\nA total of 137 patients (60 with non-small-cell lung cancer [NSCLC], 55 with colorectal cancer, and 22 with other solid tumors) received divarasib. No dose-limiting toxic effects or treatment-related deaths were reported.",
          "begin_section": "abstract",
          "offset_in_begin_section": 333,
          "end_section": "abstract",
          "offset_in_end_section": 738
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38052910",
          "text": "Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients with KRAS G12C-positive CRC (n = 29) from arm C of an ongoing phase 1b trial. The primary objective was to evaluate safety.",
          "begin_section": "abstract",
          "offset_in_begin_section": 397,
          "end_section": "abstract",
          "offset_in_end_section": 621
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38052910",
          "text": "The safety profile of this combination was consistent with those of single-agent divarasib and cetuximab. Treatment-related adverse events led to divarasib dose reductions in four patients (13.8%); there were no treatment withdrawals. The objective response rate was 62.5% (95% confidence interval: 40.6%, 81.2%) in KRAS G12C inhibitor-naive patients (n = 24).",
          "begin_section": "abstract",
          "offset_in_begin_section": 684,
          "end_section": "abstract",
          "offset_in_end_section": 1044
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37611121",
          "text": "BACKGROUND\nDivarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. METHODS\nIn a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation. The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 506
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37611121",
          "text": "The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed. RESULTS\nA total of 137 patients (60 with non-small-cell lung cancer [NSCLC], 55 with colorectal cancer, and 22 with other solid tumors) received divarasib.",
          "begin_section": "abstract",
          "offset_in_begin_section": 333,
          "end_section": "abstract",
          "offset_in_end_section": 664
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38052910",
          "text": "Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS-MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC.",
          "begin_section": "abstract",
          "offset_in_begin_section": 105,
          "end_section": "abstract",
          "offset_in_end_section": 396
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37611121",
          "text": "BACKGROUND\nDivarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. METHODS\nIn a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 332
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38052910",
          "text": "Treatment-related adverse events led to divarasib dose reductions in four patients (13.8%); there were no treatment withdrawals. The objective response rate was 62.5% (95% confidence interval: 40.6%, 81.2%) in KRAS G12C inhibitor-naive patients (n = 24).",
          "begin_section": "abstract",
          "offset_in_begin_section": 790,
          "end_section": "abstract",
          "offset_in_end_section": 1044
        }
      ],
      "ideal_answer": "The target of divarasib is the KRAS G12C mutation, which is commonly found in advanced or metastatic solid tumors, including colorectal cancer.",
      "exact_answer": [
        [
          "The target of divarasib is KRAS G12C."
        ]
      ]
    },
    {
      "id": "65f77a71c4010b4d7800003b",
      "type": "factoid",
      "body": "What is the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/32431130",
        "https://pubmed.ncbi.nlm.nih.gov/17301528",
        "https://pubmed.ncbi.nlm.nih.gov/33433410",
        "https://pubmed.ncbi.nlm.nih.gov/20221830",
        "https://pubmed.ncbi.nlm.nih.gov/8186171",
        "https://pubmed.ncbi.nlm.nih.gov/37572218",
        "https://pubmed.ncbi.nlm.nih.gov/17566846",
        "https://pubmed.ncbi.nlm.nih.gov/18006266",
        "https://pubmed.ncbi.nlm.nih.gov/16410698",
        "https://pubmed.ncbi.nlm.nih.gov/7478433"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8186171",
          "text": "CONCLUSIONS\nProtracted venous infusion 5-FU is an active and well tolerated palliative treatment for advanced colorectal cancer. The addition of interferon-alpha at the point of 5-FU refractory disease resulted in further significant response in a small number of patients. Further randomised studies, including quality-of-life end-points, are needed before the use of interferon-alpha can be recommended as a modulator of 5-FU in the clinical setting.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1819,
          "end_section": "abstract",
          "offset_in_end_section": 2271
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8186171",
          "text": "CONCLUSIONS\nProtracted venous infusion 5-FU is an active and well tolerated palliative treatment for advanced colorectal cancer. The addition of interferon-alpha at the point of 5-FU refractory disease resulted in further significant response in a small number of patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1819,
          "end_section": "abstract",
          "offset_in_end_section": 2092
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8186171",
          "text": "PATIENTS AND METHODS\nPatients with advanced colorectal cancer were treated with 5-FU (300 mg/m2/day) given as a protracted venous infusion via an indwelling central venous catheter and portable battery driven pump. At the time the tumour became refractory to 5-FU, interferon-alpha was added and further outcome evaluated.",
          "begin_section": "abstract",
          "offset_in_begin_section": 519,
          "end_section": "abstract",
          "offset_in_end_section": 841
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8186171",
          "text": "PATIENTS AND METHODS\nPatients with advanced colorectal cancer were treated with 5-FU (300 mg/m2/day) given as a protracted venous infusion via an indwelling central venous catheter and portable battery driven pump. At the time the tumour became refractory to 5-FU, interferon-alpha was added and further outcome evaluated. RESULTS\nOne hundred twenty-four patients were entered on the study, 118 of whom had measurable disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 519,
          "end_section": "abstract",
          "offset_in_end_section": 947
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8186171",
          "text": "BACKGROUND\nThe management of patients with advanced colorectal cancer remains dependent on the optimal use of 5-Fluorouracil (5-FU). Enhanced 5-FU activity can be achieved by either adding a modulator or by altering the administration schedule, in particular using a protracted venous infusion. Based on encouraging phase II data using bolus 5-FU and interferon-alpha, we designed a study to investigate the activity of this modulator in patients with colorectal cancer refractory to protracted venous infusion 5-FU.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 516
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8186171",
          "text": "Median survival of the whole group was 7.5 months. CONCLUSIONS\nProtracted venous infusion 5-FU is an active and well tolerated palliative treatment for advanced colorectal cancer. The addition of interferon-alpha at the point of 5-FU refractory disease resulted in further significant response in a small number of patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1766,
          "end_section": "abstract",
          "offset_in_end_section": 2092
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17301528",
          "text": "It can be given with good tolerance for patients with refractory advanced or recurrent colorectal cancer on an outpatient basis with due care especially for neutropenia.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1102,
          "end_section": "abstract",
          "offset_in_end_section": 1271
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8186171",
          "text": "Based on encouraging phase II data using bolus 5-FU and interferon-alpha, we designed a study to investigate the activity of this modulator in patients with colorectal cancer refractory to protracted venous infusion 5-FU. PATIENTS AND METHODS\nPatients with advanced colorectal cancer were treated with 5-FU (300 mg/m2/day) given as a protracted venous infusion via an indwelling central venous catheter and portable battery driven pump.",
          "begin_section": "abstract",
          "offset_in_begin_section": 295,
          "end_section": "abstract",
          "offset_in_end_section": 733
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8186171",
          "text": "Based on encouraging phase II data using bolus 5-FU and interferon-alpha, we designed a study to investigate the activity of this modulator in patients with colorectal cancer refractory to protracted venous infusion 5-FU. PATIENTS AND METHODS\nPatients with advanced colorectal cancer were treated with 5-FU (300 mg/m2/day) given as a protracted venous infusion via an indwelling central venous catheter and portable battery driven pump. At the time the tumour became refractory to 5-FU, interferon-alpha was added and further outcome evaluated.",
          "begin_section": "abstract",
          "offset_in_begin_section": 295,
          "end_section": "abstract",
          "offset_in_end_section": 841
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16410698",
          "text": "In summary,treatment with L-OHP as salvage chemotherapy can possibly contribute to prolongation of survival time in cases of refractory advanced colorectal cancer. It is useful to combine L-OHP with high-dose continuous administration of 5-FU,namely FOLFOX regimens.FOLFOX 6 is the most useful of the FOLFOX regimens because it is simple and can be administered on an outpatient basis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1436,
          "end_section": "abstract",
          "offset_in_end_section": 1821
        }
      ],
      "ideal_answer": "In HER2neu amplificated refractory advanced colorectal cancer patients, the appropriate treatment option is the combination of HER2-targeted therapy with chemotherapy. This can include the use of trastuzumab, a monoclonal antibody targeting HER2, in combination with chemotherapy agents such as 5-fluorouracil (5-FU) or oxaliplatin. The addition of trastuzumab to chemotherapy has shown improved outcomes in HER2-positive colorectal cancer patients, including increased response rates and prolonged survival. However, further studies are needed to determine the optimal treatment regimen and the role of other HER2-targeted agents in this patient population.",
      "exact_answer": [
        [
          "The appropriate treatment for HER2/neu amplificated refractory advanced colorectal cancer patients is targeted therapy with anti-HER2 agents, such as trastuzumab or pertuzumab, in combination with chemotherapy."
        ]
      ]
    },
    {
      "id": "66088f67fdcbea915f00000e",
      "type": "summary",
      "body": "What is a basket trial?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/36625301",
        "https://pubmed.ncbi.nlm.nih.gov/29984488",
        "https://pubmed.ncbi.nlm.nih.gov/35128970",
        "https://pubmed.ncbi.nlm.nih.gov/34236938",
        "https://pubmed.ncbi.nlm.nih.gov/27716293",
        "https://pubmed.ncbi.nlm.nih.gov/32779393",
        "https://pubmed.ncbi.nlm.nih.gov/26960332",
        "https://pubmed.ncbi.nlm.nih.gov/35358718",
        "https://pubmed.ncbi.nlm.nih.gov/37934000",
        "https://pubmed.ncbi.nlm.nih.gov/35614479"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29984488",
          "text": "Basket trials comprise a class of experimental designs used to study solid malignancies that are devised to evaluate the effectiveness of a therapeutic strategy among patients defined by the presence of a particular drug target (often a genetic mutation) rather than a particular tumor histology. Acknowledging the potential for differential effectiveness on the basis of traditional criteria for cancer subtyping, evaluations of treatment effectiveness are conducted with respect to the \"baskets\" which collectively represent a partition of the targeted patient population consisting of discrete subtypes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 402,
          "end_section": "abstract",
          "offset_in_end_section": 1008
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29984488",
          "text": "Thus, precision medicine challenges conventional paradigms of clinical translational which have relied on estimates of population-averaged effects to guide clinical practice. Basket trials comprise a class of experimental designs used to study solid malignancies that are devised to evaluate the effectiveness of a therapeutic strategy among patients defined by the presence of a particular drug target (often a genetic mutation) rather than a particular tumor histology.",
          "begin_section": "abstract",
          "offset_in_begin_section": 227,
          "end_section": "abstract",
          "offset_in_end_section": 698
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29984488",
          "text": "Thus, precision medicine challenges conventional paradigms of clinical translational which have relied on estimates of population-averaged effects to guide clinical practice. Basket trials comprise a class of experimental designs used to study solid malignancies that are devised to evaluate the effectiveness of a therapeutic strategy among patients defined by the presence of a particular drug target (often a genetic mutation) rather than a particular tumor histology. Acknowledging the potential for differential effectiveness on the basis of traditional criteria for cancer subtyping, evaluations of treatment effectiveness are conducted with respect to the \"baskets\" which collectively represent a partition of the targeted patient population consisting of discrete subtypes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 227,
          "end_section": "abstract",
          "offset_in_end_section": 1008
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34236938",
          "text": "By means of Monte-Carlo simulations, we compare the efficiency of our proposed cluster-based basket trial design with a standard approach proposed recently which only allows for complete pooling or separate analyses. The results suggest that our new design offers a considerable advantage in power, sensitivity and specificity as well as in average sample size compared to the standard approach.",
          "begin_section": "abstract",
          "offset_in_begin_section": 929,
          "end_section": "abstract",
          "offset_in_end_section": 1324
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34236938",
          "text": "The work presented here tries to find an adequate compromise between these two extremes by implying rules for clustering some baskets, which are reasonably homogeneous. By means of Monte-Carlo simulations, we compare the efficiency of our proposed cluster-based basket trial design with a standard approach proposed recently which only allows for complete pooling or separate analyses. The results suggest that our new design offers a considerable advantage in power, sensitivity and specificity as well as in average sample size compared to the standard approach.",
          "begin_section": "abstract",
          "offset_in_begin_section": 760,
          "end_section": "abstract",
          "offset_in_end_section": 1324
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32779393",
          "text": "In this study, we developed a new basket trial design that accounts for the uncertainties of homogeneity and heterogeneity of response rates among subpopulations using the Bayesian model averaging approach. We demonstrated the utility of the proposed method by comparing our approach against other methods for the two methodological groups using simulated and actual data. On an average, the proposed methods offered an intermediate performance between the BHM-weak and BHM-strong methods.",
          "begin_section": "abstract",
          "offset_in_begin_section": 771,
          "end_section": "abstract",
          "offset_in_end_section": 1260
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32779393",
          "text": "Recently developed statistical methods for evaluating the response rate in basket trials can be generally categorized into two groups: (a) those that account for the degrees of homogeneity/heterogeneity of response rates among subpopulations, and (b) those using borrowed response rate information across subpopulations to improve the statistical efficiency using Bayesian hierarchical models.",
          "begin_section": "abstract",
          "offset_in_begin_section": 377,
          "end_section": "abstract",
          "offset_in_end_section": 770
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29984488",
          "text": "Acknowledging the potential for differential effectiveness on the basis of traditional criteria for cancer subtyping, evaluations of treatment effectiveness are conducted with respect to the \"baskets\" which collectively represent a partition of the targeted patient population consisting of discrete subtypes. Yet, designs of early basket trials have been criticized for their reliance on basketwise analysis strategies that suffered from limited power in the presence of imbalanced enrollment as well as failed to convey to the clinical community evidentiary measures for consistent effectiveness among the studied clinical subtypes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 699,
          "end_section": "abstract",
          "offset_in_end_section": 1333
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35128970",
          "text": "METHODS\nThe sensitivity of the multisource exchangeability model to prior specification under differing degrees of response heterogeneity is explored through simulation. Then, a multisource exchangeability model design that incorporates control of the false-discovery rate is presented and a simulation study compares the operating characteristics to a design where the family-wise error rate is controlled and to the frequentist approach of treating the baskets as independent. Simulations are based on the original design of a real-world clinical trial, the SUMMIT trial, which investigated Neratinib treatment for a variety of solid tumors.",
          "begin_section": "abstract",
          "offset_in_begin_section": 757,
          "end_section": "abstract",
          "offset_in_end_section": 1400
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27716293",
          "text": "Basket- and integrated protocol designs are two of these new strategies and have been applied in a handful oncologic trials. We have taken the concept outside the realm of oncology and report about a first-in-human integrated protocol design that facilitates the transition from phase Ia in healthy volunteers to phase Ib in patients with rare complement-mediated disorders driven by the classical pathway. RESULTS\nWe have been conducting a prospective, double-blind, randomized, placebo-controlled first-in-human study with TNT009, which is a humanized monoclonal antibody directed against the C1s subunit of human complement component C1.",
          "begin_section": "abstract",
          "offset_in_begin_section": 96,
          "end_section": "abstract",
          "offset_in_end_section": 738
        }
      ],
      "ideal_answer": "A basket trial is an experimental design used to study solid malignancies that evaluates the effectiveness of a therapeutic strategy among patients defined by the presence of a particular drug target (often a genetic mutation) rather than a specific tumor histology. In basket trials, patients are grouped into 'baskets' based on the presence of a specific drug target, and treatment effectiveness is evaluated within these subgroups rather than based on traditional cancer subtyping criteria. This approach challenges conventional paradigms of clinical practice that rely on population-averaged effects and allows for more personalized and targeted treatment strategies in precision medicine.",
      "exact_answer": "n/a"
    },
    {
      "id": "660d2d6afdcbea915f00003b",
      "type": "list",
      "body": "What are atypical symptoms of gluten allergy?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/26043918",
        "https://pubmed.ncbi.nlm.nih.gov/26109797",
        "https://pubmed.ncbi.nlm.nih.gov/27024953",
        "https://pubmed.ncbi.nlm.nih.gov/22237879",
        "https://pubmed.ncbi.nlm.nih.gov/30945820",
        "https://pubmed.ncbi.nlm.nih.gov/31402697",
        "https://pubmed.ncbi.nlm.nih.gov/33053456",
        "https://pubmed.ncbi.nlm.nih.gov/25873118",
        "https://pubmed.ncbi.nlm.nih.gov/23083989",
        "https://pubmed.ncbi.nlm.nih.gov/26201175"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23083989",
          "text": "Gluten sensitivity has been best recognized and understood in the context of two conditions, celiac disease and wheat allergy. However, some individuals complain of symptoms in response to ingestion of \"gluten,\" without histologic or serologic evidence of celiac disease or wheat allergy. The term non-celiac gluten sensitivity (NCGS) has been suggested for this condition, although a role for gluten proteins as the sole trigger of the associated symptoms remains to be established.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 483
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23083989",
          "text": "Gluten sensitivity has been best recognized and understood in the context of two conditions, celiac disease and wheat allergy. However, some individuals complain of symptoms in response to ingestion of \"gluten,\" without histologic or serologic evidence of celiac disease or wheat allergy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 288
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23083989",
          "text": "However, some individuals complain of symptoms in response to ingestion of \"gluten,\" without histologic or serologic evidence of celiac disease or wheat allergy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 127,
          "end_section": "abstract",
          "offset_in_end_section": 288
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30945820",
          "text": "Psychiatric symptoms can be a rare but serious manifestation of this new clinical entity. CASE REPORT\nA 13-year-old girl consulted the paediatrician with abdominal pain, diarrhoea, bloating, and compulsive thoughts and fears; these disappeared on a gluten-free diet. Celiac disease and wheat allergy were excluded.",
          "begin_section": "abstract",
          "offset_in_begin_section": 100,
          "end_section": "abstract",
          "offset_in_end_section": 416
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23083989",
          "text": "However, some individuals complain of symptoms in response to ingestion of \"gluten,\" without histologic or serologic evidence of celiac disease or wheat allergy. The term non-celiac gluten sensitivity (NCGS) has been suggested for this condition, although a role for gluten proteins as the sole trigger of the associated symptoms remains to be established. This article reviews the available information regarding symptomatology, epidemiology and genetics, serology and histology, and in vitro and in vivo experimental data on the pathophysiology of NCGS.",
          "begin_section": "abstract",
          "offset_in_begin_section": 127,
          "end_section": "abstract",
          "offset_in_end_section": 682
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30945820",
          "text": "CASE REPORT\nA 13-year-old girl consulted the paediatrician with abdominal pain, diarrhoea, bloating, and compulsive thoughts and fears; these disappeared on a gluten-free diet. Celiac disease and wheat allergy were excluded. Double-blind placebo-controlled gluten challenge confirmed the diagnosis NCGS.",
          "begin_section": "abstract",
          "offset_in_begin_section": 192,
          "end_section": "abstract",
          "offset_in_end_section": 495
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30945820",
          "text": "Celiac disease and wheat allergy were excluded. Double-blind placebo-controlled gluten challenge confirmed the diagnosis NCGS. CONCLUSION\nConsider a diagnosis of NCGS in patients with psychiatric symptoms in combination with abdominal symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 369,
          "end_section": "abstract",
          "offset_in_end_section": 615
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27024953",
          "text": "Clinical analysis showed the occupational allergy to gluten in the form of rhinitis, asthma and airborne dermatistis in 9 subjects, whose symptoms disappeared during isolation from occupational exposure despite the use of a normal diet.",
          "begin_section": "abstract",
          "offset_in_begin_section": 486,
          "end_section": "abstract",
          "offset_in_end_section": 722
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27024953",
          "text": "The aim of the study was clinical analysis of 13 patients, who demonstrated elevated levels of gluten specific IgE and identification of the most allergenic protein fractions from several samples of wheat using serum of examined subjects. Clinical analysis showed the occupational allergy to gluten in the form of rhinitis, asthma and airborne dermatistis in 9 subjects, whose symptoms disappeared during isolation from occupational exposure despite the use of a normal diet. In case of 4 patients with severe forms of chronic urticaria and atopic dermatitis, who are also allergic to grass pollen at the same time, the introduction of a gluten-free diet resulted in improvement of health conditions.",
          "begin_section": "abstract",
          "offset_in_begin_section": 247,
          "end_section": "abstract",
          "offset_in_end_section": 947
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/26109797",
          "text": "Similar clinical manifestations can be observed in these disorders, yet there are peculiar pathogenetic pathways involved in their development. Celiac disease and wheat allergy have been extensively studied, while non-celiac gluten sensitivity is a relatively novel clinical entity, believed to be closely related to other gastrointestinal functional syndromes. The diagnosis of celiac disease and wheat allergy is based on a combination of findings from the patient's clinical history and specific tests, including serology and duodenal biopsies in case of celiac disease, or laboratory and functional assays for wheat allergy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 418,
          "end_section": "abstract",
          "offset_in_end_section": 1046
        }
      ],
      "ideal_answer": "Atypical symptoms of gluten allergy can include psychiatric symptoms such as compulsive thoughts and fears, as well as dermatological symptoms like rhinitis, asthma, and airborne dermatitis. Other atypical symptoms may include chronic urticaria, atopic dermatitis, and improvement of health conditions with a gluten-free diet.",
      "exact_answer": [
        [
          "Psychiatric symptoms"
        ],
        [
          "Rhinitis"
        ],
        [
          "Asthma"
        ],
        [
          "Airborne dermatitis"
        ],
        [
          "Chronic urticaria"
        ]
      ]
    },
    {
      "id": "65d136081930410b1300003a",
      "type": "yesno",
      "body": "Is transdermal glyceryl trinitrate effective for stroke?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/21609410",
        "https://pubmed.ncbi.nlm.nih.gov/7531993",
        "https://pubmed.ncbi.nlm.nih.gov/31973594",
        "https://pubmed.ncbi.nlm.nih.gov/12518122",
        "https://pubmed.ncbi.nlm.nih.gov/23979751",
        "https://pubmed.ncbi.nlm.nih.gov/9014793",
        "https://pubmed.ncbi.nlm.nih.gov/10422642",
        "https://pubmed.ncbi.nlm.nih.gov/10511361",
        "https://pubmed.ncbi.nlm.nih.gov/28762896",
        "https://pubmed.ncbi.nlm.nih.gov/3928505"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21609410",
          "text": "CONCLUSIONS\nTransdermal glyceryl trinitrate (5 mg) significantly lowered 24 h blood pressure by 9/5 mmHg (equivalent to a 6% reduction) in both dipping and nondipping patients with acute/subacute stroke.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1800,
          "end_section": "abstract",
          "offset_in_end_section": 2003
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21609410",
          "text": "CONCLUSIONS\nTransdermal glyceryl trinitrate (5 mg) significantly lowered 24 h blood pressure by 9/5 mmHg (equivalent to a 6% reduction) in both dipping and nondipping patients with acute/subacute stroke. This reduction in blood pressure is clinically relevant and is unlikely to be excessive.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1800,
          "end_section": "abstract",
          "offset_in_end_section": 2092
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31973594",
          "text": "Transdermal delivery of glyceryl trinitrate: clinical applications in acute stroke.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 83
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28762896",
          "text": "AIM\nTo test the safety and efficacy of four days of transdermal glyceryl trinitrate (5 mg/day) versus sham in patients with ultra-acute presumed stroke who are recruited by paramedics prior to hospital presentation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 319,
          "end_section": "abstract",
          "offset_in_end_section": 534
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21609410",
          "text": "Aims This study assesses the effects of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in patients with recent stroke. METHODS\nOne hundred and seven patients with acute ischaemic or haemorrhagic stroke were included.",
          "begin_section": "abstract",
          "offset_in_begin_section": 111,
          "end_section": "abstract",
          "offset_in_end_section": 348
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28762896",
          "text": "Ambulance-delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: Rationale, design and protocol for the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial (ISRCTN26986053).",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 235
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21609410",
          "text": "The effect of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in acute/subacute stroke.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 105
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21609410",
          "text": "Aims This study assesses the effects of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in patients with recent stroke.",
          "begin_section": "abstract",
          "offset_in_begin_section": 111,
          "end_section": "abstract",
          "offset_in_end_section": 248
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21609410",
          "text": "Patients whose blood pressure did not dip at night had a worse functional outcome at three-months. CONCLUSIONS\nTransdermal glyceryl trinitrate (5 mg) significantly lowered 24 h blood pressure by 9/5 mmHg (equivalent to a 6% reduction) in both dipping and nondipping patients with acute/subacute stroke. This reduction in blood pressure is clinically relevant and is unlikely to be excessive.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1699,
          "end_section": "abstract",
          "offset_in_end_section": 2092
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21609410",
          "text": "Patients whose blood pressure did not dip at night had a worse functional outcome at three-months. CONCLUSIONS\nTransdermal glyceryl trinitrate (5 mg) significantly lowered 24 h blood pressure by 9/5 mmHg (equivalent to a 6% reduction) in both dipping and nondipping patients with acute/subacute stroke.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1699,
          "end_section": "abstract",
          "offset_in_end_section": 2003
        }
      ],
      "ideal_answer": "Yes, transdermal glyceryl trinitrate has been found to be effective in lowering blood pressure in patients with acute/subacute stroke. In a study, it significantly lowered 24-hour blood pressure by 9/5 mmHg (equivalent to a 6% reduction) in both dipping and nondipping patients. This reduction in blood pressure is clinically relevant and unlikely to be excessive. Additionally, patients whose blood pressure did not dip at night had a worse functional outcome at three months.",
      "exact_answer": "yes"
    },
    {
      "id": "65f7794dc4010b4d78000037",
      "type": "summary",
      "body": "What is the mechanism by which the microbiota modulates the effectiveness of immunotherapy?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/36499564",
        "https://pubmed.ncbi.nlm.nih.gov/31634731",
        "https://pubmed.ncbi.nlm.nih.gov/36944780",
        "https://pubmed.ncbi.nlm.nih.gov/32522267",
        "https://pubmed.ncbi.nlm.nih.gov/33435800",
        "https://pubmed.ncbi.nlm.nih.gov/35847121",
        "https://pubmed.ncbi.nlm.nih.gov/35786465",
        "https://pubmed.ncbi.nlm.nih.gov/36279081",
        "https://pubmed.ncbi.nlm.nih.gov/31409678",
        "https://pubmed.ncbi.nlm.nih.gov/32580024"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32580024",
          "text": "Advancement in our understanding of the mechanism behind microbiota-mediated modulation of immune response is paramount for their utilization as cancer therapeutics. These microbial therapies in combination with conventional immunotherapeutic methods have the potential to transform the pre-existing treatment strategies to personalized cancer therapy. In this review, we have summarized the current status of research in the field and discussed the role of microbiota as an immune system modulator in context of cancer and their impact on immunotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 521,
          "end_section": "abstract",
          "offset_in_end_section": 1075
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32580024",
          "text": "Recently, several pre-clinical and clinical studies across diverse cancer types reported the influence of gut microbiota on the host immune response to immunotherapy. Advancement in our understanding of the mechanism behind microbiota-mediated modulation of immune response is paramount for their utilization as cancer therapeutics. These microbial therapies in combination with conventional immunotherapeutic methods have the potential to transform the pre-existing treatment strategies to personalized cancer therapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 354,
          "end_section": "abstract",
          "offset_in_end_section": 873
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32580024",
          "text": "Advancement in our understanding of the mechanism behind microbiota-mediated modulation of immune response is paramount for their utilization as cancer therapeutics. These microbial therapies in combination with conventional immunotherapeutic methods have the potential to transform the pre-existing treatment strategies to personalized cancer therapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 521,
          "end_section": "abstract",
          "offset_in_end_section": 873
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32522267",
          "text": "In this context, the intestinal microbiota has shown great potential in the immunotherapy of cancer. The intestinal microbiota not only regulates the immune function of the body, but also optimizes the therapeutic effect of immune checkpoint inhibitors, thus reducing the occurrence of complications. Therefore, manipulating the intestinal microbiota is expected to enhance the effectiveness of immune checkpoint inhibitors and reduce adverse reactions, which will lead to new breakthroughs in immunotherapy and cancer management.",
          "begin_section": "abstract",
          "offset_in_begin_section": 645,
          "end_section": "abstract",
          "offset_in_end_section": 1175
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32522267",
          "text": "In this context, the intestinal microbiota has shown great potential in the immunotherapy of cancer. The intestinal microbiota not only regulates the immune function of the body, but also optimizes the therapeutic effect of immune checkpoint inhibitors, thus reducing the occurrence of complications.",
          "begin_section": "abstract",
          "offset_in_begin_section": 645,
          "end_section": "abstract",
          "offset_in_end_section": 945
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36279081",
          "text": "It has revolutionized the management of advanced malignant tumors by activating T cells, promoting cytotoxic signaling pathways, and killing tumor cells, effectively improving the overall survival of patients. However, resistance to immunotherapy and immune-related adverse events remain challenges for immunotherapy. It has been demonstrated in previous studies that modulating intestinal microbiota can enhance immunotherapy response and reduce complications.",
          "begin_section": "abstract",
          "offset_in_begin_section": 216,
          "end_section": "abstract",
          "offset_in_end_section": 677
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36499564",
          "text": "However, the underlying mechanism of AD immunotherapy is not known. Importantly, preclinical and clinical studies have highlighted that the gut microbiota exerts a major influence on the efficacy of cancer immunotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 678,
          "end_section": "abstract",
          "offset_in_end_section": 898
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36499564",
          "text": "However, the underlying mechanism of AD immunotherapy is not known. Importantly, preclinical and clinical studies have highlighted that the gut microbiota exerts a major influence on the efficacy of cancer immunotherapy. However, the role of the gut microbiota in AD immunotherapy has not been explored.",
          "begin_section": "abstract",
          "offset_in_begin_section": 678,
          "end_section": "abstract",
          "offset_in_end_section": 981
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32580024",
          "text": "Recently, several pre-clinical and clinical studies across diverse cancer types reported the influence of gut microbiota on the host immune response to immunotherapy. Advancement in our understanding of the mechanism behind microbiota-mediated modulation of immune response is paramount for their utilization as cancer therapeutics.",
          "begin_section": "abstract",
          "offset_in_begin_section": 354,
          "end_section": "abstract",
          "offset_in_end_section": 686
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32580024",
          "text": "These microbial therapies in combination with conventional immunotherapeutic methods have the potential to transform the pre-existing treatment strategies to personalized cancer therapy. In this review, we have summarized the current status of research in the field and discussed the role of microbiota as an immune system modulator in context of cancer and their impact on immunotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 687,
          "end_section": "abstract",
          "offset_in_end_section": 1075
        }
      ],
      "ideal_answer": "The mechanism by which the microbiota modulates the effectiveness of immunotherapy is not fully understood, but several mechanisms have been proposed. One mechanism is through the production of metabolites by the microbiota that can directly or indirectly affect immune cell function and tumor growth. Another mechanism is through the modulation of the gut barrier function, which can influence the trafficking of immune cells to the tumor microenvironment. Additionally, the microbiota can interact with the host immune system and influence the response to immunotherapy through the activation of specific immune pathways.",
      "exact_answer": "n/a"
    },
    {
      "id": "660a912dfdcbea915f000028",
      "type": "summary",
      "body": "What is the results of diphthamide deficiency?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/30312900",
        "https://pubmed.ncbi.nlm.nih.gov/32576952",
        "https://pubmed.ncbi.nlm.nih.gov/35781884",
        "https://pubmed.ncbi.nlm.nih.gov/37675463",
        "https://pubmed.ncbi.nlm.nih.gov/34507998",
        "https://pubmed.ncbi.nlm.nih.gov/22869748",
        "https://pubmed.ncbi.nlm.nih.gov/35482014",
        "https://pubmed.ncbi.nlm.nih.gov/25352115",
        "https://pubmed.ncbi.nlm.nih.gov/28245596",
        "https://pubmed.ncbi.nlm.nih.gov/23971743"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30312900",
          "text": "We have analyzed the phenotypes of diphthamide deficient cells and found that diphthamide deficiency reduces selenocysteine incorporation into selenoproteins. Additional phenotypes resulting from diphthamide deficiency include altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress and increased selenite tolerance.",
          "begin_section": "abstract",
          "offset_in_begin_section": 206,
          "end_section": "abstract",
          "offset_in_end_section": 564
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30312900",
          "text": "We have analyzed the phenotypes of diphthamide deficient cells and found that diphthamide deficiency reduces selenocysteine incorporation into selenoproteins. Additional phenotypes resulting from diphthamide deficiency include altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress and increased selenite tolerance. Diphthamide-eEF2 occupies the aminoacyl-tRNA translocation site at which UGA either stalls translation or decodes selenocysteine.",
          "begin_section": "abstract",
          "offset_in_begin_section": 206,
          "end_section": "abstract",
          "offset_in_end_section": 694
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30312900",
          "text": "Additional phenotypes resulting from diphthamide deficiency include altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress and increased selenite tolerance.",
          "begin_section": "abstract",
          "offset_in_begin_section": 365,
          "end_section": "abstract",
          "offset_in_end_section": 564
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30312900",
          "text": "Additional phenotypes resulting from diphthamide deficiency include altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress and increased selenite tolerance. Diphthamide-eEF2 occupies the aminoacyl-tRNA translocation site at which UGA either stalls translation or decodes selenocysteine.",
          "begin_section": "abstract",
          "offset_in_begin_section": 365,
          "end_section": "abstract",
          "offset_in_end_section": 694
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30312900",
          "text": "Nevertheless, cells lacking diphthamide can carry out protein synthesis and are viable. We have analyzed the phenotypes of diphthamide deficient cells and found that diphthamide deficiency reduces selenocysteine incorporation into selenoproteins. Additional phenotypes resulting from diphthamide deficiency include altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress and increased selenite tolerance.",
          "begin_section": "abstract",
          "offset_in_begin_section": 118,
          "end_section": "abstract",
          "offset_in_end_section": 564
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34507998",
          "text": "Diphthamide deficiency in yeast suppresses the translation of TORC1-activating proteins Vam6 and Rtc1. Interestingly, TORC1 signaling also promotes diphthamide biosynthesis, suggesting that diphthamide forms a positive feedback loop to promote translation under nutrient-rich conditions. Our results provide an explanation for why diphthamide is evolutionarily conserved and why diphthamide deletion can cause severe developmental defects.",
          "begin_section": "abstract",
          "offset_in_begin_section": 490,
          "end_section": "abstract",
          "offset_in_end_section": 929
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35781884",
          "text": "Also, we generated hepatocyte-specific Dph1-deficient mice and showed that diphthamide-deficient EEF2 resulted in a reduced translation elongation rate in the hepatocytes and led to mild liver damage with fatty accumulation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 682,
          "end_section": "abstract",
          "offset_in_end_section": 906
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37675463",
          "text": "Ten additional human DPH1 (G113R, A114T, H132P, H132R, S136R, C137F, L138P, Y152C, S221P, H240R) and two DPH2 (H105P, C341Y) variants showed reduced functionality and hence are deficiency-susceptibility alleles. Some variants locate close to the active enzyme center and may affect catalysis, while others may impact on enzyme activation. In sum, our study has identified functionally compromised alleles of DPH1 and DPH2 genes that likely cause diphthamide deficiency syndrome.",
          "begin_section": "abstract",
          "offset_in_begin_section": 889,
          "end_section": "abstract",
          "offset_in_end_section": 1367
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35781884",
          "text": "Also, we generated hepatocyte-specific Dph1-deficient mice and showed that diphthamide-deficient EEF2 resulted in a reduced translation elongation rate in the hepatocytes and led to mild liver damage with fatty accumulation. After N-diethylnitrosamine (DEN)-induced acute liver injury, p53-mediated pericentral hepatocyte death was increased, and compensatory proliferation was reduced in Dph1-deficient mice. Consistent with these effects, Dph1 deficiency decreased the incidence of DEN-induced pericentral-derived HCC and revealed a protective effect against p53 loss.",
          "begin_section": "abstract",
          "offset_in_begin_section": 682,
          "end_section": "abstract",
          "offset_in_end_section": 1252
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30312900",
          "text": "Additional phenotypes resulting from diphthamide deficiency include altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress and increased selenite tolerance. Diphthamide-eEF2 occupies the aminoacyl-tRNA translocation site at which UGA either stalls translation or decodes selenocysteine. Its position is in close proximity and mutually exclusive to the ribosomal binding site of release/recycling factor ABCE1, which harbors a redox-sensitive Fe-S cluster and, like diphthamide, is present in eukaryotes and archaea but not in eubacteria.",
          "begin_section": "abstract",
          "offset_in_begin_section": 365,
          "end_section": "abstract",
          "offset_in_end_section": 945
        }
      ],
      "ideal_answer": "Diphthamide deficiency results in reduced selenocysteine incorporation into selenoproteins. It also leads to altered tRNA-synthetase and selenoprotein transcript levels. Other phenotypes include hypersensitivity to oxidative stress and increased selenite tolerance. Diphthamide deficiency can cause severe developmental defects and mild liver damage with fatty accumulation. It also affects translation elongation rate and can impact enzyme activation.",
      "exact_answer": "n/a"
    },
    {
      "id": "660c06b8fdcbea915f00002e",
      "type": "summary",
      "body": "What is the cause of Sydenham's chorea?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/12791195",
        "https://pubmed.ncbi.nlm.nih.gov/32851928",
        "https://pubmed.ncbi.nlm.nih.gov/26296451",
        "https://pubmed.ncbi.nlm.nih.gov/7189038",
        "https://pubmed.ncbi.nlm.nih.gov/20350965",
        "https://pubmed.ncbi.nlm.nih.gov/31965299",
        "https://pubmed.ncbi.nlm.nih.gov/15911817",
        "https://pubmed.ncbi.nlm.nih.gov/3939747",
        "https://pubmed.ncbi.nlm.nih.gov/32566771",
        "https://pubmed.ncbi.nlm.nih.gov/12621982"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32566771",
          "text": "Sydenham chorea (SC) is the most common acquired cause of chorea in children. (SC) is the neurological manifestation of rheumatic fever.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 136
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12791195",
          "text": "Sydenham chorea is an important cause of acquired chorea in childhood. Although the symptoms of chorea frequently resolve spontaneously in a matter of months, abnormal movements can be debilitating when they are present. Neuropsychologic symptoms may antedate the motor abnormality, may be persistent, and often are of great concern.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 333
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12791195",
          "text": "Sydenham chorea is an important cause of acquired chorea in childhood. Although the symptoms of chorea frequently resolve spontaneously in a matter of months, abnormal movements can be debilitating when they are present.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 220
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12791195",
          "text": "Sydenham chorea is an important cause of acquired chorea in childhood.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 70
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32566771",
          "text": "Sydenham chorea (SC) is the most common acquired cause of chorea in children.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 77
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12621982",
          "text": "For secondary prevention she received long-term oral penicillin. Sydenham chorea is a manifestation of rheumatic fever and occurs after a throat infection by group A streptococci. The disease is characteristic and consists of a combination of choreic movements, hypotonia and emotional lability.",
          "begin_section": "abstract",
          "offset_in_begin_section": 320,
          "end_section": "abstract",
          "offset_in_end_section": 615
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32566771",
          "text": "Sydenham chorea (SC) is the most common acquired cause of chorea in children. (SC) is the neurological manifestation of rheumatic fever. Rheumatic fever is still reported in Saudi Arabia, although less frequently.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 213
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/7189038",
          "text": "To document possible changing characteristics of Sydenham chorea, we reviewed records of 240 patients with this diagnosis who were seen between 1951 and 1976. A dramatic progressive decline in the number of cases was observed. The syndrome occurred mainly in childhood.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 269
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12791195",
          "text": "Neuropsychologic symptoms may antedate the motor abnormality, may be persistent, and often are of great concern. To date, there have been no adequate, double-blind, randomized studies to evaluate the symptomatic treatment of Sydenham chorea. This article will review proposed treatment options and dosing strategies.",
          "begin_section": "abstract",
          "offset_in_begin_section": 221,
          "end_section": "abstract",
          "offset_in_end_section": 537
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/7189038",
          "text": "Dysarthria, probably of extrapyramidal origin, was frequent but neurologic abnormalities other than diffuse encephalopathy were rare. One-third of the patients had coexisting heart disease. Repeat attacks of Sydenham chorea occurred, but the recurrence rate was much less than noted in previous studies.",
          "begin_section": "abstract",
          "offset_in_begin_section": 468,
          "end_section": "abstract",
          "offset_in_end_section": 771
        }
      ],
      "ideal_answer": "Sydenham chorea (SC) is the neurological manifestation of rheumatic fever. It occurs after a throat infection by group A streptococci.",
      "exact_answer": "n/a"
    },
    {
      "id": "65d375011930410b1300004a",
      "type": "list",
      "body": "What are active ingredients of Xultophy pill?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/31819371",
        "https://pubmed.ncbi.nlm.nih.gov/23019888",
        "https://pubmed.ncbi.nlm.nih.gov/37000070",
        "https://pubmed.ncbi.nlm.nih.gov/36467890",
        "https://pubmed.ncbi.nlm.nih.gov/37747012",
        "https://pubmed.ncbi.nlm.nih.gov/30006093",
        "https://pubmed.ncbi.nlm.nih.gov/37663478",
        "https://pubmed.ncbi.nlm.nih.gov/25282890",
        "https://pubmed.ncbi.nlm.nih.gov/36341127",
        "https://pubmed.ncbi.nlm.nih.gov/25282911"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30006093",
          "text": "AIMS\nXultophy is the first fixed co-formulation pen containing insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide, authorized for type 2 diabetes patients since 2014.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 193
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30006093",
          "text": "AIMS\nXultophy is the first fixed co-formulation pen containing insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide, authorized for type 2 diabetes patients since 2014. The aim was to review the clinical effectiveness of Xultophy across two hospitals in Wales.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 285
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30006093",
          "text": "AIMS\nXultophy is the first fixed co-formulation pen containing insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide, authorized for type 2 diabetes patients since 2014. The aim was to review the clinical effectiveness of Xultophy across two hospitals in Wales. METHODS\nRetrospective review of patients commenced on Xultophy between April 2016 and January 2018 was taken.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 397
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31819371",
          "text": "RESULTS\nThe comprehensive network pharmacology approach was successfully to identify 45 active ingredients in LWDH Pill. 45 active ingredients hit by 163 potential targets related to T2DM. Ten of the more highly predictive components (such as :quercetin, Kaempferol, Stigmasterol, beta-sitosterol, Kadsurenone, Diosgenin, hancinone C, Hederagenin, Garcinone B, Isofucosterol) are involved in anti-inflammatory, anti-oxidative stress, and the reduction of beta cell damage.",
          "begin_section": "abstract",
          "offset_in_begin_section": 670,
          "end_section": "abstract",
          "offset_in_end_section": 1142
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37663478",
          "text": "This study aimed to investigate the active ingredients and therapeutic mechanisms of Jingu Tongxiao Pill (JGTXP), a commonly used Chinese patent medicine, in treating osteoarthritis (OA) via network pharmacology analysis combined with experimental validation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 259
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30006093",
          "text": "METHODS\nRetrospective review of patients commenced on Xultophy between April 2016 and January 2018 was taken. Data related to glycemic control, weight and medication use were collected.",
          "begin_section": "abstract",
          "offset_in_begin_section": 288,
          "end_section": "abstract",
          "offset_in_end_section": 473
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30006093",
          "text": "Xultophy was well-tolerated, however, abdominal cramps and nausea limited use in three patients. Baseline HbA1c and weight were 84.7 mmol/mol and 101.5 kg.",
          "begin_section": "abstract",
          "offset_in_begin_section": 626,
          "end_section": "abstract",
          "offset_in_end_section": 781
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30006093",
          "text": "METHODS\nRetrospective review of patients commenced on Xultophy between April 2016 and January 2018 was taken. Data related to glycemic control, weight and medication use were collected. RESULTS\nNinety-one patients were initiated on Xultophy, and 60 patients had follow-up for at least 6 months with a mean age of 57.3 years (47% male).",
          "begin_section": "abstract",
          "offset_in_begin_section": 288,
          "end_section": "abstract",
          "offset_in_end_section": 625
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30006093",
          "text": "Xultophy was well-tolerated, however, abdominal cramps and nausea limited use in three patients. Baseline HbA1c and weight were 84.7 mmol/mol and 101.5 kg. There were significant HbA1c reductions of 9.9 mmol/mol (p < 0.0001) and 13.4 mmol/mol (p < 0.008) at 6 and 12 months, and non-significant changes in weight.",
          "begin_section": "abstract",
          "offset_in_begin_section": 626,
          "end_section": "abstract",
          "offset_in_end_section": 939
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30006093",
          "text": "Data related to glycemic control, weight and medication use were collected. RESULTS\nNinety-one patients were initiated on Xultophy, and 60 patients had follow-up for at least 6 months with a mean age of 57.3 years (47% male).",
          "begin_section": "abstract",
          "offset_in_begin_section": 398,
          "end_section": "abstract",
          "offset_in_end_section": 625
        }
      ],
      "ideal_answer": "The active ingredients of Xultophy pill are insulin degludec and liraglutide, which is a glucagon-like peptide-1 (GLP-1) analogue.",
      "exact_answer": [
        [
          "insulin degludec"
        ],
        [
          "liraglutide"
        ]
      ]
    },
    {
      "id": "65f775e8c4010b4d7800002d",
      "type": "yesno",
      "body": "Should UGT1A1 alteration be routinely determined in colorectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/26830078",
        "https://pubmed.ncbi.nlm.nih.gov/22559977",
        "https://pubmed.ncbi.nlm.nih.gov/21287524",
        "https://pubmed.ncbi.nlm.nih.gov/15280927",
        "https://pubmed.ncbi.nlm.nih.gov/25981652",
        "https://pubmed.ncbi.nlm.nih.gov/23686699",
        "https://pubmed.ncbi.nlm.nih.gov/30583998",
        "https://pubmed.ncbi.nlm.nih.gov/18594531",
        "https://pubmed.ncbi.nlm.nih.gov/24382596",
        "https://pubmed.ncbi.nlm.nih.gov/23236239"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30583998",
          "text": "The aim of this study was to determine whether the presence of the variant allele UGT1A1*28, harbouring seven TA repetitions, (TA)7, in the homozygous state, is associated with precancerous colonic lesions and/or with specific colorectal cancer characteristics. MATERIAL AND METHODS\nAll patients treated for colorectal cancer in a tertiary care centre, between January 2009 and December 2013, who had routine UGT1A1 genotyping for irinotecan dose-adjustment were included. Data were retrospectively collected.",
          "begin_section": "abstract",
          "offset_in_begin_section": 284,
          "end_section": "abstract",
          "offset_in_end_section": 795
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30583998",
          "text": "The aim of this study was to determine whether the presence of the variant allele UGT1A1*28, harbouring seven TA repetitions, (TA)7, in the homozygous state, is associated with precancerous colonic lesions and/or with specific colorectal cancer characteristics. MATERIAL AND METHODS\nAll patients treated for colorectal cancer in a tertiary care centre, between January 2009 and December 2013, who had routine UGT1A1 genotyping for irinotecan dose-adjustment were included.",
          "begin_section": "abstract",
          "offset_in_begin_section": 284,
          "end_section": "abstract",
          "offset_in_end_section": 758
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23686699",
          "text": "The aim of this study was to investigate the associations between UDP-glucuronosyltransferase (UGT) 1A1 polymorphisms and irinotecan-induced toxicities in Chinese advanced colorectal cancer patients. The genotypes of UGT1A1 6 and UGT1A1 28 were analyzed by PCR amplification and Sanger sequencing in 276 advanced colorectal cancer patients receiving irinotecan-containing chemotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 385
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25981652",
          "text": "We retrospectively investigated UGT1A1 genetic polymorphisms and the occurrences of irinotecan-induced neutropenia in 25 patients of colorectal cancer at our hospital.",
          "begin_section": "abstract",
          "offset_in_begin_section": 256,
          "end_section": "abstract",
          "offset_in_end_section": 423
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24382596",
          "text": "Previous reports of the influence of UGT1A1 gene polymorphisms on the pharmacokinetics of irinotecan metabolism have not assessed Asian patients treated with FOLFIRI plus bevacizumab for advanced and recurrent colorectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 228
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23686699",
          "text": "The aim of this study was to investigate the associations between UDP-glucuronosyltransferase (UGT) 1A1 polymorphisms and irinotecan-induced toxicities in Chinese advanced colorectal cancer patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 199
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/26830078",
          "text": "Both UGT1A1(*)28 and (*)6 polymorphisms may have an increased risk of irinotecan-induced neutropenia in Thai colorectal cancer patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1007,
          "end_section": "abstract",
          "offset_in_end_section": 1143
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21287524",
          "text": "Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 82
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/26830078",
          "text": "Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 121
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23686699",
          "text": "UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 129
        }
      ],
      "ideal_answer": "Answer: The routine determination of UGT1A1 alteration in colorectal cancer patients is recommended to assess the risk of irinotecan-induced toxicities and guide personalized treatment decisions.",
      "exact_answer": "yes"
    },
    {
      "id": "66088b42fdcbea915f000009",
      "type": "list",
      "body": "Please list sources of orthobiologics",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/31466571",
        "https://pubmed.ncbi.nlm.nih.gov/30466724",
        "https://pubmed.ncbi.nlm.nih.gov/37071148",
        "https://pubmed.ncbi.nlm.nih.gov/28577781",
        "https://pubmed.ncbi.nlm.nih.gov/32446585",
        "https://pubmed.ncbi.nlm.nih.gov/33959220",
        "https://pubmed.ncbi.nlm.nih.gov/36032640",
        "https://pubmed.ncbi.nlm.nih.gov/34039511",
        "https://pubmed.ncbi.nlm.nih.gov/24600055",
        "https://pubmed.ncbi.nlm.nih.gov/28577782"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30466724",
          "text": "Orthobiologics are a group of biological materials and substrates that promote bone, ligament, muscle, and tendon healing. These substances include bone autograft, bone allograft, demineralized bone matrix, bone graft substitutes, bone marrow aspirate concentrate, platelet-rich plasma, bone morphogenetic proteins, platelet-derived growth factor, parathyroid hormone, and vitamin D and calcium.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 395
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28577782",
          "text": "Orthobiologics are biological substances that allow injured muscles, tendons, ligaments, and bone to heal more quickly. They are found naturally in the body; at higher concentrations they can aid in the healing process. These substances include autograft bone, allograft bone, demineralized bone matrix, bone morphogenic proteins, growth factors, stem cells, plasma-rich protein, and ceramic grafts.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 399
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37071148",
          "text": "METHODS\nThis review of the literature presents the methods, clinical applications, impact, cost-effectiveness, and outcomes, as well as the current indications and future perspectives of orthobiologics, namely, platelet-rich plasma, mesenchymal stem cells, bone marrow aspirate concentrate, growth factors, and tissue engineering. RESULTS\nCurrently available studies have used variable methods of research including biologic materials as well as patient populations and outcome measurements, therefore making comparison of studies difficult. Key features for the study and use of orthobiologics include minimal invasiveness, great healing potential, and reasonable cost as a nonoperative treatment option.",
          "begin_section": "abstract",
          "offset_in_begin_section": 337,
          "end_section": "abstract",
          "offset_in_end_section": 1044
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37071148",
          "text": "RESULTS\nCurrently available studies have used variable methods of research including biologic materials as well as patient populations and outcome measurements, therefore making comparison of studies difficult. Key features for the study and use of orthobiologics include minimal invasiveness, great healing potential, and reasonable cost as a nonoperative treatment option. Their clinical applications have been described for common orthopaedic pathologies such as osteoarthritis, articular cartilage defects, bone defects and fracture nonunions, ligament injuries, and tendinopathies.",
          "begin_section": "abstract",
          "offset_in_begin_section": 670,
          "end_section": "abstract",
          "offset_in_end_section": 1256
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24600055",
          "text": "However, a clear consensus over the best orthobiologic substance and the method of preparation and usage of these substances is lacking. Much of the confusion is due to the fact that studies ranging from RCTs to case reports present variable results, and the interpretations are wide-ranging.",
          "begin_section": "abstract",
          "offset_in_begin_section": 549,
          "end_section": "abstract",
          "offset_in_end_section": 841
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28577782",
          "text": "Orthobiologics are biological substances that allow injured muscles, tendons, ligaments, and bone to heal more quickly. They are found naturally in the body; at higher concentrations they can aid in the healing process.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 219
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30466724",
          "text": "Orthobiologics are a group of biological materials and substrates that promote bone, ligament, muscle, and tendon healing. These substances include bone autograft, bone allograft, demineralized bone matrix, bone graft substitutes, bone marrow aspirate concentrate, platelet-rich plasma, bone morphogenetic proteins, platelet-derived growth factor, parathyroid hormone, and vitamin D and calcium. Properties of orthobiologics in bone healing include osteoconduction, osteoinduction, and osteogenesis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 499
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24600055",
          "text": "Investigators have published results of laboratory as well as clinical studies, using orthobiologics like platelet rich plasma, stem cells, autologous conditioned serum etc., with variable results. However, a clear consensus over the best orthobiologic substance and the method of preparation and usage of these substances is lacking. Much of the confusion is due to the fact that studies ranging from RCTs to case reports present variable results, and the interpretations are wide-ranging.",
          "begin_section": "abstract",
          "offset_in_begin_section": 351,
          "end_section": "abstract",
          "offset_in_end_section": 841
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33959220",
          "text": "The orthobiologics included in this article are hyaluronic acid, platelet rich plasma, bone marrow, adipose tissue and expanded mesenchymal stem cells.",
          "begin_section": "abstract",
          "offset_in_begin_section": 218,
          "end_section": "abstract",
          "offset_in_end_section": 369
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37071148",
          "text": "RESULTS\nCurrently available studies have used variable methods of research including biologic materials as well as patient populations and outcome measurements, therefore making comparison of studies difficult. Key features for the study and use of orthobiologics include minimal invasiveness, great healing potential, and reasonable cost as a nonoperative treatment option.",
          "begin_section": "abstract",
          "offset_in_begin_section": 670,
          "end_section": "abstract",
          "offset_in_end_section": 1044
        }
      ],
      "ideal_answer": "Sources of orthobiologics include bone autograft, bone allograft, demineralized bone matrix, bone graft substitutes, bone marrow aspirate concentrate, platelet-rich plasma, bone morphogenetic proteins, platelet-derived growth factor, parathyroid hormone, and vitamin D and calcium.",
      "exact_answer": [
        [
          "Bone autograft"
        ],
        [
          "Bone allograft"
        ],
        [
          "Demineralized bone matrix"
        ],
        [
          "Bone graft substitutes"
        ],
        [
          "Bone marrow aspirate concentrate"
        ]
      ]
    },
    {
      "id": "65f84eadc4010b4d7800004c",
      "type": "yesno",
      "body": "Are advanced directives an expression of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/17285032",
        "https://pubmed.ncbi.nlm.nih.gov/17039293",
        "https://pubmed.ncbi.nlm.nih.gov/25727566",
        "https://pubmed.ncbi.nlm.nih.gov/3985517",
        "https://pubmed.ncbi.nlm.nih.gov/14657785",
        "https://pubmed.ncbi.nlm.nih.gov/1617972",
        "https://pubmed.ncbi.nlm.nih.gov/12240520",
        "https://pubmed.ncbi.nlm.nih.gov/26217430",
        "https://pubmed.ncbi.nlm.nih.gov/17363852",
        "https://pubmed.ncbi.nlm.nih.gov/10347494"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17363852",
          "text": "Advance directives are expressions of choice. They are also legally binding documents and represent the wishes of a patient, but often with little prior knowledge of the patient, practitioners may be unsure whether to act on an advance directive.",
          "begin_section": "abstract",
          "offset_in_begin_section": 447,
          "end_section": "abstract",
          "offset_in_end_section": 693
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17363852",
          "text": "Advance directives are expressions of choice.",
          "begin_section": "abstract",
          "offset_in_begin_section": 447,
          "end_section": "abstract",
          "offset_in_end_section": 492
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/1617972",
          "text": "Advance directives: implications for critical care.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 51
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/3985517",
          "text": "Although the complexity and unpredictability of health care circumstances make it impossible to guarantee complete control over therapeutic measures to be used when survival is in question, physicians should offer their patients the opportunity to reflect on their values and wishes and to express them explicitly. The ideal advanced directive should clearly state the author's intentions; contain clear documentation regarding authorship; be flexible, allowing family and caregivers to respond appropriately to changing circumstances; be available when needed; and be supported by legal powers that grant patients the right of enforcement and grant health care providers protection from liability. Advanced directives can be set as instruction directives or proxy directives, each form having advantages and disadvantages.",
          "begin_section": "abstract",
          "offset_in_begin_section": 180,
          "end_section": "abstract",
          "offset_in_end_section": 1003
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/3985517",
          "text": "Although the complexity and unpredictability of health care circumstances make it impossible to guarantee complete control over therapeutic measures to be used when survival is in question, physicians should offer their patients the opportunity to reflect on their values and wishes and to express them explicitly. The ideal advanced directive should clearly state the author's intentions; contain clear documentation regarding authorship; be flexible, allowing family and caregivers to respond appropriately to changing circumstances; be available when needed; and be supported by legal powers that grant patients the right of enforcement and grant health care providers protection from liability.",
          "begin_section": "abstract",
          "offset_in_begin_section": 180,
          "end_section": "abstract",
          "offset_in_end_section": 878
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/14657785",
          "text": "Advance directives have been widely promoted as a means to maintain some control over one's life in the event of decisional incompetence. This study used data from a recent postal survey conducted in Quebec, Canada to: 1) estimate the prevalence of formal and informal advance directives for health care and research among community-dwelling older adults presumed free of cognitive deficits; and 2) characterize those who have communicated their preferences regarding health care and research participation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 117,
          "end_section": "abstract",
          "offset_in_end_section": 624
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17039293",
          "text": "Advance directives allow competent persons to extend their right of self-determination into the future, by recording choices that are intended to influence their future care should they become unable to make choices.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 216
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17363852",
          "text": "Advance directives are expressions of choice. They are also legally binding documents and represent the wishes of a patient, but often with little prior knowledge of the patient, practitioners may be unsure whether to act on an advance directive. This paper makes some attempt to examine key components of this debate.",
          "begin_section": "abstract",
          "offset_in_begin_section": 447,
          "end_section": "abstract",
          "offset_in_end_section": 765
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/1617972",
          "text": "RESULTS\nThe recent Cruzan case and passage of the Patient Self-Determination Act have led to an ethical and legal recognition of advance directives, and therefore, critical care practitioners must be familiar with these documents. A living will is a mechanism by which patients can communicate their desires for medical treatment at the end of life.",
          "begin_section": "abstract",
          "offset_in_begin_section": 296,
          "end_section": "abstract",
          "offset_in_end_section": 645
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17039293",
          "text": "Advance directives allow competent persons to extend their right of self-determination into the future, by recording choices that are intended to influence their future care should they become unable to make choices. They are considered tools to facilitate end-of-life decision making.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 285
        }
      ],
      "ideal_answer": "Yes, advance directives are expressions of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition. Advance directives allow competent individuals to document their choices and preferences regarding medical treatment and end-of-life care, ensuring that their wishes are respected even if they are unable to communicate or make decisions at that time.",
      "exact_answer": "yes"
    },
    {
      "id": "65cf69541930410b13000006",
      "type": "list",
      "body": "Which drugs were tested in the CodeBreaK 300 clinical trial?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37101895",
        "https://pubmed.ncbi.nlm.nih.gov/37101896",
        "https://pubmed.ncbi.nlm.nih.gov/26681895",
        "https://pubmed.ncbi.nlm.nih.gov/37098232",
        "https://pubmed.ncbi.nlm.nih.gov/34389867",
        "https://pubmed.ncbi.nlm.nih.gov/1296491",
        "https://pubmed.ncbi.nlm.nih.gov/37921413",
        "https://pubmed.ncbi.nlm.nih.gov/27690710",
        "https://pubmed.ncbi.nlm.nih.gov/37830786",
        "https://pubmed.ncbi.nlm.nih.gov/24973822"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37921413",
          "text": "Findings from the phase III CodeBreaK 300 trial indicate that adding the EGFR inhibitor panitumumab to sotorasib bests standard care for chemorefractory KRASG12C colorectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 135,
          "end_section": "abstract",
          "offset_in_end_section": 315
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37101895",
          "text": "The CodeBreaK 200 phase III trial data have recently resulted and showed an improved PFS with the use of sotorasib at 5.6 months compared to that of standard docetaxel of 4.5 months in locally advanced or unresectable metastatic KRAS G12C NSCLC previously treated with at least one platinum-based chemotherapy and checkpoint inhibitor.",
          "begin_section": "abstract",
          "offset_in_begin_section": 622,
          "end_section": "abstract",
          "offset_in_end_section": 957
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37101895",
          "text": "It was also shown to be tolerable with most subjects experiencing grade one or two adverse events, most commonly diarrhea and nausea. The CodeBreaK 200 phase III trial data have recently resulted and showed an improved PFS with the use of sotorasib at 5.6 months compared to that of standard docetaxel of 4.5 months in locally advanced or unresectable metastatic KRAS G12C NSCLC previously treated with at least one platinum-based chemotherapy and checkpoint inhibitor.",
          "begin_section": "abstract",
          "offset_in_begin_section": 488,
          "end_section": "abstract",
          "offset_in_end_section": 957
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37101895",
          "text": "The phase I clinical trial resulted in a confirmed response of 32% and progression free survival (PFS) of 6.3 months while the phase II trial resulted in a confirmed response of 37.1% and a PFS of 6.8 months. It was also shown to be tolerable with most subjects experiencing grade one or two adverse events, most commonly diarrhea and nausea. The CodeBreaK 200 phase III trial data have recently resulted and showed an improved PFS with the use of sotorasib at 5.6 months compared to that of standard docetaxel of 4.5 months in locally advanced or unresectable metastatic KRAS G12C NSCLC previously treated with at least one platinum-based chemotherapy and checkpoint inhibitor.",
          "begin_section": "abstract",
          "offset_in_begin_section": 279,
          "end_section": "abstract",
          "offset_in_end_section": 957
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37101895",
          "text": "The CodeBreaK 200 phase III trial data have recently resulted and showed an improved PFS with the use of sotorasib at 5.6 months compared to that of standard docetaxel of 4.5 months in locally advanced or unresectable metastatic KRAS G12C NSCLC previously treated with at least one platinum-based chemotherapy and checkpoint inhibitor. The lower than expected PFS of sotorasib from the phase III trial opens up opportunities for other G12C inhibitors to join the field. Indeed, adagrasib, another G12C inhibitor just recently gained FDA accelerated approval in NSCLC patients based on the KRYSTAL-1 study where the response rate was 43% with a median duration of response of 8.5 months.",
          "begin_section": "abstract",
          "offset_in_begin_section": 622,
          "end_section": "abstract",
          "offset_in_end_section": 1308
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37101895",
          "text": "The CodeBreaK 200 phase III trial data have recently resulted and showed an improved PFS with the use of sotorasib at 5.6 months compared to that of standard docetaxel of 4.5 months in locally advanced or unresectable metastatic KRAS G12C NSCLC previously treated with at least one platinum-based chemotherapy and checkpoint inhibitor. The lower than expected PFS of sotorasib from the phase III trial opens up opportunities for other G12C inhibitors to join the field.",
          "begin_section": "abstract",
          "offset_in_begin_section": 622,
          "end_section": "abstract",
          "offset_in_end_section": 1091
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37101895",
          "text": "It was also shown to be tolerable with most subjects experiencing grade one or two adverse events, most commonly diarrhea and nausea. The CodeBreaK 200 phase III trial data have recently resulted and showed an improved PFS with the use of sotorasib at 5.6 months compared to that of standard docetaxel of 4.5 months in locally advanced or unresectable metastatic KRAS G12C NSCLC previously treated with at least one platinum-based chemotherapy and checkpoint inhibitor. The lower than expected PFS of sotorasib from the phase III trial opens up opportunities for other G12C inhibitors to join the field.",
          "begin_section": "abstract",
          "offset_in_begin_section": 488,
          "end_section": "abstract",
          "offset_in_end_section": 1091
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37830786",
          "text": "Due to design flaws and disappointing progression-free survival data in CodeBreaK 200, a confirmatory phase III trial for the KRASG12C inhibitor sotorasib, the drug's full approval as a second-line option for metastatic KRASG12C non-small cell lung cancer may be delayed and will likely hinge on further studies.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 312
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37921413",
          "text": "To boost KRASG12C inhibitor efficacy and counter cancer cells' ability to mount resistance, combination strategies are being utilized. Findings from the phase III CodeBreaK 300 trial indicate that adding the EGFR inhibitor panitumumab to sotorasib bests standard care for chemorefractory KRASG12C colorectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 315
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37921413",
          "text": "Findings from the phase III CodeBreaK 300 trial indicate that adding the EGFR inhibitor panitumumab to sotorasib bests standard care for chemorefractory KRASG12C colorectal cancer. Joint SHP2 blockade is another approach that shows signs of activity in reversing acquired KRASG12C inhibitor resistance, according to preliminary phase I data.",
          "begin_section": "abstract",
          "offset_in_begin_section": 135,
          "end_section": "abstract",
          "offset_in_end_section": 476
        }
      ],
      "ideal_answer": "The CodeBreaK 300 clinical trial tested the combination of the EGFR inhibitor panitumumab and the KRASG12C inhibitor sotorasib.",
      "exact_answer": [
        [
          "panitumumab"
        ],
        [
          "sotorasib"
        ]
      ]
    },
    {
      "id": "65f779edc4010b4d78000039",
      "type": "yesno",
      "body": "Is surgical resection an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/36400657",
        "https://pubmed.ncbi.nlm.nih.gov/34431576",
        "https://pubmed.ncbi.nlm.nih.gov/35837187",
        "https://pubmed.ncbi.nlm.nih.gov/36030556",
        "https://pubmed.ncbi.nlm.nih.gov/35371084",
        "https://pubmed.ncbi.nlm.nih.gov/32634770",
        "https://pubmed.ncbi.nlm.nih.gov/36139613",
        "https://pubmed.ncbi.nlm.nih.gov/35958603",
        "https://pubmed.ncbi.nlm.nih.gov/35352512",
        "https://pubmed.ncbi.nlm.nih.gov/16412603"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36030556",
          "text": "CONCLUSIONS\nFor patients with dMMR/MSI-H locally advanced rectal cancer who achieved cCR during anti-PD-1 immunotherapy, adopting immunotherapy as curative-intent treatment might be an alternative option. Longer follow-up and larger cohorts are warranted to verify this innovative treatment approach.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1433,
          "end_section": "abstract",
          "offset_in_end_section": 1733
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36030556",
          "text": "CONCLUSIONS\nFor patients with dMMR/MSI-H locally advanced rectal cancer who achieved cCR during anti-PD-1 immunotherapy, adopting immunotherapy as curative-intent treatment might be an alternative option.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1433,
          "end_section": "abstract",
          "offset_in_end_section": 1637
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34431576",
          "text": "The patient underwent a total mesorectal excision at day 30. In the extirpated tissue, a complete pathological response was confirmed. CONCLUSION\nIn MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 996,
          "end_section": "abstract",
          "offset_in_end_section": 1310
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35837187",
          "text": "Furthermore, immunotherapy is an attractive alternative to the use of combination chemotherapy regimens when treating synchronous primary cancers such as in the setting of inherited cancer syndromes. Case Description\nHere we present a case of a middle-aged woman diagnosed with dMMR/MSI-H locally advanced rectal cancer with synchronous upper tract urothelial cancer secondary to Lynch syndrome.",
          "begin_section": "abstract",
          "offset_in_begin_section": 341,
          "end_section": "abstract",
          "offset_in_end_section": 738
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35371084",
          "text": "Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 119
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32634770",
          "text": "Treatment options for locally advanced rectal cancer have continued to consist largely of chemotherapy, chemoradiation, and/or surgical resection. For patients who are unable to undergo these therapeutic modalities or who do not to experience a response to them, treatment options are limited. We report 3 cases of mismatch repair-deficient (dMMR) locally advanced adenocarcinoma of the rectum that showed significant response with neoadjuvant immunotherapy-based systemic treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 483
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34431576",
          "text": "In the extirpated tissue, a complete pathological response was confirmed. CONCLUSION\nIn MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1057,
          "end_section": "abstract",
          "offset_in_end_section": 1310
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36400657",
          "text": "Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 106
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32634770",
          "text": "Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 107
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35837187",
          "text": "Furthermore, immunotherapy is an attractive alternative to the use of combination chemotherapy regimens when treating synchronous primary cancers such as in the setting of inherited cancer syndromes. Case Description\nHere we present a case of a middle-aged woman diagnosed with dMMR/MSI-H locally advanced rectal cancer with synchronous upper tract urothelial cancer secondary to Lynch syndrome. The patient was first treated using neoadjuvant chemotherapy followed by chemoradiation, resulting in only a partial pathologic response.",
          "begin_section": "abstract",
          "offset_in_begin_section": 341,
          "end_section": "abstract",
          "offset_in_end_section": 876
        }
      ],
      "ideal_answer": "Based on the provided context, surgical resection is the standard treatment for locally advanced rectal cancer. However, in patients with dMMR/MSI-H locally advanced rectal cancer who achieve a complete pathological response (cCR) during neoadjuvant immunotherapy, adopting immunotherapy as a curative-intent treatment might be considered as an alternative option. This approach requires longer follow-up and larger cohorts to verify its effectiveness.",
      "exact_answer": "no"
    },
    {
      "id": "66081d61fdcbea915f000007",
      "type": "yesno",
      "body": "Is One-carbon (1C)  metabolism associated with folate?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/18804690",
        "https://pubmed.ncbi.nlm.nih.gov/19812215",
        "https://pubmed.ncbi.nlm.nih.gov/1916088",
        "https://pubmed.ncbi.nlm.nih.gov/33326752",
        "https://pubmed.ncbi.nlm.nih.gov/33212887",
        "https://pubmed.ncbi.nlm.nih.gov/20645850",
        "https://pubmed.ncbi.nlm.nih.gov/27641100",
        "https://pubmed.ncbi.nlm.nih.gov/33616629",
        "https://pubmed.ncbi.nlm.nih.gov/7074014",
        "https://pubmed.ncbi.nlm.nih.gov/26700149"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18804690",
          "text": "Disruption of folate-mediated one-carbon metabolism is associated with many pathologies and developmental anomalies, yet the biochemical mechanisms and causal metabolic pathways responsible for the initiation and/or progression of folate-associated pathologies have yet to be established. This chapter focuses on our current understanding of mammalian folate-mediated one-carbon metabolism, its cellular compartmentation, and knowledge gaps that limit our understanding of one-carbon metabolism and its regulation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 871,
          "end_section": "abstract",
          "offset_in_end_section": 1385
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27641100",
          "text": "One-carbon (1C) metabolism, mediated by the folate cofactor, supports multiple physiological processes. These include biosynthesis (purines and thymidine), amino acid homeostasis (glycine, serine, and methionine), epigenetic maintenance, and redox defense. Both within eukaryotic cells and across organs, 1C metabolic reactions are compartmentalized.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 350
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27641100",
          "text": "One-carbon (1C) metabolism, mediated by the folate cofactor, supports multiple physiological processes. These include biosynthesis (purines and thymidine), amino acid homeostasis (glycine, serine, and methionine), epigenetic maintenance, and redox defense.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 256
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33326752",
          "text": "Folate metabolism supplies one-carbon (1C) units for biosynthesis and methylation and has long been a target for cancer chemotherapy. Mitochondrial serine catabolism is considered the sole contributor of folate-mediated 1C units in proliferating cancer cells. Here, we show that under physiological folate levels in the cell environment, cytosolic serine-hydroxymethyltransferase (SHMT1) is the predominant source of 1C units in a variety of cancers, while mitochondrial 1C flux is overly repressed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 499
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33326752",
          "text": "Folate metabolism supplies one-carbon (1C) units for biosynthesis and methylation and has long been a target for cancer chemotherapy. Mitochondrial serine catabolism is considered the sole contributor of folate-mediated 1C units in proliferating cancer cells.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 259
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19812215",
          "text": "One-carbon metabolism-genome interactions in folate-associated pathologies.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 75
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19812215",
          "text": "Impairments in folate-mediated 1-carbon metabolism are associated with several common diseases and developmental anomalies including intestinal cancers, vascular disease, cognitive decline, and neural tube defects.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 214
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19812215",
          "text": "This review focuses on the regulation of folate-mediated 1-carbon metabolism and its role in maintaining genome integrity and on strategies for establishing the metabolic pathways and mechanisms that underlie folate-associated pathologies.",
          "begin_section": "abstract",
          "offset_in_begin_section": 954,
          "end_section": "abstract",
          "offset_in_end_section": 1193
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18804690",
          "text": "Disruption of folate-mediated one-carbon metabolism is associated with many pathologies and developmental anomalies, yet the biochemical mechanisms and causal metabolic pathways responsible for the initiation and/or progression of folate-associated pathologies have yet to be established.",
          "begin_section": "abstract",
          "offset_in_begin_section": 871,
          "end_section": "abstract",
          "offset_in_end_section": 1159
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18804690",
          "text": "Increasing evidence indicates that folate-dependent de novo thymidylate biosynthesis occurs in the nucleus of certain cell types. Disruption of folate-mediated one-carbon metabolism is associated with many pathologies and developmental anomalies, yet the biochemical mechanisms and causal metabolic pathways responsible for the initiation and/or progression of folate-associated pathologies have yet to be established. This chapter focuses on our current understanding of mammalian folate-mediated one-carbon metabolism, its cellular compartmentation, and knowledge gaps that limit our understanding of one-carbon metabolism and its regulation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 741,
          "end_section": "abstract",
          "offset_in_end_section": 1385
        }
      ],
      "ideal_answer": "Yes, one-carbon (1C) metabolism is associated with folate. Folate serves as a cofactor in 1C metabolism, providing 1C units for various physiological processes such as biosynthesis, amino acid homeostasis, epigenetic maintenance, and redox defense. Disruption of folate-mediated 1C metabolism is associated with various pathologies and developmental anomalies.",
      "exact_answer": "yes"
    },
    {
      "id": "660bb7f9fdcbea915f000029",
      "type": "factoid",
      "body": "What type of drug is administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/2577304",
        "https://pubmed.ncbi.nlm.nih.gov/33423644",
        "https://pubmed.ncbi.nlm.nih.gov/32577553",
        "https://pubmed.ncbi.nlm.nih.gov/20407380",
        "https://pubmed.ncbi.nlm.nih.gov/20015308",
        "https://pubmed.ncbi.nlm.nih.gov/19496457",
        "https://pubmed.ncbi.nlm.nih.gov/20710059",
        "https://pubmed.ncbi.nlm.nih.gov/2670624",
        "https://pubmed.ncbi.nlm.nih.gov/18951220",
        "https://pubmed.ncbi.nlm.nih.gov/33749675"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33423644",
          "text": "Efficacy and Safety of Corticosteroids' Administration for Pulmonary Immaturity in Anticipated Preterm Delivery.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 112
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32577553",
          "text": "BACKGROUND\nRespiratory distress syndrome (RDS), a consequence of lung immaturity, is a serious complication of preterm birth and the primary cause of early neonatal mortality. Administration of antenatal steroids is a standard care method for mothers with anticipated preterm labor. However, the gestational age range at which antenatal corticosteroids (ACS) provide benefit has been subjected to debate.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 404
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32577553",
          "text": "BACKGROUND\nRespiratory distress syndrome (RDS), a consequence of lung immaturity, is a serious complication of preterm birth and the primary cause of early neonatal mortality. Administration of antenatal steroids is a standard care method for mothers with anticipated preterm labor.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 282
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32577553",
          "text": "Antenatal corticosteroids and fetal lung immaturity in preterm birth.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 69
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2577304",
          "text": "Prevention and treatment of fetal lung immaturity.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 50
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19496457",
          "text": "[Prevention of the neonatal lung immaturity].",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 45
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2670624",
          "text": "Over the last 10 years the strategy for the prevention of neonatal respiratory distress syndrome (RDS) has been directed towards the acceleration of fetal lung maturity in utero by means of drugs administered to the mother, the most thoroughly investigated being glucocorticoids (GC). Many reports indicate that the administration of GC decreases the incidence of RDS in the neonate delivered between 28 and 32 weeks and weighing less than 1500 g. The type of GC and the drug-delivery interval are critical. Harmful potential side effects of GC have led to the testing of other drugs capable of accelerating fetal lung maturity, among them ambroxol and aminophylline.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 667
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33423644",
          "text": "The administration of antenatal corticosteroids, in cases of imminent preterm delivery, can enhance fetal lung maturation and reduce the incidence of respiratory distress syndrome, leading to improved neonatal outcomes. The scope of this narrative review was to synthesize available evidence on the efficacy and safety of corticosteroids' administration during antenatal period, in cases of anticipated preterm delivery.",
          "begin_section": "abstract",
          "offset_in_begin_section": 168,
          "end_section": "abstract",
          "offset_in_end_section": 588
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2670624",
          "text": "Over the last 10 years the strategy for the prevention of neonatal respiratory distress syndrome (RDS) has been directed towards the acceleration of fetal lung maturity in utero by means of drugs administered to the mother, the most thoroughly investigated being glucocorticoids (GC). Many reports indicate that the administration of GC decreases the incidence of RDS in the neonate delivered between 28 and 32 weeks and weighing less than 1500 g. The type of GC and the drug-delivery interval are critical.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 507
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2670624",
          "text": "Over the last 10 years the strategy for the prevention of neonatal respiratory distress syndrome (RDS) has been directed towards the acceleration of fetal lung maturity in utero by means of drugs administered to the mother, the most thoroughly investigated being glucocorticoids (GC).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 284
        }
      ],
      "ideal_answer": "Glucocorticoids (GC) are the type of drug administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated.",
      "exact_answer": [
        [
          "Glucocorticoids (GC)"
        ]
      ]
    },
    {
      "id": "65d132101930410b13000035",
      "type": "yesno",
      "body": "Is Depatuxizumab mafodotin effective for glioblastoma?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37257422",
        "https://pubmed.ncbi.nlm.nih.gov/33201054",
        "https://pubmed.ncbi.nlm.nih.gov/29077941",
        "https://pubmed.ncbi.nlm.nih.gov/29794826",
        "https://pubmed.ncbi.nlm.nih.gov/30990907",
        "https://pubmed.ncbi.nlm.nih.gov/34204877",
        "https://pubmed.ncbi.nlm.nih.gov/29075855",
        "https://pubmed.ncbi.nlm.nih.gov/29982805",
        "https://pubmed.ncbi.nlm.nih.gov/35849035",
        "https://pubmed.ncbi.nlm.nih.gov/33601293"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29075855",
          "text": "Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 164
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29982805",
          "text": "Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 175
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34204877",
          "text": "Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 185
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29077941",
          "text": "Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 157
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33601293",
          "text": "Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 185
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35849035",
          "text": "Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 110
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34204877",
          "text": "BACKGROUND\nDepatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2 trial produced interesting results for the combination regimen of Depatux-M and temozolomide in EGFR-amplified glioblastoma patients at first recurrence. For the first time worldwide, our work investigated the clinical outcome and safety of this combination in a real-life population.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 516
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34204877",
          "text": "BACKGROUND\nDepatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2 trial produced interesting results for the combination regimen of Depatux-M and temozolomide in EGFR-amplified glioblastoma patients at first recurrence.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 385
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29077941",
          "text": "Background\nWe recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 218
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29077941",
          "text": "Background\nWe recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A). The purpose of this study was to evaluate the safety and pharmacokinetics of depatux-m, either in combination with temozolomide in newly diagnosed or recurrent glioblastoma (arm B) or as monotherapy in recurrent glioblastoma (arm C).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 452
        }
      ],
      "ideal_answer": "Depatuxizumab mafodotin has shown efficacy in the treatment of glioblastoma, particularly in patients with EGFR amplification. Clinical trials and real-world studies have demonstrated positive outcomes when depatuxizumab mafodotin is used as monotherapy or in combination with temozolomide. However, further research is needed to fully establish its effectiveness and determine its optimal use in the management of glioblastoma.",
      "exact_answer": "yes"
    },
    {
      "id": "66099af7fdcbea915f000020",
      "type": "yesno",
      "body": "Is the use of Bevacizumab indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/16724868",
        "https://pubmed.ncbi.nlm.nih.gov/15612152",
        "https://pubmed.ncbi.nlm.nih.gov/20087037",
        "https://pubmed.ncbi.nlm.nih.gov/19942597",
        "https://pubmed.ncbi.nlm.nih.gov/21368463",
        "https://pubmed.ncbi.nlm.nih.gov/26037783",
        "https://pubmed.ncbi.nlm.nih.gov/20385517",
        "https://pubmed.ncbi.nlm.nih.gov/32668865",
        "https://pubmed.ncbi.nlm.nih.gov/34779646",
        "https://pubmed.ncbi.nlm.nih.gov/25315029"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16724868",
          "text": "Bevacizumab has acceptable tolerability in patients with advanced colorectal cancer, breast cancer, or NSCLC, with the majority of adverse events being generally mild and clinically manageable. Thus, bevacizumab provides a highly effective addition to standard chemotherapeutic regimens for advanced colorectal cancer, breast cancer, and NSCLC.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1107,
          "end_section": "abstract",
          "offset_in_end_section": 1451
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16724868",
          "text": "Thus, bevacizumab provides a highly effective addition to standard chemotherapeutic regimens for advanced colorectal cancer, breast cancer, and NSCLC.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1301,
          "end_section": "abstract",
          "offset_in_end_section": 1451
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16724868",
          "text": "In the second-line treatment of advanced colorectal cancer, patients who received bevacizumab in combination with a fluorouracil/leucovorin plus oxaliplatin (FOLFOX4) regimen had an overall survival time that was 2 months longer than that in patients receiving FOLFOX4.",
          "begin_section": "abstract",
          "offset_in_begin_section": 426,
          "end_section": "abstract",
          "offset_in_end_section": 695
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21368463",
          "text": "SUBJECTS\n13 patients( 7 men and 6 women) with advanced, recurrent colorectal cancer were treated by mFOLFOX6 regimen with first-line bevacizumab from August 2008 to July 2009.",
          "begin_section": "abstract",
          "offset_in_begin_section": 257,
          "end_section": "abstract",
          "offset_in_end_section": 432
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21368463",
          "text": "SUBJECTS\n13 patients( 7 men and 6 women) with advanced, recurrent colorectal cancer were treated by mFOLFOX6 regimen with first-line bevacizumab from August 2008 to July 2009. The median age was 64.",
          "begin_section": "abstract",
          "offset_in_begin_section": 257,
          "end_section": "abstract",
          "offset_in_end_section": 455
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21368463",
          "text": "SUBJECTS\n13 patients( 7 men and 6 women) with advanced, recurrent colorectal cancer were treated by mFOLFOX6 regimen with first-line bevacizumab from August 2008 to July 2009. The median age was 64. 4 years (51 to 79 years old) with 10 and 3 patients having a PS score of 0 and 1.",
          "begin_section": "abstract",
          "offset_in_begin_section": 257,
          "end_section": "abstract",
          "offset_in_end_section": 537
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20385517",
          "text": "[Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)].",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 146
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25315029",
          "text": "Results of phase III trials demonstrate that adding intravenous bevacizumab to antineoplastic agents improves progression-free survival and/or overall survival in patients with advanced cancer, including when used as first- or second-line therapy in metastatic colorectal cancer, as first-line therapy in advanced nonsquamous non-small cell lung cancer, as first-line therapy in metastatic renal cell carcinoma, as first-line therapy in metastatic breast cancer, and as first-line therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer or in recurrent, platinum-sensitive or platinum-resistant disease. Results of these studies are supported by the findings of routine oncology practice studies conducted in real-world settings.",
          "begin_section": "abstract",
          "offset_in_begin_section": 100,
          "end_section": "abstract",
          "offset_in_end_section": 848
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20087037",
          "text": "METHODS\nFrom April, 2007 to February, 2009, 23 colorectal cancer patients were treated with Bevacizumab. We evaluated the adverse events and the time to progression (TTP). RESULTS\nThe median age of the patients was 60 years old.",
          "begin_section": "abstract",
          "offset_in_begin_section": 261,
          "end_section": "abstract",
          "offset_in_end_section": 491
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15612152",
          "text": "Two clinical trials show that the addition of bevacizumab to a regimen of either fluorouracil plus leucovorin (FL) or FL combined with irinotecan (IFL), significantly improves response rate and time to tumour progression and increases overall survival for patients with advanced colorectal cancer (ACC).",
          "begin_section": "abstract",
          "offset_in_begin_section": 191,
          "end_section": "abstract",
          "offset_in_end_section": 494
        }
      ],
      "ideal_answer": "The use of bevacizumab after progression to a previous regimen with bevacizumab is not indicated in advanced colorectal cancer patients. Bevacizumab has shown efficacy as a first-line treatment in combination with chemotherapy, but its benefit as a second-line therapy after progression is limited. Alternative treatment options should be considered in patients who have progressed on bevacizumab-based regimens.",
      "exact_answer": "yes"
    },
    {
      "id": "65f48fa2c4010b4d7800000f",
      "type": "list",
      "body": "Please list the psychoactive drugs used to treat mental health disorders.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/2873081",
        "https://pubmed.ncbi.nlm.nih.gov/18604365",
        "https://pubmed.ncbi.nlm.nih.gov/35543545",
        "https://pubmed.ncbi.nlm.nih.gov/2675194",
        "https://pubmed.ncbi.nlm.nih.gov/31087719",
        "https://pubmed.ncbi.nlm.nih.gov/20919508",
        "https://pubmed.ncbi.nlm.nih.gov/21113253",
        "https://pubmed.ncbi.nlm.nih.gov/16785271",
        "https://pubmed.ncbi.nlm.nih.gov/35090311",
        "https://pubmed.ncbi.nlm.nih.gov/33529282"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2873081",
          "text": "Many psychologists function in mental health clinics and mental institutions where psychoactive drugs are prescribed and administered or treat patients in therapy for whom psychoactive drugs have been prescribed. Six years ago, psychoactive drugs available to patients and physicians were reviewed for psychologists (Murray, 1978). The variety of psychoactive drugs is greater now, and this review summarizes their impact on the brain and the nervous system and describes their effects on patients' behavior.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 508
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2873081",
          "text": "Many psychologists function in mental health clinics and mental institutions where psychoactive drugs are prescribed and administered or treat patients in therapy for whom psychoactive drugs have been prescribed. Six years ago, psychoactive drugs available to patients and physicians were reviewed for psychologists (Murray, 1978).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 331
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/2873081",
          "text": "Many psychologists function in mental health clinics and mental institutions where psychoactive drugs are prescribed and administered or treat patients in therapy for whom psychoactive drugs have been prescribed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 212
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18604365",
          "text": "[Common mental disorders and the use of psychoactive drugs: the impact of socioeconomic conditions].",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 100
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31087719",
          "text": "Can we use psychoactive drugs to treat pruritus?",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 48
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21113253",
          "text": "The use of psychoactive drugs in mental illnesses is often involved with hematologic side effects including impaired platelet function. Subsequently, the risk for the development of cardiovascular diseases may be higher in these patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 129,
          "end_section": "abstract",
          "offset_in_end_section": 367
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35090311",
          "text": "Psychoactive substances are a class of chemical substances which could cause public health threats. Cognitive disorders are a category of mental health disorders that primarily affect cognitive abilities.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 204
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21113253",
          "text": "The use of psychoactive drugs in mental illnesses is often involved with hematologic side effects including impaired platelet function.",
          "begin_section": "abstract",
          "offset_in_begin_section": 129,
          "end_section": "abstract",
          "offset_in_end_section": 264
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35543545",
          "text": "OBJECTIVES\nThe study assessed the presence of new psychoactive substances (NPS) in comparison to \"classic\" drugs in the group of newly admitted patients with mental and behavioral disorders due to the use of psychoactive substances diagnosis (section F11-19 according to ICD-10). MATERIAL AND METHODS\nData from anamnesis and the blood and urine samples were collected from 116 patients diagnosed with mental and behavioral disorders due to psychoactive substance use.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 469
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21113253",
          "text": "The use of psychoactive drugs in mental illnesses is often involved with hematologic side effects including impaired platelet function. Subsequently, the risk for the development of cardiovascular diseases may be higher in these patients. Interestingly, platelets that play a key role in cardiovascular complications contain quite a number of neuronal receptors which are involved in psychotic disorders.",
          "begin_section": "abstract",
          "offset_in_begin_section": 129,
          "end_section": "abstract",
          "offset_in_end_section": 533
        }
      ],
      "ideal_answer": "The psychoactive drugs commonly used to treat mental health disorders include antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants.",
      "exact_answer": [
        [
          "Antidepressants"
        ],
        [
          "Antipsychotics"
        ],
        [
          "Anxiolytics"
        ],
        [
          "Mood stabilizers"
        ],
        [
          "Stimulants"
        ]
      ]
    },
    {
      "id": "660d2299fdcbea915f000038",
      "type": "list",
      "body": "List of attenuated viral vaccines still in use.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/1368409",
        "https://pubmed.ncbi.nlm.nih.gov/9192350",
        "https://pubmed.ncbi.nlm.nih.gov/10099898",
        "https://pubmed.ncbi.nlm.nih.gov/33070999",
        "https://pubmed.ncbi.nlm.nih.gov/22570186",
        "https://pubmed.ncbi.nlm.nih.gov/34276608",
        "https://pubmed.ncbi.nlm.nih.gov/2576588",
        "https://pubmed.ncbi.nlm.nih.gov/15935875",
        "https://pubmed.ncbi.nlm.nih.gov/20375174",
        "https://pubmed.ncbi.nlm.nih.gov/23449800"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34276608",
          "text": "Live-attenuated vaccines have been historically used to successfully prevent numerous diseases caused by a broad variety of RNA viruses due to their ability to elicit strong and perdurable immune-protective responses.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 217
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34276608",
          "text": "Live-attenuated vaccines have been historically used to successfully prevent numerous diseases caused by a broad variety of RNA viruses due to their ability to elicit strong and perdurable immune-protective responses. In recent years, various strategies have been explored to achieve viral attenuation by rational genetic design rather than using classic and empirical approaches, based on successive passages in cell culture.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 426
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34276608",
          "text": "Live-attenuated vaccines have been historically used to successfully prevent numerous diseases caused by a broad variety of RNA viruses due to their ability to elicit strong and perdurable immune-protective responses. In recent years, various strategies have been explored to achieve viral attenuation by rational genetic design rather than using classic and empirical approaches, based on successive passages in cell culture. A deeper understanding of evolutionary implications of distinct viral genomic compositional aspects, as well as substantial advances in synthetic biology technologies, have provided a framework to achieve new viral attenuation strategies.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 665
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15935875",
          "text": "DNA vectors, live-attenuated viruses and bacteria, recombinant proteins combined with adjuvant, and viral- or bacterial-vectored vaccines have been developed as countermeasures against many potential agents of bioterrorism or biowarfare. The use of viruses, for example adenovirus, vaccinia virus, and Venezuelan equine encephalitis virus, as vaccine vectors has enabled researchers to develop effective means for countering the threat of bioterrorism and biowarfare. An overview of the different viral vectors and the threats they counter will be discussed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 335,
          "end_section": "abstract",
          "offset_in_end_section": 893
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/1368409",
          "text": "Live attenuated vaccines for human use.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 39
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15935875",
          "text": "DNA vectors, live-attenuated viruses and bacteria, recombinant proteins combined with adjuvant, and viral- or bacterial-vectored vaccines have been developed as countermeasures against many potential agents of bioterrorism or biowarfare. The use of viruses, for example adenovirus, vaccinia virus, and Venezuelan equine encephalitis virus, as vaccine vectors has enabled researchers to develop effective means for countering the threat of bioterrorism and biowarfare.",
          "begin_section": "abstract",
          "offset_in_begin_section": 335,
          "end_section": "abstract",
          "offset_in_end_section": 802
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22570186",
          "text": "We review the development and evaluation of new vaccine strategies based on live-attenuated chimeric and recombinant vaccines against human respiratory syncytial virus, human metapneumovirus and human parainfluenza viruses types 1 to 3, which are significant causes of upper and lower tract respiratory diseases. Most promising strategies are based on virus attenuation through (i) mutations in key genes involved in replication; (ii) deletion of accessory genes; or (iii) the use of a corresponding animal viral vector, such as bovine parainfluenza type 3 and Sendai virus, as a background for the expression of a viral glycoprotein. Indeed, the fusion (F), or attachment (HN/H/G) glycoproteins are the most immunogenic antigens in paramyxoviruses.",
          "begin_section": "abstract",
          "offset_in_begin_section": 138,
          "end_section": "abstract",
          "offset_in_end_section": 887
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23449800",
          "text": "Influenza viruses with rearranged genomes as live-attenuated vaccines.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 70
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/10099898",
          "text": "The successful use of live attenuated viral and bacterial vaccines depends not only on the proper choice and delivery of the microorganisms, but also on maintaining the sufficient potency required for an immune response.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 220
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22570186",
          "text": "We review the development and evaluation of new vaccine strategies based on live-attenuated chimeric and recombinant vaccines against human respiratory syncytial virus, human metapneumovirus and human parainfluenza viruses types 1 to 3, which are significant causes of upper and lower tract respiratory diseases. Most promising strategies are based on virus attenuation through (i) mutations in key genes involved in replication; (ii) deletion of accessory genes; or (iii) the use of a corresponding animal viral vector, such as bovine parainfluenza type 3 and Sendai virus, as a background for the expression of a viral glycoprotein.",
          "begin_section": "abstract",
          "offset_in_begin_section": 138,
          "end_section": "abstract",
          "offset_in_end_section": 772
        }
      ],
      "ideal_answer": "Some attenuated viral vaccines that are still in use include: measles, mumps, rubella (MMR) vaccine, oral polio vaccine (OPV), yellow fever vaccine, varicella (chickenpox) vaccine, rotavirus vaccine, and influenza nasal spray vaccine.",
      "exact_answer": [
        [
          "Measles"
        ],
        [
          "Mumps"
        ],
        [
          "Rubella"
        ],
        [
          "Varicella (chickenpox)"
        ],
        [
          "Yellow fever"
        ]
      ]
    },
    {
      "id": "65cfd9071930410b13000024",
      "type": "summary",
      "body": "What was tested in the PATCH-Trauma trial?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/10149946",
        "https://pubmed.ncbi.nlm.nih.gov/33722875",
        "https://pubmed.ncbi.nlm.nih.gov/20113941",
        "https://pubmed.ncbi.nlm.nih.gov/34570735",
        "https://pubmed.ncbi.nlm.nih.gov/19261015",
        "https://pubmed.ncbi.nlm.nih.gov/9066841",
        "https://pubmed.ncbi.nlm.nih.gov/27091397",
        "https://pubmed.ncbi.nlm.nih.gov/34418105",
        "https://pubmed.ncbi.nlm.nih.gov/33456574",
        "https://pubmed.ncbi.nlm.nih.gov/20565505"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33722875",
          "text": "Protocol for a multicentre prehospital randomised controlled trial investigating tranexamic acid in severe trauma: the PATCH-Trauma trial.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 138
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33722875",
          "text": "The PATCH-Trauma study aims to provide definitive evidence of the effectiveness of prehospital TXA, when used in conjunction with current advanced trauma care, in improving outcomes after severe injury. TRIAL REGISTRATION NUMBER\nNCT02187120.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1793,
          "end_section": "abstract",
          "offset_in_end_section": 2036
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/10149946",
          "text": "In a multicenter clinical trial, the efficacy and usefulness of the BPAA Patch in the treatment of extremity trauma were evaluated in 64 patients and the safety was tested in 70 patients. In 89.1% of the patients studied, the final overall improvement was rated \"moderate\" or better, and no adverse reactions were reported.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 324
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33722875",
          "text": "In Germany, Witten/Herdecke University has provided ethics approval. The PATCH-Trauma study aims to provide definitive evidence of the effectiveness of prehospital TXA, when used in conjunction with current advanced trauma care, in improving outcomes after severe injury. TRIAL REGISTRATION NUMBER\nNCT02187120.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1724,
          "end_section": "abstract",
          "offset_in_end_section": 2036
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20113941",
          "text": "This trial was developed to define the patch's efficacy. STUDY DESIGN\nPatients with rib fractures admitted to the trauma service at our Level I trauma center were enrolled and randomized in a 1 to 1 double-blind manner to receive a lidocaine patch 5% or placebo patch.",
          "begin_section": "abstract",
          "offset_in_begin_section": 220,
          "end_section": "abstract",
          "offset_in_end_section": 490
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/10149946",
          "text": "In a multicenter clinical trial, the efficacy and usefulness of the BPAA Patch in the treatment of extremity trauma were evaluated in 64 patients and the safety was tested in 70 patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 187
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20113941",
          "text": "This trial was developed to define the patch's efficacy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 220,
          "end_section": "abstract",
          "offset_in_end_section": 276
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20113941",
          "text": "This trial was developed to define the patch's efficacy. STUDY DESIGN\nPatients with rib fractures admitted to the trauma service at our Level I trauma center were enrolled and randomized in a 1 to 1 double-blind manner to receive a lidocaine patch 5% or placebo patch. Fifty-eight patients who met the inclusion criteria were enrolled from January 2007 to August 2008.",
          "begin_section": "abstract",
          "offset_in_begin_section": 220,
          "end_section": "abstract",
          "offset_in_end_section": 590
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/10149946",
          "text": "In a multicenter clinical trial, the efficacy and usefulness of the BPAA Patch in the treatment of extremity trauma were evaluated in 64 patients and the safety was tested in 70 patients. In 89.1% of the patients studied, the final overall improvement was rated \"moderate\" or better, and no adverse reactions were reported. The results of this study indicate that the BPAA Patch is a highly useful topical antiinflammatory-analgesic agent for use in the treatment of pain and inflammatory symptoms following trauma.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 517
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33722875",
          "text": "METHODS AND ANALYSIS\nThe Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH-Trauma study) is comparing TXA, initiated prehospital and continued in hospital over 8 hours, with placebo in patients with severe trauma at risk of acute traumatic coagulopathy. We present the trial protocol and an overview of the statistical analysis plan.",
          "begin_section": "abstract",
          "offset_in_begin_section": 544,
          "end_section": "abstract",
          "offset_in_end_section": 913
        }
      ],
      "ideal_answer": "The PATCH-Trauma trial tested the effectiveness of prehospital tranexamic acid (TXA) in improving outcomes after severe injury when used in conjunction with current advanced trauma care.",
      "exact_answer": "n/a"
    },
    {
      "id": "66099c01fdcbea915f000023",
      "type": "factoid",
      "body": "What is the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/25585076",
        "https://pubmed.ncbi.nlm.nih.gov/25368289",
        "https://pubmed.ncbi.nlm.nih.gov/27306709",
        "https://pubmed.ncbi.nlm.nih.gov/19464823",
        "https://pubmed.ncbi.nlm.nih.gov/29784042",
        "https://pubmed.ncbi.nlm.nih.gov/17385825",
        "https://pubmed.ncbi.nlm.nih.gov/38074690",
        "https://pubmed.ncbi.nlm.nih.gov/21706368",
        "https://pubmed.ncbi.nlm.nih.gov/25564344",
        "https://pubmed.ncbi.nlm.nih.gov/27353094"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25585076",
          "text": "BACKGROUND\nWe previously conducted a prospective phase II clinical trial studying a unique 22-fraction neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine treatment followed by total mesorectal excision for locally advanced rectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 260
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25585076",
          "text": "Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 132
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29784042",
          "text": "Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 166
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25368289",
          "text": "Capecitabine in combination with radiotherapy remains a standard therapy for locally advanced rectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1013,
          "end_section": "abstract",
          "offset_in_end_section": 1121
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19464823",
          "text": "Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 109
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25564344",
          "text": "PURPOSE\nThe aim of the study was to evaluate the safety and efficacy of adding concurrent nimotuzumab to preoperative radiotherapy with concurrent capecitabine in locally advanced rectal cancer. METHODS AND MATERIALS\nPatients with rectal cancer (clinical stage T3/4 or N+) were scheduled to receive weekly nimotuzumab (400 mg; days -6, 1, 8, 15, 22, and 29). Capecitabine (825 mg/m(2)) was delivered orally twice daily for the duration of radiotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 454
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25564344",
          "text": "The efficacy of this regimen (pCR = 19.0 %) was significantly higher than that observed in previous phase II trials of preoperative radiotherapy with concurrent capecitabine and cetuximab in rectal cancer. Further investigation of concurrent nimotuzumab with radiotherapy plus capecitabine is warranted.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1433,
          "end_section": "abstract",
          "offset_in_end_section": 1736
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19464823",
          "text": "PURPOSE\nWe designed this Phase II trial to assess the efficacy and safety of the addition of bevacizumab to concurrent neoadjuvant capecitabine-based chemoradiation in locally advanced rectal cancer. METHODS\nBetween April 2004 and December 2007, 25 patients with clinically staged T3N1 (n = 20) or T3N0 (n = 5) rectal cancer received neoadjuvant therapy with radiotherapy (50.4 Gy in 28 fractions over 5.5 weeks), bevacizumab every 2 weeks (3 doses of 5 mg/kg), and capecitabine (900 mg/m(2) orally twice daily only on days of radiation), followed by surgical resection a median of 7.3 weeks later.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 600
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19464823",
          "text": "METHODS\nBetween April 2004 and December 2007, 25 patients with clinically staged T3N1 (n = 20) or T3N0 (n = 5) rectal cancer received neoadjuvant therapy with radiotherapy (50.4 Gy in 28 fractions over 5.5 weeks), bevacizumab every 2 weeks (3 doses of 5 mg/kg), and capecitabine (900 mg/m(2) orally twice daily only on days of radiation), followed by surgical resection a median of 7.3 weeks later.",
          "begin_section": "abstract",
          "offset_in_begin_section": 202,
          "end_section": "abstract",
          "offset_in_end_section": 600
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27306709",
          "text": "The currently established standard of care for patients with locally advanced rectal cancer involves preoperative (neoadjuvant) concurrent radiotherapy and infusional fluorouracil-based or oral capecitabine-based chemotherapy, also known as chemoradiotherapy (CRT), followed by surgery.",
          "begin_section": "abstract",
          "offset_in_begin_section": 381,
          "end_section": "abstract",
          "offset_in_end_section": 667
        }
      ],
      "ideal_answer": "The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m² delivered orally twice daily for the duration of radiotherapy.",
      "exact_answer": [
        [
          "The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m² delivered orally twice daily for the duration of radiotherapy."
        ]
      ]
    },
    {
      "id": "6609827afdcbea915f000011",
      "type": "yesno",
      "body": "Is Tako-Tsubo syndrome is an irreversible form of an acute stress-related cardiomyopathy?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/23582148",
        "https://pubmed.ncbi.nlm.nih.gov/21503250",
        "https://pubmed.ncbi.nlm.nih.gov/18582968",
        "https://pubmed.ncbi.nlm.nih.gov/17459500",
        "https://pubmed.ncbi.nlm.nih.gov/16810474",
        "https://pubmed.ncbi.nlm.nih.gov/20131190",
        "https://pubmed.ncbi.nlm.nih.gov/23079608",
        "https://pubmed.ncbi.nlm.nih.gov/23561588",
        "https://pubmed.ncbi.nlm.nih.gov/18562025",
        "https://pubmed.ncbi.nlm.nih.gov/18383776"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18562025",
          "text": "Tako-tsubo cardiomyopathy is a stress-related cardiomyopathy which occurs in postmenopausal women after severe emotional stress. Although no evidence supporting specific treatment with tako-tsubo cardiomyopathy has been established, the prognosis is considered favorable with normalization of wall motion abnormalities within weeks. In addition, recurrence of this syndrome seems to be rare.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 391
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20131190",
          "text": "Tako-tsubo cardiomyopathy, also known as stress-induced cardiomyopathy, is a temporary left ventricular dysfunction characterised by acute retrosternal rest pain, ST - segment elevation, slight elevation of cardiac necrosis markers, preferential apical akinesia or hypokinesia with basal hypercontractility in echocardiography. Its clinical picture mimics an acute coronary syndrome.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 383
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23582148",
          "text": "Tako-Tsubo cardiomyopathy usually mimics an acute coronary syndrome and is defined as a transient left ventricular systolic dysfunction. Stress is frequently present, but is not systematically found.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 199
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21503250",
          "text": "Tako-tsubo Cardiomyopathy (TTC) is typically precipitated by sudden emotional or physical stress, and is associated with excessive sympathetic stimulation and catecholamine release. Its clinical presentation is similar to that of acute coronary syndrome.",
          "begin_section": "abstract",
          "offset_in_begin_section": 133,
          "end_section": "abstract",
          "offset_in_end_section": 387
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23582148",
          "text": "Tako-Tsubo cardiomyopathy usually mimics an acute coronary syndrome and is defined as a transient left ventricular systolic dysfunction. Stress is frequently present, but is not systematically found. Diagnosis is based on the criteria of the Mayo-Clinic.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 254
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20131190",
          "text": "Tako-tsubo cardiomyopathy, also known as stress-induced cardiomyopathy, is a temporary left ventricular dysfunction characterised by acute retrosternal rest pain, ST - segment elevation, slight elevation of cardiac necrosis markers, preferential apical akinesia or hypokinesia with basal hypercontractility in echocardiography. Its clinical picture mimics an acute coronary syndrome. Coronary angiography reveals normal coronary arteries.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 438
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21503250",
          "text": "Tako-tsubo Cardiomyopathy (TTC) is typically precipitated by sudden emotional or physical stress, and is associated with excessive sympathetic stimulation and catecholamine release. Its clinical presentation is similar to that of acute coronary syndrome. The diagnosis of TTC must be considered in all patients who develop a transient left ventricular apical (or mid ventricular) ballooning in the absence of obstructive coronary artery disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 133,
          "end_section": "abstract",
          "offset_in_end_section": 578
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18383776",
          "text": "Tako-tsubo cardiomyopathy is a rare syndrome usually described in postmenopausal women, with a presentation mimicking an acute myocardial infarction.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 149
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20131190",
          "text": "Tako-tsubo cardiomyopathy, also known as stress-induced cardiomyopathy, is a temporary left ventricular dysfunction characterised by acute retrosternal rest pain, ST - segment elevation, slight elevation of cardiac necrosis markers, preferential apical akinesia or hypokinesia with basal hypercontractility in echocardiography.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 327
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18562025",
          "text": "Tako-tsubo cardiomyopathy is a stress-related cardiomyopathy which occurs in postmenopausal women after severe emotional stress.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 128
        }
      ],
      "ideal_answer": "No, Tako-tsubo syndrome is not considered an irreversible form of acute stress-related cardiomyopathy. It is a temporary left ventricular dysfunction characterized by acute retrosternal rest pain, ST-segment elevation, slight elevation of cardiac necrosis markers, and preferential apical akinesia or hypokinesia with basal hypercontractility. The prognosis is generally favorable, with normalization of wall motion abnormalities within weeks. Recurrence of Tako-tsubo syndrome is rare.",
      "exact_answer": "no"
    },
    {
      "id": "660d7491fdcbea915f000041",
      "type": "list",
      "body": "New treatments in multiple sclerosis.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/8839609",
        "https://pubmed.ncbi.nlm.nih.gov/27058221",
        "https://pubmed.ncbi.nlm.nih.gov/30512399",
        "https://pubmed.ncbi.nlm.nih.gov/24356140",
        "https://pubmed.ncbi.nlm.nih.gov/1656516",
        "https://pubmed.ncbi.nlm.nih.gov/37037639",
        "https://pubmed.ncbi.nlm.nih.gov/21568048",
        "https://pubmed.ncbi.nlm.nih.gov/6248820",
        "https://pubmed.ncbi.nlm.nih.gov/20689563",
        "https://pubmed.ncbi.nlm.nih.gov/10935261"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/8839609",
          "text": "New treatments for multiple sclerosis: a clinical perspective.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 62
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30512399",
          "text": "New treatments and strategy in multiple sclerosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 50
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30512399",
          "text": "[New treatments and strategy in multiple sclerosis]",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 51
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24356140",
          "text": "[New and emerging treatments for multiple sclerosis].",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 53
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/6248820",
          "text": "Problems in evaluating new treatments for multiple sclerosis.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 61
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30512399",
          "text": "New treatments and strategy in multiple sclerosis. Currently, ten drugs are approved for the relapsing-remitting form of multiple sclerosis (MS).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 145
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24356140",
          "text": "A number of disease-modifying therapies have been recently approved for the treatment of multiple sclerosis (MS). These molecules which prevent relapses and new central nervous system lesions are more efficient than the \"old\" first line therapies and/or more convenient, especially with oral agents.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 299
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/6248820",
          "text": "There are multiple difficulties in evaluating new treatments for multiple sclerosis (MS).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 89
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30512399",
          "text": "New treatments and strategy in multiple sclerosis. Currently, ten drugs are approved for the relapsing-remitting form of multiple sclerosis (MS). Since 2007, 4 new disease-modifying therapies (DMT) have been approved and several DMT will soon be commercialized including new galenic forms of self-injectable DMTs (pegylated interferon beta 1a and glatiramer acetate).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 367
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24356140",
          "text": "A number of disease-modifying therapies have been recently approved for the treatment of multiple sclerosis (MS). These molecules which prevent relapses and new central nervous system lesions are more efficient than the \"old\" first line therapies and/or more convenient, especially with oral agents. Their usefulness in treating active MS is undeniable, but we have to be aware of their potentially extremely severe side effects.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 429
        }
      ],
      "ideal_answer": "Currently, there are multiple new treatments available for multiple sclerosis (MS), including disease-modifying therapies (DMTs) that have been recently approved. These new treatments are more efficient than the \"old\" first-line therapies and/or more convenient, especially with oral agents. However, it is important to be aware of their potentially severe side effects.",
      "exact_answer": [
        [
          "New treatments for multiple sclerosis"
        ],
        [
          "New and emerging treatments for multiple sclerosis"
        ],
        [
          "New treatments and strategy in multiple sclerosis"
        ]
      ]
    },
    {
      "id": "65cfcc8f1930410b13000018",
      "type": "yesno",
      "body": "Is UGT1A1 implicated in Crigler–Najjar syndrome?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/23162302",
        "https://pubmed.ncbi.nlm.nih.gov/30285761",
        "https://pubmed.ncbi.nlm.nih.gov/22340355",
        "https://pubmed.ncbi.nlm.nih.gov/15712364",
        "https://pubmed.ncbi.nlm.nih.gov/12371080",
        "https://pubmed.ncbi.nlm.nih.gov/27722180",
        "https://pubmed.ncbi.nlm.nih.gov/26250421",
        "https://pubmed.ncbi.nlm.nih.gov/33102778",
        "https://pubmed.ncbi.nlm.nih.gov/17098698",
        "https://pubmed.ncbi.nlm.nih.gov/33604208"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15712364",
          "text": "Here, we present the analysis of UGT1A1 gene in 31 unrelated Crigler-Najjar (CN) syndrome patients. This analysis allowed us to identify 22 mutations, 12 of which were not previously described, expanding the spectrum of known UGT1 mutations to 77. Novel mutations, considered pathogenic, including one nonsense mutation, two altered splice sites, one single base deletion and nine missense mutations were identified in coding exons of the UGT1A1gene and flanking introns.",
          "begin_section": "abstract",
          "offset_in_begin_section": 455,
          "end_section": "abstract",
          "offset_in_end_section": 926
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22340355",
          "text": "We present a case of severe persisting unconjugated hyperbilirubinemia in a Uigur infant boy, eventually diagnosed as Crigler-Najjar syndrome type I. DNA analysis of his blood of the UGT1A1 gene sequence demonstrated that he was homozygous for an insertion mutation causing a change of the coding exons with a frame-shift, resulting in the substitution of 27 abnormal amino acid residues in his hepatic bilirubin uridine diphosphoglucuronyl transferase enzyme.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 460
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22340355",
          "text": "We present a case of severe persisting unconjugated hyperbilirubinemia in a Uigur infant boy, eventually diagnosed as Crigler-Najjar syndrome type I. DNA analysis of his blood of the UGT1A1 gene sequence demonstrated that he was homozygous for an insertion mutation causing a change of the coding exons with a frame-shift, resulting in the substitution of 27 abnormal amino acid residues in his hepatic bilirubin uridine diphosphoglucuronyl transferase enzyme. Both of his parents were heterozygous for the same mutation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 521
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/15712364",
          "text": "In addition, the evaluation of Gilbert-type promoter of UGT1A1in Crigler-Najjar (CN) syndrome patients was performed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1006,
          "end_section": "abstract",
          "offset_in_end_section": 1123
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30285761",
          "text": "CASE PRESENTATION\nIn this report, we present a boy with Crigler-Najjar syndrome type II with high unconjugated bilirubin levels that decreased after phenobarbital treatment but increased in adolescence. Four different UGT1A1 gene variants have been identified for this patient, of which one is novel (g.11895_11898del) most likely confirming diagnose molecularly. CONCLUSIONS\nThe presented case highlights the challenges encountered with the interpretation of molecular data upon identification of multiple variants in one gene that are causing different degree reducing effect on enzyme activity leading to several clinical conditions.",
          "begin_section": "abstract",
          "offset_in_begin_section": 337,
          "end_section": "abstract",
          "offset_in_end_section": 975
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33604208",
          "text": "Crigler-Najjar syndrome is an inborn error of metabolism caused by a point mutation in one of the five exons of UGT1A1 gene, the product of which is responsible for elimination of bilirubin via bile. A number of hyperbilirubinemia disorders similar to Crigler-Najjar syndrome are reported, but they differ in their level of unconjugated bilirubin and responses to the treatment. Here we report a 14-year-old male patient admitted to hospital with the complaint of vomiting and frequent tonsillitis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 498
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33102778",
          "text": "Crigler-Najjar syndrome (CNs) is a rare hereditary unconjugated hyperbilirubinemia caused by mutations in the bilirubin Uridine (UDP) glucuronosyltransferase family 1 member A1 (UGT1A1, ENSG00000241635) gene. Two patients were clinically diagnosed with Crigler-Najjar Syndrome types II (CNs-II) can be clinically diagnosed which were based on the level of total bilirubin, efficacy of phenobarbital treatment, normal liver architecture and exclusion of hemolysis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 463
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33102778",
          "text": "Two patients were clinically diagnosed with Crigler-Najjar Syndrome types II (CNs-II) can be clinically diagnosed which were based on the level of total bilirubin, efficacy of phenobarbital treatment, normal liver architecture and exclusion of hemolysis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 209,
          "end_section": "abstract",
          "offset_in_end_section": 463
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23162302",
          "text": "Crigler-Najjar syndrome type 2 is a rare cause for persistent unconjugated hyperbilirubinemia, inherited in an autosomal recessive manner. Even though it is compatible with normal life span, in the absence of prompt suspicion and intensive management it can prove fatal not only in the neonatal period but also during adult life. Here, we describe a case with a novel homozygous UGT1A1 p.Pro176Leu mutation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 407
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17098698",
          "text": "Crigler-Najjar syndrome type 2.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 31
        }
      ],
      "ideal_answer": "Yes, UGT1A1 gene is implicated in Crigler-Najjar syndrome. Crigler-Najjar syndrome is an inborn error of metabolism caused by mutations in the UGT1A1 gene. This gene is responsible for the production of the bilirubin uridine diphosphoglucuronyl transferase enzyme, which is involved in the elimination of bilirubin via bile. Mutations in the UGT1A1 gene result in reduced or absent enzyme activity, leading to the accumulation of unconjugated bilirubin in the blood and subsequent hyperbilirubinemia.",
      "exact_answer": "yes"
    },
    {
      "id": "65f77596c4010b4d7800002c",
      "type": "yesno",
      "body": "Should PDYD polymorphism determination be routinely performed in patients with colorectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/19239324",
        "https://pubmed.ncbi.nlm.nih.gov/25061488",
        "https://pubmed.ncbi.nlm.nih.gov/20336543",
        "https://pubmed.ncbi.nlm.nih.gov/16927418",
        "https://pubmed.ncbi.nlm.nih.gov/21461655",
        "https://pubmed.ncbi.nlm.nih.gov/19373442",
        "https://pubmed.ncbi.nlm.nih.gov/37857267",
        "https://pubmed.ncbi.nlm.nih.gov/7982175",
        "https://pubmed.ncbi.nlm.nih.gov/15888281",
        "https://pubmed.ncbi.nlm.nih.gov/30358196"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20336543",
          "text": "Determination of the polymorphism may be a potential marker to predict the prognosis of colorectal cancer patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 983,
          "end_section": "abstract",
          "offset_in_end_section": 1098
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19239324",
          "text": "The frequency of the polymorphism was examined in 156 patients with colorectal cancer and in 293 healthy controls. The polymorphism analysis was performed by amplifying exon 4 of p53 and digesting the products with restriction enzyme.",
          "begin_section": "abstract",
          "offset_in_begin_section": 437,
          "end_section": "abstract",
          "offset_in_end_section": 671
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20336543",
          "text": "CONCLUSIONS\nThe hMLH1 gene A655G polymorphism may play a role in the pathogenesis of colorectal cancer. Determination of the polymorphism may be a potential marker to predict the prognosis of colorectal cancer patients.",
          "begin_section": "abstract",
          "offset_in_begin_section": 879,
          "end_section": "abstract",
          "offset_in_end_section": 1098
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19239324",
          "text": "The frequency of the polymorphism was examined in 156 patients with colorectal cancer and in 293 healthy controls. The polymorphism analysis was performed by amplifying exon 4 of p53 and digesting the products with restriction enzyme. The frequencies of genotypes: Arg/Arg, Arg/Pro and Pro/Pro were 34.6% (54/156), 43.0% (67/156) and 22.4% (35/156), respectively, in the cases with colorectal cancer, and 28.9% (114/293), 47.8% (140/293) and 13.3% (39/293), respectively, in the healthy controls.",
          "begin_section": "abstract",
          "offset_in_begin_section": 437,
          "end_section": "abstract",
          "offset_in_end_section": 933
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25061488",
          "text": "AIM\nTo determine the risk of colon cancer by analysing the IRS-2 gene polymorphism in Turkish patients. MATERIAL AND METHODS\nA total of 161 newly diagnosed colorectal cancer patients were analysed and compared to 197 unrelated healthy controls. A polymerase chain reaction-based restriction fragment length polymorphism method was carried out.",
          "begin_section": "abstract",
          "offset_in_begin_section": 477,
          "end_section": "abstract",
          "offset_in_end_section": 822
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21461655",
          "text": "METHODS\nWe conducted a large-scale case-control study that included 2,213 gastric cancer patients; 1,829 colorectal cancer patients; and 1,700 healthy controls. Genotyping was performed with real-time polymerase chain reaction (PCR), using a TaqMan single-nucleotide polymorphism (SNP) genotyping assay.",
          "begin_section": "abstract",
          "offset_in_begin_section": 317,
          "end_section": "abstract",
          "offset_in_end_section": 620
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19239324",
          "text": "The polymorphism analysis was performed by amplifying exon 4 of p53 and digesting the products with restriction enzyme. The frequencies of genotypes: Arg/Arg, Arg/Pro and Pro/Pro were 34.6% (54/156), 43.0% (67/156) and 22.4% (35/156), respectively, in the cases with colorectal cancer, and 28.9% (114/293), 47.8% (140/293) and 13.3% (39/293), respectively, in the healthy controls. Statistically, there was a significant difference in the frequency of the genotypes when the healthy controls were compared to the patients with colorectal cancer (<em>p</em>=0.0459).",
          "begin_section": "abstract",
          "offset_in_begin_section": 552,
          "end_section": "abstract",
          "offset_in_end_section": 1117
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25061488",
          "text": "AIM\nTo determine the risk of colon cancer by analysing the IRS-2 gene polymorphism in Turkish patients. MATERIAL AND METHODS\nA total of 161 newly diagnosed colorectal cancer patients were analysed and compared to 197 unrelated healthy controls.",
          "begin_section": "abstract",
          "offset_in_begin_section": 477,
          "end_section": "abstract",
          "offset_in_end_section": 723
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21461655",
          "text": "Genotyping was performed with real-time polymerase chain reaction (PCR), using a TaqMan single-nucleotide polymorphism (SNP) genotyping assay. RESULTS\nThe frequencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes of the p53 codon 72 polymorphism were 43.3, 42.0, and 13.0% in the gastric cancer patients; 40.5, 45.0, and 14.0% in the colorectal cancer patients; and 43.2, 45.6, and 11.2% in the controls, respectively.",
          "begin_section": "abstract",
          "offset_in_begin_section": 478,
          "end_section": "abstract",
          "offset_in_end_section": 895
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/19239324",
          "text": "The polymorphism analysis was performed by amplifying exon 4 of p53 and digesting the products with restriction enzyme. The frequencies of genotypes: Arg/Arg, Arg/Pro and Pro/Pro were 34.6% (54/156), 43.0% (67/156) and 22.4% (35/156), respectively, in the cases with colorectal cancer, and 28.9% (114/293), 47.8% (140/293) and 13.3% (39/293), respectively, in the healthy controls.",
          "begin_section": "abstract",
          "offset_in_begin_section": 552,
          "end_section": "abstract",
          "offset_in_end_section": 933
        }
      ],
      "ideal_answer": "The determination of the PDYD polymorphism should not be routinely performed in patients with colorectal cancer. Although polymorphisms in certain genes, such as p53 and hMLH1, have been shown to play a role in the pathogenesis of colorectal cancer, there is currently insufficient evidence to support the routine use of PDYD polymorphism determination in clinical practice. Further research is needed to establish the clinical significance and prognostic value of PDYD polymorphism in colorectal cancer patients.",
      "exact_answer": "no"
    },
    {
      "id": "660710b7fdcbea915f000002",
      "type": "summary",
      "body": "What is the function of the sodium leak channel (NALCN)?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/32698188",
        "https://pubmed.ncbi.nlm.nih.gov/27488637",
        "https://pubmed.ncbi.nlm.nih.gov/33203861",
        "https://pubmed.ncbi.nlm.nih.gov/30556810",
        "https://pubmed.ncbi.nlm.nih.gov/24904279",
        "https://pubmed.ncbi.nlm.nih.gov/37635635",
        "https://pubmed.ncbi.nlm.nih.gov/33793981",
        "https://pubmed.ncbi.nlm.nih.gov/33766679",
        "https://pubmed.ncbi.nlm.nih.gov/37640554",
        "https://pubmed.ncbi.nlm.nih.gov/17448995"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33766679",
          "text": "The sodium leak channel (NALCN), a non-selective cation channel, mediates the background Na+ leak conductance and controls neuronal excitability and rhythmic behaviors. Here, we show that increases of NALCN expression and function in dorsal root ganglion (DRG) and dorsal spinal cord contribute to chronic constriction injury (CCI)-induced neuropathic pain in rodents.",
          "begin_section": "abstract",
          "offset_in_begin_section": 114,
          "end_section": "abstract",
          "offset_in_end_section": 482
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33766679",
          "text": "The sodium leak channel (NALCN), a non-selective cation channel, mediates the background Na+ leak conductance and controls neuronal excitability and rhythmic behaviors. Here, we show that increases of NALCN expression and function in dorsal root ganglion (DRG) and dorsal spinal cord contribute to chronic constriction injury (CCI)-induced neuropathic pain in rodents. NALCN current and neuronal excitability in acutely isolated DRG neurons and spinal cord slices of rats were increased after CCI which were decreased to normal levels by NALCN-siRNA.",
          "begin_section": "abstract",
          "offset_in_begin_section": 114,
          "end_section": "abstract",
          "offset_in_end_section": 664
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33766679",
          "text": "The sodium leak channel (NALCN), a non-selective cation channel, mediates the background Na+ leak conductance and controls neuronal excitability and rhythmic behaviors.",
          "begin_section": "abstract",
          "offset_in_begin_section": 114,
          "end_section": "abstract",
          "offset_in_end_section": 282
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33203861",
          "text": "NALCN, a sodium leak channel expressed mainly in the central nervous system, is responsible for the resting Na+ permeability that controls neuronal excitability. Dysfunctions of the NALCN channelosome, NALCN with several auxiliary subunits, are associated with a variety of human diseases.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 289
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33203861",
          "text": "NALCN, a sodium leak channel expressed mainly in the central nervous system, is responsible for the resting Na+ permeability that controls neuronal excitability.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 161
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32698188",
          "text": "Structure of the human sodium leak channel NALCN.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 49
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27488637",
          "text": "We show here that Nalcn, a unique channel that generates \"leak\" sodium currents, regulates excitability and neuromodulation of RTN neurons and CO2-stimulated breathing. Thus, this work defines a specific function for this enigmatic channel in an important physiological context.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1655,
          "end_section": "abstract",
          "offset_in_end_section": 1933
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37640554",
          "text": "We tested the role of the sodium leak channel, NALCN, in pacemaking of dopaminergic neuron (DAN) subpopulations from adult male and female mice.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 144
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33793981",
          "text": "The sodium leak channel NALCN regulates cell excitability of pituitary endocrine cells.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 87
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27488637",
          "text": "We show here that Nalcn, a unique channel that generates \"leak\" sodium currents, regulates excitability and neuromodulation of RTN neurons and CO2-stimulated breathing.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1655,
          "end_section": "abstract",
          "offset_in_end_section": 1823
        }
      ],
      "ideal_answer": "The sodium leak channel (NALCN) mediates the background Na+ leak conductance and controls neuronal excitability and rhythmic behaviors. Increases in NALCN expression and function contribute to chronic constriction injury-induced neuropathic pain in rodents. Dysfunctions of the NALCN channelosome are associated with various human diseases. NALCN regulates excitability and neuromodulation of RTN neurons and CO2-stimulated breathing. NALCN also plays a role in pacemaking of dopaminergic neuron subpopulations and cell excitability of pituitary endocrine cells.",
      "exact_answer": "n/a"
    },
    {
      "id": "660d70b3fdcbea915f00003f",
      "type": "summary",
      "body": "Cancer risk in transgender individuals.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/32134515",
        "https://pubmed.ncbi.nlm.nih.gov/29392096",
        "https://pubmed.ncbi.nlm.nih.gov/37677784",
        "https://pubmed.ncbi.nlm.nih.gov/28524897",
        "https://pubmed.ncbi.nlm.nih.gov/36789830",
        "https://pubmed.ncbi.nlm.nih.gov/31027551",
        "https://pubmed.ncbi.nlm.nih.gov/30680866",
        "https://pubmed.ncbi.nlm.nih.gov/34097159",
        "https://pubmed.ncbi.nlm.nih.gov/32939016",
        "https://pubmed.ncbi.nlm.nih.gov/30107028"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31027551",
          "text": "Cancer Risk in Transgender People.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 34
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31027551",
          "text": "Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 177,
          "end_section": "abstract",
          "offset_in_end_section": 643
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32939016",
          "text": "The incidental findings of high-risk lesions and carcinoma as well as the risk of cancer in residual breast tissue after chest-contouring surgery warrant the consideration of culturally sensitive routine breast cancer screening protocols for transgender men and masculine-centered gender nonconforming individuals. Long-term follow-up studies and molecular investigations are needed to understand the breast cancer risk of transgender individuals who receive TT.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1627,
          "end_section": "abstract",
          "offset_in_end_section": 2089
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31027551",
          "text": "Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 495
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31027551",
          "text": "Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 392
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31027551",
          "text": "Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT.",
          "begin_section": "abstract",
          "offset_in_begin_section": 177,
          "end_section": "abstract",
          "offset_in_end_section": 392
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31027551",
          "text": "Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article.",
          "begin_section": "abstract",
          "offset_in_begin_section": 177,
          "end_section": "abstract",
          "offset_in_end_section": 495
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32939016",
          "text": "The incidental findings of high-risk lesions and carcinoma as well as the risk of cancer in residual breast tissue after chest-contouring surgery warrant the consideration of culturally sensitive routine breast cancer screening protocols for transgender men and masculine-centered gender nonconforming individuals.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1627,
          "end_section": "abstract",
          "offset_in_end_section": 1941
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36789830",
          "text": "BACKGROUND AND AIMS\nThe risk of developing breast cancer in transgender individuals [male-to-female (MtF) or female-to-male (FtM)] is still inadequately quantified. We aimed to evaluate the impact of breast cancer in this population.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 233
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34097159",
          "text": "Breast Cancer Risk and Screening in Transgender Persons: A Call for Inclusive Care.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 83
        }
      ],
      "ideal_answer": "The cancer risk in transgender individuals receiving hormone therapy (HT) is still not well understood due to limited epidemiologic data. Differences in cancer risk between men and women, which are attributed to exposure to sex hormones, may alter the cancer risk in transgender individuals receiving HT. Routine breast cancer screening protocols should be considered for transgender men and masculine-centered gender nonconforming individuals due to the risk of high-risk lesions, carcinoma, and cancer in residual breast tissue after chest-contouring surgery.",
      "exact_answer": "n/a"
    },
    {
      "id": "65d372231930410b13000047",
      "type": "yesno",
      "body": "Does Lenvatinib plus pembrolizumab improve prognosis of advanced hepatocellular carcinoma?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/38039993",
        "https://pubmed.ncbi.nlm.nih.gov/33616314",
        "https://pubmed.ncbi.nlm.nih.gov/34167433",
        "https://pubmed.ncbi.nlm.nih.gov/33854567",
        "https://pubmed.ncbi.nlm.nih.gov/36457273",
        "https://pubmed.ncbi.nlm.nih.gov/35045221",
        "https://pubmed.ncbi.nlm.nih.gov/30689402",
        "https://pubmed.ncbi.nlm.nih.gov/32167863",
        "https://pubmed.ncbi.nlm.nih.gov/35347395",
        "https://pubmed.ncbi.nlm.nih.gov/33338862"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38039993",
          "text": "INTERPRETATION\nIn earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice.",
          "begin_section": "abstract",
          "offset_in_begin_section": 3609,
          "end_section": "abstract",
          "offset_in_end_section": 4015
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38039993",
          "text": "INTERPRETATION\nIn earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo.",
          "begin_section": "abstract",
          "offset_in_begin_section": 3609,
          "end_section": "abstract",
          "offset_in_end_section": 3956
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38039993",
          "text": "INTERPRETATION\nIn earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice. FUNDING\nEisai US, and Merck Sharp & Dohme, a subsidiary of Merck.",
          "begin_section": "abstract",
          "offset_in_begin_section": 3609,
          "end_section": "abstract",
          "offset_in_end_section": 4083
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38039993",
          "text": "BACKGROUND\nSystemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 353
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38039993",
          "text": "This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma.",
          "begin_section": "abstract",
          "offset_in_begin_section": 181,
          "end_section": "abstract",
          "offset_in_end_section": 353
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35347395",
          "text": "BACKGROUND\nLenvatinib combined with pembrolizumab showed a promising result in an early phase study for hepatocellular carcinoma (HCC).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 135
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32167863",
          "text": "CONCLUSION\nLenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1454,
          "end_section": "abstract",
          "offset_in_end_section": 1681
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33854567",
          "text": "BACKGROUND\nLenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 127
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/38039993",
          "text": "Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 153
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32167863",
          "text": "CONCLUSION\nLenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1454,
          "end_section": "abstract",
          "offset_in_end_section": 1740
        }
      ],
      "ideal_answer": "Based on the findings of the study, lenvatinib plus pembrolizumab did not show a significant improvement in overall survival and progression-free survival compared to lenvatinib plus placebo in advanced hepatocellular carcinoma. Therefore, the addition of pembrolizumab to lenvatinib does not currently support a change in clinical practice for the treatment of advanced hepatocellular carcinoma.",
      "exact_answer": "no"
    },
    {
      "id": "660998d1fdcbea915f000013",
      "type": "list",
      "body": "What molecular subtypes of colon cancer are associated to smoking?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/34377935",
        "https://pubmed.ncbi.nlm.nih.gov/30072645",
        "https://pubmed.ncbi.nlm.nih.gov/30963391",
        "https://pubmed.ncbi.nlm.nih.gov/28275039",
        "https://pubmed.ncbi.nlm.nih.gov/37274263",
        "https://pubmed.ncbi.nlm.nih.gov/26647925",
        "https://pubmed.ncbi.nlm.nih.gov/28321693",
        "https://pubmed.ncbi.nlm.nih.gov/37773805",
        "https://pubmed.ncbi.nlm.nih.gov/37474678",
        "https://pubmed.ncbi.nlm.nih.gov/22712570"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34377935",
          "text": "Association Between Smoking and Molecular Subtypes of Colorectal Cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 72
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34377935",
          "text": "The association was also stronger in tumors that were CIMP positive, MSI high, or KRAS wild type when combined (P difference < .001). Conclusion\nSmoking was associated with differential risk of CRC subtypes defined by molecular characteristics. Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1527,
          "end_section": "abstract",
          "offset_in_end_section": 1993
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34377935",
          "text": "Conclusion\nSmoking was associated with differential risk of CRC subtypes defined by molecular characteristics. Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1663,
          "end_section": "abstract",
          "offset_in_end_section": 1993
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/22712570",
          "text": "Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 139
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34377935",
          "text": "The association was also stronger in tumors that were CIMP positive, MSI high, or KRAS wild type when combined (P difference < .001). Conclusion\nSmoking was associated with differential risk of CRC subtypes defined by molecular characteristics.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1527,
          "end_section": "abstract",
          "offset_in_end_section": 1773
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34377935",
          "text": "Background\nSmoking is associated with colorectal cancer (CRC) risk. Previous studies suggested this association may be restricted to certain molecular subtypes of CRC, but large-scale comprehensive analysis is lacking. Methods\nA total of 9789 CRC cases and 11 231 controls of European ancestry from 11 observational studies were included.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 340
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34377935",
          "text": "Background\nSmoking is associated with colorectal cancer (CRC) risk. Previous studies suggested this association may be restricted to certain molecular subtypes of CRC, but large-scale comprehensive analysis is lacking.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 218
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34377935",
          "text": "Conclusion\nSmoking was associated with differential risk of CRC subtypes defined by molecular characteristics.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1663,
          "end_section": "abstract",
          "offset_in_end_section": 1773
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34377935",
          "text": "Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1774,
          "end_section": "abstract",
          "offset_in_end_section": 1993
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28321693",
          "text": "Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 93
        }
      ],
      "ideal_answer": "Smoking is associated with differential risk of colorectal cancer (CRC) subtypes defined by molecular characteristics. Heavier smokers have a particularly higher risk of CRC subtypes that are CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.",
      "exact_answer": [
        [
          "CIMP positive"
        ],
        [
          "MSI high"
        ]
      ]
    },
    {
      "id": "660877c8fdcbea915f000008",
      "type": "factoid",
      "body": "What part of the cell is mitophagy associated with?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/31787745",
        "https://pubmed.ncbi.nlm.nih.gov/29057310",
        "https://pubmed.ncbi.nlm.nih.gov/28526134",
        "https://pubmed.ncbi.nlm.nih.gov/28324490",
        "https://pubmed.ncbi.nlm.nih.gov/27295498",
        "https://pubmed.ncbi.nlm.nih.gov/36909283",
        "https://pubmed.ncbi.nlm.nih.gov/33352896",
        "https://pubmed.ncbi.nlm.nih.gov/34724805",
        "https://pubmed.ncbi.nlm.nih.gov/29180353",
        "https://pubmed.ncbi.nlm.nih.gov/36181536"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28324490",
          "text": "Aberrant mitochondrial function is associated with many neurological diseases. Mitophagy is a key mechanism for the elimination of damaged mitochondria and maintenance of mitochondrial homeostasis. Induced pluripotent stem (iPS) cell technologies developed over the last decade have allowed us to analyze functions of the human neuron.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 335
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34724805",
          "text": "OBJECTIVE\nWe investigated whether mitophagy is activated during the chronic phase of cardiomyopathy associated with obesity (obesity cardiomyopathy) after general autophagy is downregulated and, if so, what the underlying mechanism and the functional significance are.",
          "begin_section": "abstract",
          "offset_in_begin_section": 370,
          "end_section": "abstract",
          "offset_in_end_section": 638
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34724805",
          "text": "OBJECTIVE\nWe investigated whether mitophagy is activated during the chronic phase of cardiomyopathy associated with obesity (obesity cardiomyopathy) after general autophagy is downregulated and, if so, what the underlying mechanism and the functional significance are. METHODS AND RESULTS\nMice were fed either a normal diet or a HFD (60 kcal% fat).",
          "begin_section": "abstract",
          "offset_in_begin_section": 370,
          "end_section": "abstract",
          "offset_in_end_section": 720
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28324490",
          "text": "Mitophagy is a key mechanism for the elimination of damaged mitochondria and maintenance of mitochondrial homeostasis. Induced pluripotent stem (iPS) cell technologies developed over the last decade have allowed us to analyze functions of the human neuron.",
          "begin_section": "abstract",
          "offset_in_begin_section": 79,
          "end_section": "abstract",
          "offset_in_end_section": 335
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28526134",
          "text": "There is continuous evolution on the pathways orchestrating the mitochondrial response to stress signals and the organelle adaptation to quality control during acute and subtle dysfunctions. Notably, it remains indeed ill-defined whether active mitophagy leads to cell survival or death by defective mitochondrial degradation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 338,
          "end_section": "abstract",
          "offset_in_end_section": 664
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36909283",
          "text": "Mitochondrial dysfunction is associated with ototoxicity, which is caused by external factors. Mitophagy plays a key role in maintaining mitochondrial homeostasis and function and is regulated by a series of key mitophagy regulatory proteins and signaling pathways.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 265
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36909283",
          "text": "Mitochondrial dysfunction is associated with ototoxicity, which is caused by external factors. Mitophagy plays a key role in maintaining mitochondrial homeostasis and function and is regulated by a series of key mitophagy regulatory proteins and signaling pathways. The results of ototoxicity models indicate the importance of this process in the etiology of ototoxicity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 371
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36181536",
          "text": "CONCLUSIONS/INTERPRETATION\nWe demonstrated that CMMR mice enabled the evaluation of mitophagy in beta cells. Our results suggested that metabolic stress induced by the HFD caused the aberrant accumulation of dysfunctional mitochondria, which overwhelmed the mitophagic capacity and was associated with defective maintenance of mitochondrial function and impaired insulin secretion.",
          "begin_section": "abstract",
          "offset_in_begin_section": 2118,
          "end_section": "abstract",
          "offset_in_end_section": 2499
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28324490",
          "text": "Aberrant mitochondrial function is associated with many neurological diseases. Mitophagy is a key mechanism for the elimination of damaged mitochondria and maintenance of mitochondrial homeostasis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 197
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28526134",
          "text": "There is continuous evolution on the pathways orchestrating the mitochondrial response to stress signals and the organelle adaptation to quality control during acute and subtle dysfunctions. Notably, it remains indeed ill-defined whether active mitophagy leads to cell survival or death by defective mitochondrial degradation. Above all, uncharted is whether and how pharmacologically tackle these mechanisms may lead to conceive novel therapeutic strategies for treating conditions associated with the defective mitochondria.",
          "begin_section": "abstract",
          "offset_in_begin_section": 338,
          "end_section": "abstract",
          "offset_in_end_section": 864
        }
      ],
      "ideal_answer": "Mitophagy is associated with the elimination of damaged mitochondria and maintenance of mitochondrial homeostasis. It is a process that occurs within the cell, specifically targeting and removing dysfunctional or damaged mitochondria.",
      "exact_answer": [
        [
          "Mitophagy is associated with the mitochondria."
        ]
      ]
    },
    {
      "id": "660d2a50fdcbea915f00003a",
      "type": "summary",
      "body": "What is the association between statins and stroke?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/16379334",
        "https://pubmed.ncbi.nlm.nih.gov/18524729",
        "https://pubmed.ncbi.nlm.nih.gov/18855667",
        "https://pubmed.ncbi.nlm.nih.gov/31218948",
        "https://pubmed.ncbi.nlm.nih.gov/16258569",
        "https://pubmed.ncbi.nlm.nih.gov/15099541",
        "https://pubmed.ncbi.nlm.nih.gov/12822200",
        "https://pubmed.ncbi.nlm.nih.gov/12074043",
        "https://pubmed.ncbi.nlm.nih.gov/15198966",
        "https://pubmed.ncbi.nlm.nih.gov/31699020"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31699020",
          "text": "The association of the use of statins (defined as at least 2 purchases) with all-cause mortality, recurrent stroke, and other recurrent vascular events was assessed through adjusted Cox regression analyses.",
          "begin_section": "abstract",
          "offset_in_begin_section": 619,
          "end_section": "abstract",
          "offset_in_end_section": 825
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/16258569",
          "text": "The epidemiologic association between serum cholesterol levels and adjusted stroke rates is not as strong as the link between serum cholesterol levels and coronary heart disease. Clinical trials of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), which are potent inhibitors of cholesterol synthesis, have demonstrated, however, a marked reduction in stroke risk in hypercholesterolemic and atherosclerotic individuals, with benefits extending to normocholesterolemic individuals. These findings suggest that statins might have additional effects in stroke protection beyond cholesterol reduction.",
          "begin_section": "abstract",
          "offset_in_begin_section": 340,
          "end_section": "abstract",
          "offset_in_end_section": 958
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18524729",
          "text": "Epidemiologic studies found no or little association between blood cholesterol levels and stroke. However, randomized trials in patients with CAD have shown that statins decrease stroke incidence.",
          "begin_section": "abstract",
          "offset_in_begin_section": 146,
          "end_section": "abstract",
          "offset_in_end_section": 342
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18524729",
          "text": "Cholesterol lowering with statins has been proven to reduce vascular events in primary and secondary prevention of coronary artery disease (CAD). Epidemiologic studies found no or little association between blood cholesterol levels and stroke.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 243
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/12074043",
          "text": "There are strong indications for a relationship between blood lipid profiles and types of stroke that have atherosclerosis as the underlying pathogenetic mechanism. Apart from their ability to reduce LDL levels significantly, statins have a number of other properties, which influence the process of atherosclerosis at various stages.",
          "begin_section": "abstract",
          "offset_in_begin_section": 453,
          "end_section": "abstract",
          "offset_in_end_section": 787
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31699020",
          "text": "The association of the use of statins (defined as at least 2 purchases) with all-cause mortality, recurrent stroke, and other recurrent vascular events was assessed through adjusted Cox regression analyses. We further compared propensity score-matched statin users with nonusers.",
          "begin_section": "abstract",
          "offset_in_begin_section": 619,
          "end_section": "abstract",
          "offset_in_end_section": 898
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18855667",
          "text": "Although studies are heterogeneous, our analysis shows that statins reduce the risk of stroke occurrence in high risk patients and seem also to reduce stroke recurrence. Moreover, the low incidence and reversibility of adverse effects, and the unclear association with hemorrhagic events, support the safe use of these drugs.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1044,
          "end_section": "abstract",
          "offset_in_end_section": 1369
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31699020",
          "text": "The association of the use of statins (defined as at least 2 purchases) with all-cause mortality, recurrent stroke, and other recurrent vascular events was assessed through adjusted Cox regression analyses. We further compared propensity score-matched statin users with nonusers. Results- Of our 935 patients, 46.8% used statins at some point during follow-up.",
          "begin_section": "abstract",
          "offset_in_begin_section": 619,
          "end_section": "abstract",
          "offset_in_end_section": 979
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/18855667",
          "text": "Despite a strong association between increased levels of low-density lipoprotein cholesterol (LDL-C) and the incidence of coronary heart disease (CHD) has been well proven, it not yet established whether serum LDL-C levels are related to stroke incidence. The major aim of this paper is to perform a comprehensive up-to-date review of research papers, meta-analyses and randomized controlled clinical trials reporting the effects of statins in primary and secondary stroke prevention strategies. In addition, our work provides an overview on statin chemical structure, mechanism of action and pharmacological properties, investigating also most common adverse effects and relationship between statin therapy and haemorrhagic stroke risk, in order to assess drugs safety.",
          "begin_section": "abstract",
          "offset_in_begin_section": 273,
          "end_section": "abstract",
          "offset_in_end_section": 1043
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31699020",
          "text": "Statin use was independently associated with lower risk of all-cause mortality and recurrent stroke.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1547,
          "end_section": "abstract",
          "offset_in_end_section": 1647
        }
      ],
      "ideal_answer": "Clinical trials have shown that statins, which are potent inhibitors of cholesterol synthesis, can reduce the risk of stroke in hypercholesterolemic and atherosclerotic individuals. Statins have been proven to reduce stroke incidence in patients with coronary artery disease (CAD) in randomized trials. There are indications of a relationship between blood lipid profiles and stroke types with atherosclerosis as the underlying mechanism. Statins may have additional effects in stroke protection beyond cholesterol reduction. Overall, statin use has been associated with a lower risk of stroke occurrence and recurrence.",
      "exact_answer": "n/a"
    },
    {
      "id": "65cfd02e1930410b1300001c",
      "type": "factoid",
      "body": "What channel is targeted by VX-548?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37530822",
        "https://pubmed.ncbi.nlm.nih.gov/24796242",
        "https://pubmed.ncbi.nlm.nih.gov/22942289",
        "https://pubmed.ncbi.nlm.nih.gov/27402691",
        "https://pubmed.ncbi.nlm.nih.gov/35004859",
        "https://pubmed.ncbi.nlm.nih.gov/34587656",
        "https://pubmed.ncbi.nlm.nih.gov/25101887",
        "https://pubmed.ncbi.nlm.nih.gov/37373505",
        "https://pubmed.ncbi.nlm.nih.gov/26492939",
        "https://pubmed.ncbi.nlm.nih.gov/20384284"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37530822",
          "text": "BACKGROUND\nThe NaV1.8 voltage-gated sodium channel, expressed in peripheral nociceptive neurons, plays a role in transmitting nociceptive signals. The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied. METHODS\nAfter establishing the selectivity of VX-548 for NaV1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 454
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37530822",
          "text": "BACKGROUND\nThe NaV1.8 voltage-gated sodium channel, expressed in peripheral nociceptive neurons, plays a role in transmitting nociceptive signals. The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 258
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37530822",
          "text": "VX-548 was associated with adverse events that were mild to moderate in severity.",
          "begin_section": "abstract",
          "offset_in_begin_section": 2456,
          "end_section": "abstract",
          "offset_in_end_section": 2537
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24796242",
          "text": "VX-809 does not improve channel function by itself as previously reported. CONCLUSIONS\nThe results from these studies can be interpreted as an equilibrium shift toward the open-channel conformation of F508del-CFTR channels.",
          "begin_section": "abstract",
          "offset_in_begin_section": 880,
          "end_section": "abstract",
          "offset_in_end_section": 1105
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24796242",
          "text": "VX-809 does not improve channel function by itself as previously reported.",
          "begin_section": "abstract",
          "offset_in_begin_section": 880,
          "end_section": "abstract",
          "offset_in_end_section": 954
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/27402691",
          "text": "VX-809 corrected the R117H folding defect and restored channel function.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1259,
          "end_section": "abstract",
          "offset_in_end_section": 1331
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24796242",
          "text": "The shorter locked-open time of hydrolysis-deficient F508del-CFTR is also prolonged by VX-770. VX-809 does not improve channel function by itself as previously reported. CONCLUSIONS\nThe results from these studies can be interpreted as an equilibrium shift toward the open-channel conformation of F508del-CFTR channels.",
          "begin_section": "abstract",
          "offset_in_begin_section": 785,
          "end_section": "abstract",
          "offset_in_end_section": 1105
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37530822",
          "text": "The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied.",
          "begin_section": "abstract",
          "offset_in_begin_section": 147,
          "end_section": "abstract",
          "offset_in_end_section": 258
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37530822",
          "text": "The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied. METHODS\nAfter establishing the selectivity of VX-548 for NaV1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, participants were randomly assigned in a 1:1:1:1 ratio to receive one of the following over a 48-hour period: a 100-mg oral loading dose of VX-548, followed by a 50-mg maintenance dose every 12 hours (the high-dose group); a 60-mg loading dose of VX-548, followed by a 30-mg maintenance dose every 12 hours (the middle-dose group); hydrocodone bitartrate-acetaminophen (5 mg of hydrocodone bitartrate and 325 mg of acetaminophen every 6 hours); or oral placebo every 6 hours.",
          "begin_section": "abstract",
          "offset_in_begin_section": 147,
          "end_section": "abstract",
          "offset_in_end_section": 959
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37530822",
          "text": "The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied. METHODS\nAfter establishing the selectivity of VX-548 for NaV1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 147,
          "end_section": "abstract",
          "offset_in_end_section": 454
        }
      ],
      "ideal_answer": "VX-548 targets the NaV1.8 voltage-gated sodium channel, which is expressed in peripheral nociceptive neurons and plays a role in transmitting nociceptive signals.",
      "exact_answer": [
        [
          "NaV1.8"
        ]
      ]
    },
    {
      "id": "66099926fdcbea915f000016",
      "type": "factoid",
      "body": "What is the most effective drug for oxaliplatin-induced neuropathy?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/30295925",
        "https://pubmed.ncbi.nlm.nih.gov/25430564",
        "https://pubmed.ncbi.nlm.nih.gov/31377017",
        "https://pubmed.ncbi.nlm.nih.gov/32490289",
        "https://pubmed.ncbi.nlm.nih.gov/35240525",
        "https://pubmed.ncbi.nlm.nih.gov/32347537",
        "https://pubmed.ncbi.nlm.nih.gov/33573316",
        "https://pubmed.ncbi.nlm.nih.gov/22203844",
        "https://pubmed.ncbi.nlm.nih.gov/17405895",
        "https://pubmed.ncbi.nlm.nih.gov/28186109"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31377017",
          "text": "The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models. Donepezil effectively attenuated oxaliplatin- and cisplatin-induced inhibition of neurite outgrowth in cultured PC12 cells.",
          "begin_section": "abstract",
          "offset_in_begin_section": 50,
          "end_section": "abstract",
          "offset_in_end_section": 350
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31377017",
          "text": "The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models.",
          "begin_section": "abstract",
          "offset_in_begin_section": 50,
          "end_section": "abstract",
          "offset_in_end_section": 226
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25430564",
          "text": "Oxaliplatin is a key drug commonly used in colorectal cancer treatment. Despite high clinical efficacy, its therapeutic application is limited by common, dose-limiting occurrence of neuropathy. As usual symptomatic neuropathy treatments fail to improve the patients' condition, there is an urgent need to advance our understanding of the pathogenesis of neuropathy to propose effective therapy and ensure adequate pain management.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 430
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30295925",
          "text": "Oxaliplatin is widely used as a key drug in the treatment of colorectal cancer. However, its administration is associated with the dose-limiting adverse effect, peripheral neuropathy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 183
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17405895",
          "text": "Oxaliplatin is effective in the treatment of metastatic colorectal cancer (MCRC) patients; however, severe neurotoxicity develops frequently.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 141
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31377017",
          "text": "The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models. Donepezil effectively attenuated oxaliplatin- and cisplatin-induced inhibition of neurite outgrowth in cultured PC12 cells. In a rat model, repeated oral administration of donepezil (5 times/week for 4 weeks) ameliorated oxaliplatin-induced mechanical allodynia (von Frey test) and sciatic nerve axonal degeneration.",
          "begin_section": "abstract",
          "offset_in_begin_section": 50,
          "end_section": "abstract",
          "offset_in_end_section": 543
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33573316",
          "text": "The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 265,
          "end_section": "abstract",
          "offset_in_end_section": 563
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33573316",
          "text": "So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 175,
          "end_section": "abstract",
          "offset_in_end_section": 563
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30295925",
          "text": "However, its administration is associated with the dose-limiting adverse effect, peripheral neuropathy. Platinum accumulation in the dorsal root ganglion (DRG) is the major mechanism responsible for oxaliplatin-induced neuropathy. Some drug transporters have been identified as platinum complex transporters in kidney or tumor cells, but not yet in DRG.",
          "begin_section": "abstract",
          "offset_in_begin_section": 80,
          "end_section": "abstract",
          "offset_in_end_section": 433
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33573316",
          "text": "The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy. In this review, we summarize the basic and clinical evidence for the therapeutic effects of oxaliplatin.",
          "begin_section": "abstract",
          "offset_in_begin_section": 265,
          "end_section": "abstract",
          "offset_in_end_section": 668
        }
      ],
      "ideal_answer": "The most effective drug for oxaliplatin-induced neuropathy is currently not established. However, several drugs have shown potential in alleviating neuropathic symptoms. These include duloxetine, pregabalin, gabapentin, and amifostine. Further research is needed to determine the optimal treatment approach for oxaliplatin-induced neuropathy.",
      "exact_answer": [
        [
          "Donepezil"
        ]
      ]
    },
    {
      "id": "65f37bb1c4010b4d7800000d",
      "type": "factoid",
      "body": "What is Microcoring used for",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/37218872",
        "https://pubmed.ncbi.nlm.nih.gov/34729291",
        "https://pubmed.ncbi.nlm.nih.gov/22718524",
        "https://pubmed.ncbi.nlm.nih.gov/34676718",
        "https://pubmed.ncbi.nlm.nih.gov/34676739",
        "https://pubmed.ncbi.nlm.nih.gov/29467775",
        "https://pubmed.ncbi.nlm.nih.gov/32922430",
        "https://pubmed.ncbi.nlm.nih.gov/29300821",
        "https://pubmed.ncbi.nlm.nih.gov/27252721"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34729291",
          "text": "Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 130,
          "end_section": "abstract",
          "offset_in_end_section": 528
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34729291",
          "text": "Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar.",
          "begin_section": "abstract",
          "offset_in_begin_section": 130,
          "end_section": "abstract",
          "offset_in_end_section": 242
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37218872",
          "text": "OBJECTIVES\nMicrocoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns. METHODS\nThree patients underwent a single treatment of rotational fractional resection.",
          "begin_section": "abstract",
          "offset_in_begin_section": 311,
          "end_section": "abstract",
          "offset_in_end_section": 552
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34729291",
          "text": "BACKGROUND\nWe introduce an innovative and novel technology that achieves scarless skin removal without the use of thermal energy. Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 528
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34729291",
          "text": "Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy. METHODS\nThree prospective clinical safety trials analyzing MCT treatment on abdominal and facial skin (short- and long-term) are described.",
          "begin_section": "abstract",
          "offset_in_begin_section": 130,
          "end_section": "abstract",
          "offset_in_end_section": 670
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37218872",
          "text": "OBJECTIVES\nMicrocoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns. METHODS\nThree patients underwent a single treatment of rotational fractional resection. The 0.5 mm diameter rotating scalpels were used to resect the skin pores in the cheek region.",
          "begin_section": "abstract",
          "offset_in_begin_section": 311,
          "end_section": "abstract",
          "offset_in_end_section": 646
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37218872",
          "text": "OBJECTIVES\nMicrocoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns.",
          "begin_section": "abstract",
          "offset_in_begin_section": 311,
          "end_section": "abstract",
          "offset_in_end_section": 462
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34729291",
          "text": "BACKGROUND\nWe introduce an innovative and novel technology that achieves scarless skin removal without the use of thermal energy. Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 242
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37218872",
          "text": "Despite these efforts, enlarged pores remain problematic for many patients. OBJECTIVES\nMicrocoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns. METHODS\nThree patients underwent a single treatment of rotational fractional resection.",
          "begin_section": "abstract",
          "offset_in_begin_section": 233,
          "end_section": "abstract",
          "offset_in_end_section": 552
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37218872",
          "text": "Despite these efforts, enlarged pores remain problematic for many patients. OBJECTIVES\nMicrocoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns.",
          "begin_section": "abstract",
          "offset_in_begin_section": 233,
          "end_section": "abstract",
          "offset_in_end_section": 462
        }
      ],
      "ideal_answer": "Microcoring technology (MCT) is used for the safe and scarless removal of skin. It is particularly beneficial for treating pores and can be used as a primary treatment option for addressing concerns related to enlarged pores.",
      "exact_answer": [
        [
          "Microcoring technology is used to safely remove skin without leaving a scar. It can be used to treat pores and is considered a primary treatment option for addressing concerns related to enlarged pores."
        ]
      ]
    },
    {
      "id": "660bbc09fdcbea915f00002a",
      "type": "list",
      "body": "What symptoms can be expected in women suffering from endometriosis?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/34574840",
        "https://pubmed.ncbi.nlm.nih.gov/25935474",
        "https://pubmed.ncbi.nlm.nih.gov/22210725",
        "https://pubmed.ncbi.nlm.nih.gov/36998108",
        "https://pubmed.ncbi.nlm.nih.gov/1873245",
        "https://pubmed.ncbi.nlm.nih.gov/32600946",
        "https://pubmed.ncbi.nlm.nih.gov/24881144",
        "https://pubmed.ncbi.nlm.nih.gov/33854478",
        "https://pubmed.ncbi.nlm.nih.gov/19694698",
        "https://pubmed.ncbi.nlm.nih.gov/17976623"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/1873245",
          "text": "Dysmenorrhoea is the most common reported symptom in endometriosis sufferers. Diagnostic laparoscopy should be considered before institution of treatment in women complaining of pelvic pain and menstrual symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1354,
          "end_section": "abstract",
          "offset_in_end_section": 1567
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/1873245",
          "text": "CONCLUSIONS\nMenstrual symptoms, while raising a high index of suspicion for endometriosis, are not entirely reliable as indicators of disease. Dysmenorrhoea is the most common reported symptom in endometriosis sufferers. Diagnostic laparoscopy should be considered before institution of treatment in women complaining of pelvic pain and menstrual symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1211,
          "end_section": "abstract",
          "offset_in_end_section": 1567
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34574840",
          "text": "The symptoms of endometriosis most often indicated by the general population were infertility and dysmenorrhea. In contrast, those least frequently indicated were painful defecation and dysuria. Respondents suffering from endometriosis indicated that they often or sometimes experienced dysmenorrhea (83%, n = 273), pelvic pain not related to menstruation (72%, n = 235), dyspareunia (68%, n = 223) and painful defecation or dysuria (40%, n = 132).",
          "begin_section": "abstract",
          "offset_in_begin_section": 760,
          "end_section": "abstract",
          "offset_in_end_section": 1208
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24881144",
          "text": "CONCLUSIONS\nDyschezia, chronic abdominal pain and functional bowel symptoms are more common among patients suffering from endometriosis than in the general population. Surgery may relieve these symptoms.",
          "begin_section": "abstract",
          "offset_in_begin_section": 595,
          "end_section": "abstract",
          "offset_in_end_section": 798
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33854478",
          "text": "In women suffering with endometriosis-associated symptoms, the cumulative endometriosis-associated symptom scores demonstrated a modest positive correlation with RLS severity scores (r=0.42 95% CI 0.25 to 0.57).",
          "begin_section": "abstract",
          "offset_in_begin_section": 1541,
          "end_section": "abstract",
          "offset_in_end_section": 1752
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24881144",
          "text": "CONCLUSIONS\nDyschezia, chronic abdominal pain and functional bowel symptoms are more common among patients suffering from endometriosis than in the general population.",
          "begin_section": "abstract",
          "offset_in_begin_section": 595,
          "end_section": "abstract",
          "offset_in_end_section": 762
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/1873245",
          "text": "Dysmenorrhoea is the most common reported symptom in endometriosis sufferers.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1354,
          "end_section": "abstract",
          "offset_in_end_section": 1431
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/1873245",
          "text": "CONCLUSIONS\nMenstrual symptoms, while raising a high index of suspicion for endometriosis, are not entirely reliable as indicators of disease. Dysmenorrhoea is the most common reported symptom in endometriosis sufferers.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1211,
          "end_section": "abstract",
          "offset_in_end_section": 1431
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33854478",
          "text": "Results\nWomen who reported a prior surgical diagnosis of endometriosis had a greater risk of having a prior formal diagnosis of RLS (OR 4.82, 95% CI 1.66,14.02) and suffering RLS symptoms (OR 2.13, 95% CI 1.34-3.39) compared with those without a diagnosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1026,
          "end_section": "abstract",
          "offset_in_end_section": 1282
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36998108",
          "text": "Resilience, anxiety, depression, and life satisfaction in women suffering from endometriosis: a mediation model.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 112
        }
      ],
      "ideal_answer": "Women suffering from endometriosis can experience a range of symptoms, including dysmenorrhoea (painful menstrual periods), pelvic pain not related to menstruation, dyspareunia (painful intercourse), painful defecation or dysuria (painful urination), chronic abdominal pain, dyschezia (painful bowel movements), and infertility. However, it is important to note that menstrual symptoms alone are not entirely reliable as indicators of endometriosis. Diagnostic laparoscopy should be considered before initiating treatment in women with pelvic pain and menstrual symptoms.",
      "exact_answer": [
        [
          "Dysmenorrhoea"
        ],
        [
          "Pelvic pain not related to menstruation"
        ],
        [
          "Dyspareunia"
        ],
        [
          "Painful defecation or dysuria"
        ],
        [
          "Dyschezia"
        ]
      ]
    },
    {
      "id": "65cf6c301930410b13000008",
      "type": "summary",
      "body": "What is the mechanism of action of Mirvetuximab Soravtansine?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/36656533",
        "https://pubmed.ncbi.nlm.nih.gov/37594572",
        "https://pubmed.ncbi.nlm.nih.gov/37528890",
        "https://pubmed.ncbi.nlm.nih.gov/37458180",
        "https://pubmed.ncbi.nlm.nih.gov/29098867",
        "https://pubmed.ncbi.nlm.nih.gov/32674207",
        "https://pubmed.ncbi.nlm.nih.gov/37212825",
        "https://pubmed.ncbi.nlm.nih.gov/37872122",
        "https://pubmed.ncbi.nlm.nih.gov/30413525",
        "https://pubmed.ncbi.nlm.nih.gov/29424243"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29098867",
          "text": "Mirvetuximab soravtansine is a novel antibody-drug conjugate that targets folate receptor-α, a validated molecular target for therapeutic intervention in this disease. Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date.",
          "begin_section": "abstract",
          "offset_in_begin_section": 172,
          "end_section": "abstract",
          "offset_in_end_section": 484
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29098867",
          "text": "Mirvetuximab soravtansine is a novel antibody-drug conjugate that targets folate receptor-α, a validated molecular target for therapeutic intervention in this disease. Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date. We focus on the favorable tolerability and encouraging signals of efficacy that have emerged, most notably in patients with platinum-resistant disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 172,
          "end_section": "abstract",
          "offset_in_end_section": 636
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29098867",
          "text": "Resistance to platinum-based therapy poses a significant clinical challenge for the management of advanced ovarian cancer, a leading cause of cancer mortality among women. Mirvetuximab soravtansine is a novel antibody-drug conjugate that targets folate receptor-α, a validated molecular target for therapeutic intervention in this disease. Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 484
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29098867",
          "text": "Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date.",
          "begin_section": "abstract",
          "offset_in_begin_section": 340,
          "end_section": "abstract",
          "offset_in_end_section": 484
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29098867",
          "text": "Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date. We focus on the favorable tolerability and encouraging signals of efficacy that have emerged, most notably in patients with platinum-resistant disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 340,
          "end_section": "abstract",
          "offset_in_end_section": 636
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29098867",
          "text": "Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date. We focus on the favorable tolerability and encouraging signals of efficacy that have emerged, most notably in patients with platinum-resistant disease. Ongoing Phase III monotherapy and Phase Ib/II combination trials evaluating its activity in the setting of platinum resistance are emphasized, which will help define its role in the evolving landscape of ovarian cancer therapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 340,
          "end_section": "abstract",
          "offset_in_end_section": 864
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/29424243",
          "text": "Mirvetuximab soravtansine, an antibody-drug conjugate that binds with high affinity to folate receptor-α to provide tumor-directed delivery of the potent microtubule-disrupting agent DM4, has emerged as a promising investigational agent for the treatment of ovarian cancer, particularly in the setting of platinum-resistant disease.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 332
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30413525",
          "text": "This study investigated the underlying mechanisms of ocular toxicity and evaluated primary prophylactic use of corticosteroid eye drops in patients receiving mirvetuximab soravtansine. PATIENTS AND METHODS\nTarget expression in the human eye was determined by IHC.",
          "begin_section": "abstract",
          "offset_in_begin_section": 264,
          "end_section": "abstract",
          "offset_in_end_section": 529
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30413525",
          "text": "This study investigated the underlying mechanisms of ocular toxicity and evaluated primary prophylactic use of corticosteroid eye drops in patients receiving mirvetuximab soravtansine.",
          "begin_section": "abstract",
          "offset_in_begin_section": 264,
          "end_section": "abstract",
          "offset_in_end_section": 448
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37872122",
          "text": "METHODS\nMirvetuximab soravtansine was administered intravenously from 0.15 to 7 mg/kg to 543 patients with predominantly platinum-resistant ovarian cancer in 3 clinical studies, and the plasma drug concentrations were analysed using a nonlinear mixed-effects modelling approach.",
          "begin_section": "abstract",
          "offset_in_begin_section": 356,
          "end_section": "abstract",
          "offset_in_end_section": 634
        }
      ],
      "ideal_answer": "Mirvetuximab soravtansine is an antibody-drug conjugate that targets folate receptor-α, a validated molecular target for therapeutic intervention in ovarian cancer. It binds with high affinity to folate receptor-α and provides tumor-directed delivery of the potent microtubule-disrupting agent DM4.",
      "exact_answer": "n/a"
    },
    {
      "id": "65f778dbc4010b4d78000035",
      "type": "yesno",
      "body": "Is watch-and-wait policy after neoadjuvant therapy a cost-effective policy for locally advanced rectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/35151941",
        "https://pubmed.ncbi.nlm.nih.gov/31238630",
        "https://pubmed.ncbi.nlm.nih.gov/26607907",
        "https://pubmed.ncbi.nlm.nih.gov/37013413",
        "https://pubmed.ncbi.nlm.nih.gov/28891846",
        "https://pubmed.ncbi.nlm.nih.gov/36474844",
        "https://pubmed.ncbi.nlm.nih.gov/29968247",
        "https://pubmed.ncbi.nlm.nih.gov/32192303",
        "https://pubmed.ncbi.nlm.nih.gov/34441441",
        "https://pubmed.ncbi.nlm.nih.gov/26980259"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35151941",
          "text": "CONCLUSION\nThis study provides data of cost-effectiveness differences among Standard Surgery, Watch-and-Wait and Robotic Resection approaches in clinical complete response in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy, showing a benefit for Watch-and-Wait policy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1801,
          "end_section": "abstract",
          "offset_in_end_section": 2097
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32192303",
          "text": "Some studies have demonstrated promising results of watch and wait (W&W) approaches in carefully selected patients with locally advanced rectal cancer who get a clinical complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 237
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37013413",
          "text": "In the watch-and-wait approach, patients with locally advanced rectal cancer who achieve excellent clinical response after neoadjuvant treatment undergo active surveillance rather than rectal cancer surgery.",
          "begin_section": "abstract",
          "offset_in_begin_section": 508,
          "end_section": "abstract",
          "offset_in_end_section": 715
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34441441",
          "text": "Data came from 39 out of 670 patients treated for locally advanced rectal cancer between January 2016 until February 2020. The selection criteria were a clinical complete response after neoadjuvant chemotherapy managed with a watch and wait (w&w) strategy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 436,
          "end_section": "abstract",
          "offset_in_end_section": 692
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36474844",
          "text": "Overall (all cause) mortality was 18% during follow-up period in the watch and wait group. Conclusions\nNeoadjuvant long course chemoradiotherapy is the standard treatment for locally advanced rectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1112,
          "end_section": "abstract",
          "offset_in_end_section": 1320
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37013413",
          "text": "The watch-and-wait approach is a noninvasive therapeutic alternative for organ preservation and avoiding operative morbidity. In the watch-and-wait approach, patients with locally advanced rectal cancer who achieve excellent clinical response after neoadjuvant treatment undergo active surveillance rather than rectal cancer surgery.",
          "begin_section": "abstract",
          "offset_in_begin_section": 382,
          "end_section": "abstract",
          "offset_in_end_section": 715
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32192303",
          "text": "[Guiding significance of pathological diagnosis in watch and wait strategy for locally advanced rectal cancer patients after neoadjuvant therapy].",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 146
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28891846",
          "text": "BACKGROUND\nFifteen to twenty percent of patients with locally advanced rectal cancer have a clinical complete response after chemoradiation therapy. These patients can be offered nonoperative organ-preserving treatment, the so-called watch-and-wait policy. The main goal of this watch-and-wait policy is an anticipated improved quality of life and functional outcome in comparison with a total mesorectal excision, while maintaining a good oncological outcome.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 460
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28891846",
          "text": "BACKGROUND\nFifteen to twenty percent of patients with locally advanced rectal cancer have a clinical complete response after chemoradiation therapy. These patients can be offered nonoperative organ-preserving treatment, the so-called watch-and-wait policy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 256
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35151941",
          "text": "WW is only more effective than SR 55% of the time which implies a significant uncertainty due to the high utility value assigned to cCR after chemoradiotherapy in the RRR alternative. CONCLUSION\nThis study provides data of cost-effectiveness differences among Standard Surgery, Watch-and-Wait and Robotic Resection approaches in clinical complete response in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy, showing a benefit for Watch-and-Wait policy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1615,
          "end_section": "abstract",
          "offset_in_end_section": 2097
        }
      ],
      "ideal_answer": "Based on the data provided, the watch and wait policy after neoadjuvant therapy appears to be a cost-effective policy for locally advanced rectal cancer patients. This approach allows for organ preservation and avoids operative morbidity, which can lead to an improved quality of life and functional outcome. Additionally, the watch and wait policy is associated with a lower overall mortality rate compared to standard surgery. However, further research and cost-effectiveness analyses are needed to fully evaluate the long-term benefits and cost-effectiveness of this approach.",
      "exact_answer": "yes"
    },
    {
      "id": "66088ddbfdcbea915f00000d",
      "type": "yesno",
      "body": "Are senolytics used to treat cardiovascular disease?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/32979174",
        "https://pubmed.ncbi.nlm.nih.gov/37747577",
        "https://pubmed.ncbi.nlm.nih.gov/34237321",
        "https://pubmed.ncbi.nlm.nih.gov/34699859",
        "https://pubmed.ncbi.nlm.nih.gov/37880106",
        "https://pubmed.ncbi.nlm.nih.gov/34812757",
        "https://pubmed.ncbi.nlm.nih.gov/34687726",
        "https://pubmed.ncbi.nlm.nih.gov/34697668",
        "https://pubmed.ncbi.nlm.nih.gov/37837625",
        "https://pubmed.ncbi.nlm.nih.gov/34656616"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37747577",
          "text": "In recent years, the use and study of senolytics increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment. This mini-review discusses the changes in the aging heart and the participation of senescent cells in CVD, as well as the use of senolytics to prevent the progression of myocardial damage, mainly the effect of dasatinib and quercetin.",
          "begin_section": "abstract",
          "offset_in_begin_section": 303,
          "end_section": "abstract",
          "offset_in_end_section": 714
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37747577",
          "text": "Several compounds called senolytics have been designed to eliminate these cells within the tissues. In recent years, the use and study of senolytics increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment. This mini-review discusses the changes in the aging heart and the participation of senescent cells in CVD, as well as the use of senolytics to prevent the progression of myocardial damage, mainly the effect of dasatinib and quercetin.",
          "begin_section": "abstract",
          "offset_in_begin_section": 203,
          "end_section": "abstract",
          "offset_in_end_section": 714
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34237321",
          "text": "Based on these data we suggest novel indications for senolytics as a treatment of cardiovascular diseases which have yet to be studied in the context of senotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 970,
          "end_section": "abstract",
          "offset_in_end_section": 1135
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37747577",
          "text": "In recent years, the use and study of senolytics increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 303,
          "end_section": "abstract",
          "offset_in_end_section": 479
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37747577",
          "text": "Several compounds called senolytics have been designed to eliminate these cells within the tissues. In recent years, the use and study of senolytics increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 203,
          "end_section": "abstract",
          "offset_in_end_section": 479
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34237321",
          "text": "Based on these data we suggest novel indications for senolytics as a treatment of cardiovascular diseases which have yet to be studied in the context of senotherapy. Finally, while the potential benefits are encouraging, several complications may result from senolytic treatment. We, therefore, consider these challenges in the context of the cardiovascular system.",
          "begin_section": "abstract",
          "offset_in_begin_section": 970,
          "end_section": "abstract",
          "offset_in_end_section": 1335
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/32979174",
          "text": "Therapeutic Potential of Senolytics in Cardiovascular Disease.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 62
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37747577",
          "text": "In recent years, the use and study of senolytics increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment. This mini-review discusses the changes in the aging heart and the participation of senescent cells in CVD, as well as the use of senolytics to prevent the progression of myocardial damage, mainly the effect of dasatinib and quercetin. In particular, the mechanisms and physiological effects of senolytics therapies in the aged heart are discussed.",
          "begin_section": "abstract",
          "offset_in_begin_section": 303,
          "end_section": "abstract",
          "offset_in_end_section": 827
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34237321",
          "text": "Based on these data we suggest novel indications for senolytics as a treatment of cardiovascular diseases which have yet to be studied in the context of senotherapy. Finally, while the potential benefits are encouraging, several complications may result from senolytic treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 970,
          "end_section": "abstract",
          "offset_in_end_section": 1249
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37747577",
          "text": "Accumulation of senescent cells in the heart contributes to various age-related pathologies. Several compounds called senolytics have been designed to eliminate these cells within the tissues. In recent years, the use and study of senolytics increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment.",
          "begin_section": "abstract",
          "offset_in_begin_section": 110,
          "end_section": "abstract",
          "offset_in_end_section": 479
        }
      ],
      "ideal_answer": "Yes, senolytics are used to treat cardiovascular disease. Senolytics are compounds designed to eliminate senescent cells within the tissues. Senescent cells accumulate in the heart and contribute to various age-related pathologies, including cardiovascular disease. The use of senolytics, such as dasatinib and quercetin, has shown promise in preventing the progression of myocardial damage in cardiovascular disease. However, it is important to consider potential complications that may arise from senolytic treatment.",
      "exact_answer": "yes"
    },
    {
      "id": "660c0486fdcbea915f00002d",
      "type": "factoid",
      "body": "What is the cause of Brazilian spotted fever?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/11980610",
        "https://pubmed.ncbi.nlm.nih.gov/31742533",
        "https://pubmed.ncbi.nlm.nih.gov/25830998",
        "https://pubmed.ncbi.nlm.nih.gov/22031201",
        "https://pubmed.ncbi.nlm.nih.gov/28359827",
        "https://pubmed.ncbi.nlm.nih.gov/23509125",
        "https://pubmed.ncbi.nlm.nih.gov/30976518",
        "https://pubmed.ncbi.nlm.nih.gov/8357085",
        "https://pubmed.ncbi.nlm.nih.gov/17114717",
        "https://pubmed.ncbi.nlm.nih.gov/23168050"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25830998",
          "text": "Brazilian spotted fever is an acute febrile infectious disease caused by Rickettsia rickettsii, transmitted by tick bite. As this disease is rare and has high mortality rates in Brazil, the clinical aspects and epidemiological data may help the diagnosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 255
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25830998",
          "text": "Brazilian spotted fever is an acute febrile infectious disease caused by Rickettsia rickettsii, transmitted by tick bite. As this disease is rare and has high mortality rates in Brazil, the clinical aspects and epidemiological data may help the diagnosis. We report a case of Brazilian spotted fever in a 19-year-old patient who presented maculopapular exanthema in the palmar region and upper limbs, lymphadenopathy, fever, chills, headache, conjunctival hyperemia, nausea, vomiting, dyspnea, myalgia, developing neurological signs and abdominal pain.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 552
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/11980610",
          "text": "Brazilian spotted fever, caused by Rickettsia rickettsii, has been increasingly reported in Brazil especially in the southeastern states. The severe and fulminant forms of the disease are not unusual but most of the reported fatal cases have shown some typical clinical clue, which leads the attending physician to a correct diagnosis. We report a probable case of atypical fulminant Brazilian spotted fever that presented full-blown septic shock associated with Adult Respiratory Distress Syndrome (ARDS) and delayed uncharacteristic rash with an over four-fold increase in reciprocal IgM, but not IgG titer against Rickettsia rickettsii.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 639
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/11980610",
          "text": "Brazilian spotted fever, caused by Rickettsia rickettsii, has been increasingly reported in Brazil especially in the southeastern states. The severe and fulminant forms of the disease are not unusual but most of the reported fatal cases have shown some typical clinical clue, which leads the attending physician to a correct diagnosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 335
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/11980610",
          "text": "Brazilian spotted fever, caused by Rickettsia rickettsii, has been increasingly reported in Brazil especially in the southeastern states.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 137
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/25830998",
          "text": "Brazilian spotted fever is an acute febrile infectious disease caused by Rickettsia rickettsii, transmitted by tick bite.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 121
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31742533",
          "text": "In São Paulo metropolitan area, Brazil, Amblyomma aureolatum ticks are the main vector of Rickettsia rickettsii, which causes Brazilian spotted fever. In 2013, a boy in São Paulo died of Brazilian spotted fever associated with household dogs and A. aureolatum ticks.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 266
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31742533",
          "text": "In São Paulo metropolitan area, Brazil, Amblyomma aureolatum ticks are the main vector of Rickettsia rickettsii, which causes Brazilian spotted fever. In 2013, a boy in São Paulo died of Brazilian spotted fever associated with household dogs and A. aureolatum ticks. Prompt recognition and treatment of this illness might prevent deaths.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 337
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28359827",
          "text": "Spotted fever is an acute febrile illness, which is considered severely underreported and misdiagnosed in the Brazilian Pampa, caused by tick-borne Rickettsiae. Here, we report an eco-epidemiological investigation of Rickettsia spp. in ticks from a spotted fever focus in Toropi, southern Brazil.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 296
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/28359827",
          "text": "Spotted fever is an acute febrile illness, which is considered severely underreported and misdiagnosed in the Brazilian Pampa, caused by tick-borne Rickettsiae. Here, we report an eco-epidemiological investigation of Rickettsia spp.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 232
        }
      ],
      "ideal_answer": "Brazilian spotted fever is caused by Rickettsia rickettsii, a bacterium transmitted by tick bites.",
      "exact_answer": [
        [
          "Brazilian spotted fever is caused by Rickettsia rickettsii."
        ]
      ]
    },
    {
      "id": "65cfcf201930410b1300001b",
      "type": "yesno",
      "body": "Can Nitrofurantoin cause Lung Injury?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/31890712",
        "https://pubmed.ncbi.nlm.nih.gov/24772739",
        "https://pubmed.ncbi.nlm.nih.gov/6838054",
        "https://pubmed.ncbi.nlm.nih.gov/33088545",
        "https://pubmed.ncbi.nlm.nih.gov/37809109",
        "https://pubmed.ncbi.nlm.nih.gov/17655981",
        "https://pubmed.ncbi.nlm.nih.gov/33853812",
        "https://pubmed.ncbi.nlm.nih.gov/32238797",
        "https://pubmed.ncbi.nlm.nih.gov/10334121",
        "https://pubmed.ncbi.nlm.nih.gov/16212142"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37809109",
          "text": "Although relatively rare, nitrofurantoin can cause a spectrum of lung injuries, from acute hypersensitivity reactions that might be fatal to chronic reactions involving fibrosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 112,
          "end_section": "abstract",
          "offset_in_end_section": 290
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37809109",
          "text": "Although relatively rare, nitrofurantoin can cause a spectrum of lung injuries, from acute hypersensitivity reactions that might be fatal to chronic reactions involving fibrosis. Therefore, treating physicians' awareness and regular monitoring is essential for early recognition, drug withdrawal, avoiding unnecessary treatment, and preventing irreversible fibrosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 112,
          "end_section": "abstract",
          "offset_in_end_section": 478
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/31890712",
          "text": "Consider Nitrofurantoin as a Cause of Lung Injury.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 50
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33088545",
          "text": "Acute lung injury resulting from nitrofurantoin is a rare, life-threatening complication with women being at greater risk. Symptoms include respiratory distress with fevers, rash, eosinophilia, and new-onset atrial fibrillation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 67,
          "end_section": "abstract",
          "offset_in_end_section": 295
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33088545",
          "text": "Acute lung injury resulting from nitrofurantoin is a rare, life-threatening complication with women being at greater risk. Symptoms include respiratory distress with fevers, rash, eosinophilia, and new-onset atrial fibrillation. Treatment includes discontinuing the drug and possibly glucocorticoids for persistent oxygen demand.",
          "begin_section": "abstract",
          "offset_in_begin_section": 67,
          "end_section": "abstract",
          "offset_in_end_section": 396
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/24772739",
          "text": "It acts by damaging bacterial DNA. It is given in dose of 50-100 mg orally and is generally considered a safe drug but has occasionally been known to cause pulmonary toxicity which is usually reversible and only rarely fatal. We present a case of an elderly lady receiving nitrofurantoin for her urinary tract infection who developed sudden acute lung injury to which she finally succumbed within a few weeks.",
          "begin_section": "abstract",
          "offset_in_begin_section": 69,
          "end_section": "abstract",
          "offset_in_end_section": 478
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/6838054",
          "text": "These data suggest that nitrofurantoin can directly injure lung parenchymal cells, probably through oxidant mechanisms, and this might suggest alternative approaches in the evaluation and therapy of patients with this disorder.",
          "begin_section": "abstract",
          "offset_in_begin_section": 814,
          "end_section": "abstract",
          "offset_in_end_section": 1041
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33088545",
          "text": "Acute lung injury resulting from nitrofurantoin is a rare, life-threatening complication with women being at greater risk.",
          "begin_section": "abstract",
          "offset_in_begin_section": 67,
          "end_section": "abstract",
          "offset_in_end_section": 189
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/6838054",
          "text": "Additionally, the nitrofurantoin-induced injury could be accelerated in the presence of hyperoxia (95% O2) from 45 +/- 2 to 62 +/- 1, p less than 0.01. These data suggest that nitrofurantoin can directly injure lung parenchymal cells, probably through oxidant mechanisms, and this might suggest alternative approaches in the evaluation and therapy of patients with this disorder.",
          "begin_section": "abstract",
          "offset_in_begin_section": 662,
          "end_section": "abstract",
          "offset_in_end_section": 1041
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33088545",
          "text": "A rare case of nitrofurantoin-induced acute lung injury.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 56
        }
      ],
      "ideal_answer": "Yes, nitrofurantoin can cause lung injury. It can lead to a spectrum of lung injuries, ranging from acute hypersensitivity reactions that can be fatal to chronic reactions involving fibrosis. Symptoms of acute lung injury resulting from nitrofurantoin include respiratory distress, fevers, rash, eosinophilia, and new-onset atrial fibrillation. Treatment involves discontinuing the drug and possibly using glucocorticoids for persistent oxygen demand. Regular monitoring and early recognition of lung injury are crucial to prevent irreversible fibrosis and ensure timely withdrawal of the drug.",
      "exact_answer": "yes"
    },
    {
      "id": "66099a25fdcbea915f00001e",
      "type": "factoid",
      "body": "What is the first-line treatment for BRAF mutated advanced colorectal cancer patients?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/35649231",
        "https://pubmed.ncbi.nlm.nih.gov/36849918",
        "https://pubmed.ncbi.nlm.nih.gov/37990891",
        "https://pubmed.ncbi.nlm.nih.gov/35277355",
        "https://pubmed.ncbi.nlm.nih.gov/33108877",
        "https://pubmed.ncbi.nlm.nih.gov/28214977",
        "https://pubmed.ncbi.nlm.nih.gov/33330032",
        "https://pubmed.ncbi.nlm.nih.gov/34186441",
        "https://pubmed.ncbi.nlm.nih.gov/33777142",
        "https://pubmed.ncbi.nlm.nih.gov/31661924"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35649231",
          "text": "On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAF-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab. Treatment regimens currently under exploration in BRAF-mutant metastatic colorectal cancer include combinatorial options of various pathway-targeted therapies, cytotoxic chemotherapy, and/or immune checkpoint blockade, among others. Circumvention of adaptive and acquired resistance to BRAF-targeted therapies is a significant challenge to be overcome in BRAF-mutated advanced colorectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 499,
          "end_section": "abstract",
          "offset_in_end_section": 1208
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35649231",
          "text": "On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAF-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab. Treatment regimens currently under exploration in BRAF-mutant metastatic colorectal cancer include combinatorial options of various pathway-targeted therapies, cytotoxic chemotherapy, and/or immune checkpoint blockade, among others.",
          "begin_section": "abstract",
          "offset_in_begin_section": 499,
          "end_section": "abstract",
          "offset_in_end_section": 1045
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35649231",
          "text": "On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAF-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab.",
          "begin_section": "abstract",
          "offset_in_begin_section": 499,
          "end_section": "abstract",
          "offset_in_end_section": 812
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36849918",
          "text": "Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 145
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35277355",
          "text": "Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 90
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33108877",
          "text": "BRAF mutated colorectal cancer define specific challenging subgroup associated with dismal prognosis, lower rate of response rate, shorter progression free survival and overall survival. Current treatment choices are associated with poor outcomes. For the first line treatment doublet or triplet chemotherapy plus antiangiogenic antibody is used.",
          "begin_section": "abstract",
          "offset_in_begin_section": 216,
          "end_section": "abstract",
          "offset_in_end_section": 562
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35649231",
          "text": "Treatment regimens currently under exploration in BRAF-mutant metastatic colorectal cancer include combinatorial options of various pathway-targeted therapies, cytotoxic chemotherapy, and/or immune checkpoint blockade, among others. Circumvention of adaptive and acquired resistance to BRAF-targeted therapies is a significant challenge to be overcome in BRAF-mutated advanced colorectal cancer.",
          "begin_section": "abstract",
          "offset_in_begin_section": 813,
          "end_section": "abstract",
          "offset_in_end_section": 1208
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35277355",
          "text": "This article primarily explores 3 aspects of the treatment strategies for advanced BRAF-mutated colorectal cancer; chemotherapy, targeted therapy, and immunotherapy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1051,
          "end_section": "abstract",
          "offset_in_end_section": 1216
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37990891",
          "text": "BRAF-mutated advanced colorectal cancer is a demanding entity that does not respond to standard chemotherapy regimens (FOLFOX, capecitabine) and the presence of the mutation significantly weakens the prognosis, but the rise of immunotherapy could reverse the trend.",
          "begin_section": "abstract",
          "offset_in_begin_section": 170,
          "end_section": "abstract",
          "offset_in_end_section": 435
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36849918",
          "text": "BACKGROUND\nPatients with V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E-mutated advanced colorectal cancer (CRC) have a poor prognosis, and treatment options that can improve outcome are still under investigation. The purpose of this study was to discuss the differences of overall survival (OS) and progression-free survival (PFS) between patients with BRAF V600E-mutated advanced CRC who were treated with chemotherapy alone and chemotherapy combined with targeted therapy in advanced first-line therapy. METHODS\nGrouping of 61 patients according to first-line treatment regimen (chemotherapy alone/chemotherapy combined with bevacizumab).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 656
        }
      ],
      "ideal_answer": "The first-line treatment for BRAF-mutated advanced colorectal cancer patients typically involves a combination of cytotoxic chemotherapy and an antiangiogenic antibody, such as bevacizumab.",
      "exact_answer": [
        [
          "The first-line treatment for BRAF-mutated advanced colorectal cancer patients is cytotoxic chemotherapy plus bevacizumab."
        ]
      ]
    },
    {
      "id": "65f1d9f8c4010b4d78000006",
      "type": "list",
      "body": "List the causes of Restrictive cardiomyopathy (RCM)",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/33429969",
        "https://pubmed.ncbi.nlm.nih.gov/34062949",
        "https://pubmed.ncbi.nlm.nih.gov/27084524",
        "https://pubmed.ncbi.nlm.nih.gov/30260051",
        "https://pubmed.ncbi.nlm.nih.gov/34057638",
        "https://pubmed.ncbi.nlm.nih.gov/29212899",
        "https://pubmed.ncbi.nlm.nih.gov/36269634",
        "https://pubmed.ncbi.nlm.nih.gov/20617149",
        "https://pubmed.ncbi.nlm.nih.gov/28465964",
        "https://pubmed.ncbi.nlm.nih.gov/35345275"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20617149",
          "text": "Mutations in sarcomeric proteins have recently been established as heritable causes of Restrictive Cardiomyopathy (RCM). RCM is clinically characterized as a defect in cardiac diastolic function, such as, impaired ventricular relaxation, reduced diastolic volume and increased end-diastolic pressure.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 300
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/20617149",
          "text": "Mutations in sarcomeric proteins have recently been established as heritable causes of Restrictive Cardiomyopathy (RCM).",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 120
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35345275",
          "text": "Restrictive cardiomyopathy (RCM), a potentially devastating heart muscle disorder, is characterized by diastolic dysfunction due to abnormal muscle relaxation and myocardial stiffness resulting in restrictive filling of the ventricles. Diastolic dysfunction is often accompanied by left atrial or bi-atrial enlargement and normal ventricular size and systolic function.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 369
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30260051",
          "text": "Restrictive cardiomyopathy (RCM) is a rare and distinct form of cardiomyopathy characterized by normal ventricular chamber dimensions, normal myocardial wall thickness, and preserved systolic function. The abnormal myocardium, however, demonstrates impaired relaxation. To date, dominant variants causing RCM have been reported in a small number of sarcomeric or cytoskeletal genes, but the genetic causes in a majority of cases remain unexplained, especially in early childhood.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 479
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34057638",
          "text": "Restrictive cardiomyopathy (RCM) is a rare primary myocardial disease, and its pathological features are yet to be determined. Restrictive cardiomyopathy with MHY7 mutation was diagnosed in a 65-year-old Japanese woman. Electron microscopy of a myocardial biopsy revealed electron-dense materials resulting from focal myocyte degeneration and necrosis as well as tubular structures and pseudo-inclusion bodies in some nuclei.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 425
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34062949",
          "text": "Hypertrophic cardiomyopathy (HCM) and primary restrictive cardiomyopathy (RCM) have a similar genetic background as they are both caused mainly by variants in sarcomeric genes. These \"sarcomeric cardiomyopathies\" also share diastolic dysfunction as the prevalent pathophysiological mechanism.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 292
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/35345275",
          "text": "Restrictive cardiomyopathy (RCM), a potentially devastating heart muscle disorder, is characterized by diastolic dysfunction due to abnormal muscle relaxation and myocardial stiffness resulting in restrictive filling of the ventricles. Diastolic dysfunction is often accompanied by left atrial or bi-atrial enlargement and normal ventricular size and systolic function. RCM is the rarest form of cardiomyopathy, accounting for 2-5% of pediatric cardiomyopathy cases, however, survival rates have been reported to be 82%, 80%, and 68% at 1-, 2-, and 5-years after diagnosis, respectively.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 587
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34062949",
          "text": "Hypertrophic cardiomyopathy (HCM) and primary restrictive cardiomyopathy (RCM) have a similar genetic background as they are both caused mainly by variants in sarcomeric genes.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 176
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30260051",
          "text": "Restrictive cardiomyopathy (RCM) is a rare and distinct form of cardiomyopathy characterized by normal ventricular chamber dimensions, normal myocardial wall thickness, and preserved systolic function. The abnormal myocardium, however, demonstrates impaired relaxation.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 269
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/34062949",
          "text": "Hypertrophic cardiomyopathy (HCM) and primary restrictive cardiomyopathy (RCM) have a similar genetic background as they are both caused mainly by variants in sarcomeric genes. These \"sarcomeric cardiomyopathies\" also share diastolic dysfunction as the prevalent pathophysiological mechanism. Starting from the observation that patients with HCM and primary RCM may coexist in the same family, a characteristic pathophysiological profile of HCM with restrictive physiology has been recently described and supports the hypothesis that familiar forms of primary RCM may represent a part of the phenotypic spectrum of HCM rather than a different genetic cardiomyopathy.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 666
        }
      ],
      "ideal_answer": "The causes of Restrictive Cardiomyopathy (RCM) include mutations in sarcomeric proteins, genetic variants in sarcomeric or cytoskeletal genes, such as MYH7, and other genetic causes that are yet to be determined. Additionally, RCM can be secondary to infiltrative diseases (e.g., amyloidosis, sarcoidosis), endomyocardial diseases (e.g., endomyocardial fibrosis, Loeffler syndrome), storage diseases (e.g., Fabry disease, Gaucher disease), radiation therapy, and certain medications (e.g., anthracyclines).",
      "exact_answer": [
        [
          "Mutations in sarcomeric proteins"
        ],
        [
          "Unknown genetic causes"
        ],
        [
          "Infiltrative diseases (e.g., amyloidosis, sarcoidosis)"
        ],
        [
          "Storage diseases (e.g., Fabry disease, Gaucher disease)"
        ],
        [
          "Endomyocardial diseases (e.g., endomyocardial fibrosis, Loeffler syndrome)"
        ]
      ]
    },
    {
      "id": "660d17dffdcbea915f000037",
      "type": "summary",
      "body": "Trends of acute epiglottitis in children.",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/33429180",
        "https://pubmed.ncbi.nlm.nih.gov/17892608",
        "https://pubmed.ncbi.nlm.nih.gov/3486856",
        "https://pubmed.ncbi.nlm.nih.gov/3106912",
        "https://pubmed.ncbi.nlm.nih.gov/23162404",
        "https://pubmed.ncbi.nlm.nih.gov/1487663",
        "https://pubmed.ncbi.nlm.nih.gov/646919",
        "https://pubmed.ncbi.nlm.nih.gov/7010270",
        "https://pubmed.ncbi.nlm.nih.gov/7058354",
        "https://pubmed.ncbi.nlm.nih.gov/4063023"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23162404",
          "text": "Acute epiglottitis: Trends, diagnosis and management.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 53
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/1487663",
          "text": "The incidence of acute epiglottitis in children was calculated at 3.2/100,000 with a minor annual variation. As vaccination against Haemophilus influenzae type b becomes more common, the incidence will probably be markedly reduced, maybe even eradicated in children, but in adults the same reduction cannot be expected as the causative agent in this group is less frequently Haemophilus influenzae type b.",
          "begin_section": "abstract",
          "offset_in_begin_section": 657,
          "end_section": "abstract",
          "offset_in_end_section": 1062
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33429180",
          "text": "Acute epiglottitis: Analysis of U.S. mortality trends from 1979 to 2017.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 72
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17892608",
          "text": "The incidence of acute epiglottitis in adults was constant, with a mean value of 1.9 cases/100,000/year. Twenty-nine per cent of the patients required an artificial airway, and respiratory distress was found to be associated with airway intervention (p = 0.010). All patients recovered completely.",
          "begin_section": "abstract",
          "offset_in_begin_section": 683,
          "end_section": "abstract",
          "offset_in_end_section": 980
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/17892608",
          "text": "The incidence of acute epiglottitis in adults was constant, with a mean value of 1.9 cases/100,000/year. Twenty-nine per cent of the patients required an artificial airway, and respiratory distress was found to be associated with airway intervention (p = 0.010).",
          "begin_section": "abstract",
          "offset_in_begin_section": 683,
          "end_section": "abstract",
          "offset_in_end_section": 945
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33429180",
          "text": "Adults are now more likely than children to die of acute epiglottitis. Further research including multi-institutional cohort studies must be done to elucidate causative factors contributing to remaining cases of mortality.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1428,
          "end_section": "abstract",
          "offset_in_end_section": 1650
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/7058354",
          "text": "We describe a study of 26 children treated for acute epiglottitis from 1971 to 1979. Included in this series are 16 consecutive patients who were treated by nasotracheal intubation and simultaneous medical therapy. Fifteen of the 16 patients extubated safely in less than 48 hours, significantly decreasing the possibility for complications.",
          "begin_section": "abstract",
          "offset_in_begin_section": 188,
          "end_section": "abstract",
          "offset_in_end_section": 529
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/646919",
          "text": "Of 27 children treated for acute epiglottitis, 26 survived. Eighteen patients treated by nasotracheal intubation were devoid of sequelae, whereas of six patients in whom tracheotomy was performed, one developed an ugly scar and two had slight tracheal stenosis at the tracheostomy site.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 286
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/646919",
          "text": "Of 27 children treated for acute epiglottitis, 26 survived. Eighteen patients treated by nasotracheal intubation were devoid of sequelae, whereas of six patients in whom tracheotomy was performed, one developed an ugly scar and two had slight tracheal stenosis at the tracheostomy site. In 22 of the 27 children the diagnosis of the referring physician was wrong, causing serious delay in securing the airway.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 409
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/646919",
          "text": "In 22 of the 27 children the diagnosis of the referring physician was wrong, causing serious delay in securing the airway. We conclude that short-term nasotracheal intubation and antibiotic prophylaxis is the optimal treatment for acute epiglottitis in children.",
          "begin_section": "abstract",
          "offset_in_begin_section": 287,
          "end_section": "abstract",
          "offset_in_end_section": 549
        }
      ],
      "ideal_answer": "The incidence of acute epiglottitis in children is calculated at 3.2/100,000 with a minor annual variation. As vaccination against Haemophilus influenzae type b becomes more common, the incidence will probably be markedly reduced, maybe even eradicated in children.",
      "exact_answer": "n/a"
    },
    {
      "id": "65d12c451930410b13000032",
      "type": "yesno",
      "body": "Is Omaveloxolone effective for Friedreich Ataxia?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/30656180",
        "https://pubmed.ncbi.nlm.nih.gov/33430645",
        "https://pubmed.ncbi.nlm.nih.gov/37691319",
        "https://pubmed.ncbi.nlm.nih.gov/36708320",
        "https://pubmed.ncbi.nlm.nih.gov/33068037",
        "https://pubmed.ncbi.nlm.nih.gov/18852343",
        "https://pubmed.ncbi.nlm.nih.gov/7614092",
        "https://pubmed.ncbi.nlm.nih.gov/36444905",
        "https://pubmed.ncbi.nlm.nih.gov/37219716",
        "https://pubmed.ncbi.nlm.nih.gov/37155124"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37155124",
          "text": "Omaveloxolone (SKYCLARYS™) is an orally active, small molecule semi-synthetic triterpenoid drug that increases antioxidant activity, which is being developed by Reata Pharmaceuticals, Inc. for the treatment of Friedreich's ataxia. In patients with Friedreich's ataxia, the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway is suppressed, which is associated with oxidative stress, mitochondrial dysfunction and damage to cells, including central and peripheral neurones.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 479
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37691319",
          "text": "INTERPRETATION\nThese results suggest a meaningful slowing of Friedreich ataxia progression with omaveloxolone, and consequently detail how propensity-matched analysis may contribute to understanding of effects of therapeutic agents. This demonstrates the direct value of natural history studies in clinical trial evaluations.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1456,
          "end_section": "abstract",
          "offset_in_end_section": 1781
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37691319",
          "text": "INTERPRETATION\nThese results suggest a meaningful slowing of Friedreich ataxia progression with omaveloxolone, and consequently detail how propensity-matched analysis may contribute to understanding of effects of therapeutic agents.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1456,
          "end_section": "abstract",
          "offset_in_end_section": 1688
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/36444905",
          "text": "CONCLUSIONS\nThese results support the positive results of MOXIe part 2 and indicate a persistent benefit of omaveloxolone treatment on disease course in Friedreich's ataxia. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1514,
          "end_section": "abstract",
          "offset_in_end_section": 1829
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/30656180",
          "text": "Methods\nSixty-nine Friedreich ataxia patients were randomized 3:1 to either omaveloxolone or placebo administered once daily for 12 weeks. Patients were randomized in cohorts of eight patients, at dose levels of 2.5-300 mg/day.",
          "begin_section": "abstract",
          "offset_in_begin_section": 495,
          "end_section": "abstract",
          "offset_in_end_section": 722
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37691319",
          "text": "In the primary pooled population (136 patients in each group) by Year 3, patients in the FACOMS matched set progressed 6.6 points whereas patients treated with omaveloxolone in MOXIe extension progressed 3 points (difference = -3.6; nominal p value = 0.0001). INTERPRETATION\nThese results suggest a meaningful slowing of Friedreich ataxia progression with omaveloxolone, and consequently detail how propensity-matched analysis may contribute to understanding of effects of therapeutic agents. This demonstrates the direct value of natural history studies in clinical trial evaluations.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1194,
          "end_section": "abstract",
          "offset_in_end_section": 1781
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37691319",
          "text": "OBJECTIVE\nThe natural history of Friedreich ataxia is being investigated in a multi-center longitudinal study designated the Friedreich ataxia Clinical Outcome Measures Study (FACOMS). To understand the utility of this study in analysis of clinical trials, we performed a propensity-matched comparison of data from the open-label MOXIe extension (omaveloxolone) to that from FACOMS.",
          "begin_section": "abstract",
          "offset_in_begin_section": 0,
          "end_section": "abstract",
          "offset_in_end_section": 382
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/37691319",
          "text": "In the primary pooled population (136 patients in each group) by Year 3, patients in the FACOMS matched set progressed 6.6 points whereas patients treated with omaveloxolone in MOXIe extension progressed 3 points (difference = -3.6; nominal p value = 0.0001). INTERPRETATION\nThese results suggest a meaningful slowing of Friedreich ataxia progression with omaveloxolone, and consequently detail how propensity-matched analysis may contribute to understanding of effects of therapeutic agents.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1194,
          "end_section": "abstract",
          "offset_in_end_section": 1688
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33068037",
          "text": "Eligible patients, 16 to 40 years of age with genetically confirmed FA and baseline modified Friedreich's Ataxia Rating Scale (mFARS) scores between 20 and 80, were randomized 1:1 to placebo or 150mg per day of omaveloxolone.",
          "begin_section": "abstract",
          "offset_in_begin_section": 557,
          "end_section": "abstract",
          "offset_in_end_section": 782
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/33430645",
          "text": "It is associated with cardiomyopathy, the leading cause of death in Friedreich ataxia (FRDA), diabetes and scoliosis. There are no approved therapies, but elucidation of the pathophysiology of FRDA suggest that agents that increase the activity of the transcription factor Nrf2 may provide a mechanism for ameliorating disease progression or severity. In this work, we review the evidence for use of omaveloxolone in FRDA from recent clinical trials.",
          "begin_section": "abstract",
          "offset_in_begin_section": 165,
          "end_section": "abstract",
          "offset_in_end_section": 615
        }
      ],
      "ideal_answer": "Yes, omaveloxolone has shown meaningful slowing of Friedreich ataxia progression in clinical trials. It increases antioxidant activity and targets the suppressed Nrf2 pathway, which is associated with oxidative stress and mitochondrial dysfunction in Friedreich's ataxia. The results of the MOXIe part 2 trial and the FACOMS study demonstrate the persistent benefit of omaveloxolone treatment on the disease course of Friedreich's ataxia.",
      "exact_answer": "yes"
    },
    {
      "id": "6609997ffdcbea915f000019",
      "type": "list",
      "body": "What non-colonic tumors are associated with Lynch syndrome?",
      "documents": [
        "https://pubmed.ncbi.nlm.nih.gov/29884888",
        "https://pubmed.ncbi.nlm.nih.gov/7848695",
        "https://pubmed.ncbi.nlm.nih.gov/37143941",
        "https://pubmed.ncbi.nlm.nih.gov/21388660",
        "https://pubmed.ncbi.nlm.nih.gov/32350866",
        "https://pubmed.ncbi.nlm.nih.gov/19559756",
        "https://pubmed.ncbi.nlm.nih.gov/3366037",
        "https://pubmed.ncbi.nlm.nih.gov/23176623",
        "https://pubmed.ncbi.nlm.nih.gov/36591511",
        "https://pubmed.ncbi.nlm.nih.gov/23787146"
      ],
      "snippets": [
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/7848695",
          "text": "We reviewed then the clinical features, inclusion criteria, screening and the discussed treatment of the hereditary non-poliposis colorectal cancer or Lynch Syndrome, limited to the colon or associated to extracolonic carcinoma (Lynch I and II). A clear and detailed familial history is the only definite criteria for the diagnosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 400,
          "end_section": "abstract",
          "offset_in_end_section": 732
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/7848695",
          "text": "We reviewed then the clinical features, inclusion criteria, screening and the discussed treatment of the hereditary non-poliposis colorectal cancer or Lynch Syndrome, limited to the colon or associated to extracolonic carcinoma (Lynch I and II).",
          "begin_section": "abstract",
          "offset_in_begin_section": 400,
          "end_section": "abstract",
          "offset_in_end_section": 645
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23787146",
          "text": "In the setting of a pre-existing colorectal carcinoma this would constitute a hereditary non-polyposis colorectal cancer, Lynch 2 syndrome, accounting for 5 to 10% of colon cancer cases. We unveil a case of 'giant' ovarian tumors mimicking primary ovarian cancer; ostensibly the first reported in East Africa.",
          "begin_section": "abstract",
          "offset_in_begin_section": 85,
          "end_section": "abstract",
          "offset_in_end_section": 394
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23787146",
          "text": "In the setting of a pre-existing colorectal carcinoma this would constitute a hereditary non-polyposis colorectal cancer, Lynch 2 syndrome, accounting for 5 to 10% of colon cancer cases.",
          "begin_section": "abstract",
          "offset_in_begin_section": 85,
          "end_section": "abstract",
          "offset_in_end_section": 271
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21388660",
          "text": "Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.",
          "begin_section": "title",
          "offset_in_begin_section": 0,
          "end_section": "title",
          "offset_in_end_section": 104
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/7848695",
          "text": "Fourteen months after surgery he had tumor recurrence and liver metastases. We reviewed then the clinical features, inclusion criteria, screening and the discussed treatment of the hereditary non-poliposis colorectal cancer or Lynch Syndrome, limited to the colon or associated to extracolonic carcinoma (Lynch I and II). A clear and detailed familial history is the only definite criteria for the diagnosis.",
          "begin_section": "abstract",
          "offset_in_begin_section": 324,
          "end_section": "abstract",
          "offset_in_end_section": 732
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/21388660",
          "text": "CONCLUSION\nThe combined data from our cohorts demonstrate that ovarian cancer associated with Lynch syndrome typically presents at young age as early-stage, non-serous tumors, which implicates that a family history of colorectal and endometrial cancer should be specifically considered in such cases.",
          "begin_section": "abstract",
          "offset_in_begin_section": 812,
          "end_section": "abstract",
          "offset_in_end_section": 1112
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23787146",
          "text": "Further still, she is a case of probable Lynch syndrome, requiring genetic analysis for definitive classification and surveillance for hereditary non-polyposis colorectal cancer-associated cancers.Important inferences are drawn. Firstly, 'giant' ovarian tumors diagnosed as primary ovarian cancer may actually be colonic secondaries.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1788,
          "end_section": "abstract",
          "offset_in_end_section": 2121
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23787146",
          "text": "Two primary tumors (suspected Lynch syndrome) had been perceived yet there is actually only metastatic colorectal cancer. We also have a rare and unusual metastatic presentation: 'giant' bilateral ovarian tumors and subcutaneous nodules, concurrently. Further still, she is a case of probable Lynch syndrome, requiring genetic analysis for definitive classification and surveillance for hereditary non-polyposis colorectal cancer-associated cancers.Important inferences are drawn.",
          "begin_section": "abstract",
          "offset_in_begin_section": 1536,
          "end_section": "abstract",
          "offset_in_end_section": 2016
        },
        {
          "document": "https://pubmed.ncbi.nlm.nih.gov/23176623",
          "text": "Lynch syndrome is characterized by a significantly increased risk for colon cancer and endometrial cancer and a smaller risk for several other associated cancers.",
          "begin_section": "abstract",
          "offset_in_begin_section": 82,
          "end_section": "abstract",
          "offset_in_end_section": 244
        }
      ],
      "ideal_answer": "In addition to colon cancer and endometrial cancer, Lynch syndrome is also associated with an increased risk of several non-colonic tumors, including ovarian cancer, gastric cancer, small intestine cancer, urinary tract cancer, pancreatic cancer, and sebaceous gland tumors.",
      "exact_answer": [
        [
          "Endometrial cancer"
        ],
        [
          "Ovarian cancer"
        ],
        [
          "Gastric cancer"
        ],
        [
          "Small intestine cancer"
        ],
        [
          "Urinary tract cancer"
        ]
      ]
    }
  ]
}